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ABSTRACT
The purpose of this study was to compare the 
neuropsychological functioning; psychiatric, legal, substance 
abuse histories; community adjustment; and, recidivism rates 
between substance-abusing psychiatric inpatients with psychotic, 
affective or personality disorders.
Neuropsychological functioning was measured with 11 
measures. Psychiatric, legal and substance abuse histories were 
obtained using the Addiction Severity Index (ASI). General 
functioning was obtained using the Premorbid Adjustment Scale 
(PAS). Attitudes toward medication were obtained with the 
Ratings of Medication Influences (ROMI). Recidivism rates were 
obtained from the computerized admissions database operated by 
the Virginia Department of Mental Health, Mental Retardation, and 
Substance Abuse Services. Post-discharge community adjustment 
measures were obtained by mailing follow-up questionnaires to 
both patients and the community agency to which they were 
referred.
All 3 diagnostic groups exhibited impaired performance on 
neuropsychological measures. The psychotic group performed 
significantly more poorly than the 2 non-psychotic groups. All 
groups reported substantial childhood attention deficit 
symptomatology. All groups tended to recall visual stimuli 
better than verbal stimuli. The psychotic group reported less 
substance abuse than the other groups. Among psychotics, 
substance abuse variables predicted much of the variance in their 
recidivism rates. Among those with affective disorders, 
neuropsychological variables predicted much of the variance in 
their recidivism rates. Among those with personality disorders, 
non-medical personality and psychosocial factors are believed to 
relate to recidivism rate. Few patients followed through with 
aftercare. Those who were known to follow-through were different 
from those who were known to not follow-through in their 
substance abuse and arrest record.
The results suggest that differences exist between the 3 
diagnostic groups and that intervention programs need to be 
designed which address the unique neuropsychological capabilities 
of each group.
xi
NEUROPSYCHOLOGICAL FUNCTION, RECIDIVISM, AND 
COMMUNITY ADJUSTMENT OF THE MENTALLY ILL 
CHEMICALLY ADDICTED (MICA) PATIENT
2INTRODUCTION
Problem Description
The mental health delivery system is confounded by a 
relatively new type of patient. In the late 1960s, Pepper 
referred to them as the Young Adult Chronic Patient. Today, 
these clients are referred to as the dual-diagnosed or 
mentally ill chemically addicted (MICA).
Considerable research has been conducted on the 
comorbidity between psychiatric and substance abuse 
disorders. Pepper, Kirshner, & Ryglewicz (1981) found that 
37 percent of psychiatric patients abused alcohol and another 
37 percent abused other drugs. Holcomb and Ahr (1986) 
reported a comorbid prevalence of 43 percent. Pepper and 
Ryglewicz (1984) found comorbid prevalence of 4 9 percent. 
Safer (1987) reported a comorbid prevalence of 73 percent. 
Miller and Fine (1993) suggest that comorbidity is about 50 
percent of clinical populations. Reiger and colleagues 
(1990) reported the results of the National Institute of 
Mental Health Epidemiologic Catchment Area study: a lifetime
prevalence rate of 2 9 percent was reported for any addictive 
disorder with any mental disorder. Substance abuse was found
3to be comorbid with schizophrenia at 47 percent and with 
antisocial personality disorder at 84 percent.
The MICA population is characterized by high treatment 
and service utilization rates. MICAs utilize services more 
than either mentally ill or substance abusing populations.
The U.S. Alcohol, Drug Abuse and Mental Health Administration 
set the 1985 cost of alcohol, drug abuse and mental illness 
at $70, $44, and $104 billion respectively (Rice, Kelman, 
Miller, & Dunmeyer, 1990). No estimates of the cost of the 
MICA population are available. Based on comorbidity 
estimates, utilization patterns, and 1985 costs, a 
conservative estimate is that the MICA population may account 
for no less than $40 to 60 billion. Thus, for health care 
cost containment purposes, it is imperative that adequate 
treatment and intervention strategies be developed for this 
population.
Most professionals are perplexed when faced with 
treating the MICA patient. The MICA patient presents 
problems to the mental health delivery system which 
conventional substance abusers and persons with mental 
illness do not. One problem is that substance abuse among 
psychiatric patients may precipitate and exacerbate 
psychiatric symptomatology. There is compelling evidence 
that stimulant abuse can precipitate the onset of 
schizophrenia at an earlier age in biologically vulnerable
4individuals (Breakey, Goodell, Lorenz, & McHugh, 197 4; 
Richard, Liskow, & Perry, 1985; Tsuang, Simpson, & Kronfol, 
1982). Continued substance abuse may further impair the 
already compromised cognitive functioning of schizophrenics 
(Bellack, 1992; Mueser, Yarnold, & Bellack, 1992). Another 
problem is that individuals with primary substance abuse 
disorders have a high mortality for suicide (Hesselbrock, 
Meyer, & Keener, 1985; Whitters, Cadoret, & Widmer, 1985).
The rates of suicidal ideation, attempts and completions are 
particularly elevated among young male schizophrenics with 
substance abuse histories (Cohen, Test, & Brown, 1990; 
Landmark, Cernovsky, & Merskey, 1987). Another problem is 
that schizophrenia patients who abuse alcohol or drugs are 
often less compliant with neuroleptic treatment (Drake,
Osher, & Wallach, 1989) and report discontinuing neuroleptics 
during phases of substance abuse (Pristach & Smith, 1990). 
Furthermore, MICA compliance with traditional substance abuse 
treatment has also been found to be poor (Osher & Kofoed, 
1989; Caton, 1981).
Several reasons have been posited to explain substance 
abuse in psychiatric populations. The self-medication 
hypothesis, promoted by Khantzian (1985), suggests that 
patients abuse substances to decrease distress caused by 
major symptoms, anxiety, and depression. There has been some 
evidence (Schneier & Siris, 1987) that schizophrenia patients
5prefer to abuse stimulants in order to overcome negative 
schizophrenic symptoms of withdrawal and apathy.
Drug use and choice are also significantly determined 
by availability. Mueser, Yarnold, & Bellack (1992) reported 
that cannabis was the most commonly abused drug among 
schizophrenic patients before 1986; whereas, since 1986, 
cocaine has been the most popular drug. This utilization 
shift parallels that found in studies of the general 
population (National Institute on Drug Abuse, 1991; Pope, 
Ionescu-Pioggia, Aizley, & Varma, 1990). Further, many 
patients report that alcohol temporarily relieves psychotic 
symptoms (Freed, 1975; Hansell & Willis, 1977). Most MICAs 
report the use of substances in order to achieve a euphoric 
affective state (to "get high"), relax, alleviate boredom, 
and to stimulate and energize them (Dixon, Haas, Weiden, 
Sweeney, & Frances, 1991; Test, Wallisch, Allness, & Ripp, 
1989).
Another reason for drug use among the mentally ill is 
due to the social nature of substance abuse. Drug abuse by 
many schizophrenic patients occurs in a social setting 
(Dixon, Haas, Weiden, Sweeney, & Frances, 1990). These 
opportunities for social interaction may be characterized by 
less interpersonal stress, anxiety, discomfort, and fear of 
failure. The opportunity to interact with others similar to 
themselves who have similar values, experiences, interests
6and levels of social functioning may provide for greater 
feelings of acceptance (Mueser, Bellack, & Blanchard, 1992).
The mental health delivery system has been essentially 
unable to improve the long-term outcomes of the MICA patient. 
Service utilization patterns of MICAs (Caton, 1981; Holcomb & 
Ahr, 1988; Intaglia & Baker, 1984; Mowbray, Herman, & Hazel, 
1992; Pepper, Kirshner, & Ryglewicz, 1981; Safer, 1987; 
Schwartz & Goldfinger, 1981; Test, Knoedler, Allness, &
Burke, 1985; Thompson, 1988) strongly suggest that treatment 
effectiveness is limited. It appears that interventions 
found to be effective in the treatment of substance abuse 
disorders or those effective in the treatment of other mental 
disorders are not as effective in the treatment of 
individuals with comorbid substance abuse and mental 
disorders. This may be, in part, due to the synergistic 
effects of substance abuse upon neuropsychological 
functioning. Due to neurological impairments attributable, 
in many cases, to both the psychiatric condition and the 
abusing substances, MICAs may be less able to cognitively 
respond to conventional treatment. It is suggested that 
treatment strategies devised to accommodate the 
neurocognitive abilities and deficits of patients will be 
most engaging and, consequently, result in greater treatment 
efficacy for this population.
7MICA Assessment
A prerequisite for the effective treatment of MICAs is 
careful assessment (Lehman, Myers, & Corty, 1989; Test, 
Wallisch, Allness, & Ripp, 1989). There are several items to 
consider in the assessment of MICAs. These include 
diagnostic criteria, symptom overlap, validity of self 
report, and the reliability and validity of instruments used 
in the assessment process. Alcohol and drug abuse have long 
been recognized to confound psychiatric diagnosis (Parker, 
Meiller, & Andrews, 1960). Mueser, Bellack and Blanchard 
(1992) discuss the psychotomimetic effects of substance 
abuse. The attempt to diagnose schizophrenia without 
assessing for substance abuse may often result in 
misdiagnosis and, consequently, mistreatment (Alterman, 
Erdlen, LaPorte, & Erdlen, 1982; Hall, Popkin, & DeVaul,
1977). Diagnostic considerations include more severe course 
of the disorder, earlier age of onset (Mueser et al., 1990), 
and more severe symptomatology (Cleghorn, et al., 1991;
Drake, et al ., 1990) when schizophrenia is comorbid with 
substance abuse.
Further, chronic alcohol abuse or withdrawal from 
alcohol can cause hallucinations and delusions (Schuckit,
198 9; Victor & Hope, 1958) . Amphetamine abuse can produce 
temporary psychotic states clinically indistinguishable from
8schizophrenia (Hall, Popkin, Beresford, & Hall, 1988).
Chronic cocaine abuse can result in paranoia and delirium 
(Welti & Fishbain, 1985). Cannabis abuse can result in panic 
and paranoid symptomatology (Hollister, 1986). The 
hallucinogenic drugs, like LSD, phencyclidine and psilocybin, 
result in numerous psychotic symptoms (Hensala, Epstein, & 
Blacker, 1967).
Additional problems arise from the questionable 
validity of self-reports by substance abusers, both for 
concurrent abuse (Donovan & Marlatt, 1988) and retrospective 
ratings (Aiken, 1986). This inaccurate reporting is 
suggested (Ridgely, Goldman, £ Willenbring, 1990) to often be 
attributable to concerns for losing psychiatric treatment 
services and entitlements. Pristach and Smith (1990) 
observed that many schizophrenics are willing to acknowledge 
substance abuse on questionnaires but often deny it in 
interviews.
Another diagnostic problem is that most self-report 
scales developed for addiction populations have not been 
validated for psychiatric patients (Toland & Moss, 1989). 
There is mixed evidence suggesting the Michigan Alcoholism 
Screening Test (MAST) may be useful for the detection of 
alcoholism in schizophrenia patients (Drake et a l ., 1990; 
Gorelick, Irwin, Schmidt-Lackner, & Marder, 1990). Myer 
(1994) reported the Addiction Severity Index (ASI) is useful
9in the assessment of alcoholism among psychiatric patients. 
The problems which are found in these and other psychological 
measures are addressed in research by using a broad based 
substance abuse assessment data base. Generally, the most 
common methods for the assessment of substance abuse 
disorders in psychiatric populations are review of hospital 
records, structured clinical interviews, self-report scales, 
reports from significant others or treatment staff, and 
biological assays.
Neurological & Neuropsychological Sequelae of Substance Abuse 
Neuroimaging studies frequently indicate sulcal 
widening and ventricular dilation in alcoholics (Jernigan et 
al., 1991; Jernigan, Pfefferbaum, & Zatz, 1986; Ron, 1987; 
Wilkinson, 1987). Increased density of brain tissues 
surrounding the third ventricle has been associated with 
performance on a paired-associate learning task (Jernigan et 
a l ., 1982) and on two paired-associate learning tasks 
(Gebhardt, Naeser, & Butters, 1984) . Autopsy data confirm 
that the brains of alcoholics are smaller, with enlarged 
sulci, dilated lateral and third ventricles, and frequently 
exhibit cerebellar degeneration (Courville, 1955). Walker, 
Hunter, and Abraham (1981) reviewed animal studies confirming 
brain degeneration. The evidence suggests that there is
10
long-term recovery of some cognitive functioning after 
continued abstinence (Adams, Grant, & Reed, 1980; Grant, 
Adams, & Reed, 1984; Grant & Reed, 1985). Some structural 
abnormalities may also slowly resolve with prolonged 
abstinence (Ron, Acker, & Lishman, 1987; Wilkinson, 1987) .
The first neuropsychological study of alcoholics 
appeared in 1960 (Fitzhugh, Fitzhugh, & Reitan). Alcohol 
abuse is associated with neurocognitive impairment. Areas of 
impairment include abstract reasoning, learning, attention, 
information processing, complex perceptual-motor abilities 
(Fitzhugh et al ., 1960; 1965), and memory (Grant, 1987;
Grant, Adams, & Reed, 1986; Parsons & Leber, 1981; Tarter & 
Edwards, 1985). Verbal abilities and intelligence may remain 
unimpaired (Fitzhugh et al., 1960, 1965; Jones & Parsons,
1971, 1972). Cognitive impairment may last for months or 
years into sobriety (Brandt, Butters, Ryan, & Bayog, 1983; 
Fabian & Parsons, 1983; Parsons, Schaeffer, & Glenn, 1990; 
Ryan, DiDario, Butters, & Adinolfi, 1980). Alcoholics appear 
to have an anterograde memory deficit (Brandt et al., 1983; 
Butters, Cermak, Montgomery, & Adinolfi, 1977; Ryan &
Butters, 1980). Ryan (1980) found that alcoholics were able 
to remember normally when properly cued. Cutting (197 8) 
found deficits on picture memory following one month of 
abstinence. Guthrie and Elliott (1980) observed deficits in 
logical memory and verbal paired-associate learning. Ron,
11
Acker, and Lishman (1980) reported losses in verbal and 
nonverbal learning.
Less research has been conducted on the neurocognitive 
effects of drug use, but the results suggest considerable 
impairment (Matarazzo, 1972; Tarter & Alterman, 1984). It is 
especially measurable in verbal abilities. Perceptual-motor 
abilities are significantly impaired (Grant et al ., 1978; 
Grant & Judd, 197 6) in both visual-spatial perception 
(Goldman, Williams, & Klisz, 1983) and reduced psychomotor 
speed (Blusewicz, Schenkenberg, Dustman, & Beck, 1977).
Recall and recognition memory appear impaired (Williams & 
Rundell, 1984). Electroencephalograph abnormalities (Grant & 
Judd, 1976) are also noted. Cocaine utilization specifically 
has been observed to be related to cognitive impairments 
(Herning, Glover, Koeppl, Weddington, & Jaffe, 1990; O'Malley 
& Gawin, 1990).
Neuropsychological deficits have generally been 
hypothesized to be important in the etiology and course of 
schizophrenia (Nuechterlein & Dawsom, 1984). Schizophrenia 
patients have been found to demonstrate generalized cognitive 
deficits (Braff, 1991; Chapman & Chapman, 1973) and 
impairment in information processing, attention, and memory 
(Braff, 1991).
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Neuropsychological Assessment
In the absence of premorbid neuropsychological 
information, a standard methodology must be employed to infer 
the degree of cognitive degeneration. The method commonly 
employed within neuropsychology is the comparison of results 
to a "fund of information". This fund serves as an estimate 
of premorbid intellectual functioning (Lezak, 1983). The 
belief is that knowledge and skills learned early in life are 
more resistant to deterioration. Verbal scores are usually 
used as a comparison to other scales. While this procedure 
is often a useful premorbid estimate of general performance, 
the use of verbal skills for estimating premorbid "fund of 
information" is believed to be considerably less reliable 
with substance abusers. This is because substance abusers 
appear to manifest verbal skills impairments on a premorbid 
basis. Results of comparisons between verbal and other 
scores in substance abusers have yielded mixed results 
(Blusewicz et a l ., 1977; Holland & Watson, 1980). It is 
suggested that the best measure of premorbid functioning for 
all individuals, especially substance abusers and other 
individuals often found to have childhood attention deficit, 
is to obtain actual measures or examples of premorbid 
functioning.
Among substance abusers, impairments have often been
13
noted in the Category Test (Grant & Reed, 1985; Parsons & 
Farr, 1981), Levine Hypothesis Test (Klisz & Parsons, 1977), 
Shipley Institute of Living abstraction scale (Donovan, 
Queisser, & O'Leary, 197 6), Raven Progressive Matrices (Jones 
& Parsons, 1972), and Wisconsin Card Sorting Test (Klisz & 
Parsons, 1979; Ron, Acker, & Lishman, 1980). This pattern 
suggests impairment i n .analytical thinking and is associated 
with frontal lobe injury. Perceptual motor deficits have 
been confirmed using Halsteadfs Tactual Performance Test, the 
Trail Making Test, and the WAIS Digit Symbol test. Recently 
detoxified alcoholics have demonstrated impairment on 
perceptual tests lacking motor components, such as in the 
embedded figures test (Brandt, Butters, Ryan, & Bayog, 1983; 
Donovan et al., 1976; Sparadeo, Zwick, & Butters, 1983). 
Robertson, Stillman and Delis (1985) found that alcoholics 
perceived single, simple perceptual elements normally, but 
had difficulty organizing elements into a meaningful whole.
Treatment Implications of Neuropsychological Deficits
Studies conducted with schizophrenia patients and with 
substance abusers suggest that the level of
neuropsychological functioning has important implications for 
the efficacy of treatment interventions (Mueser et a l .,
1992). For example, memory impairments may be related to
14
greater severity of social skills deficits prior to treatment 
and may tend to predict poorer acquisition of these behaviors 
after participation in a social skills training program 
Mueser, Bellack, Douglas, & Wade, 1991).
The majority of addiction treatment programs are based 
on the 12-step approach characteristic of Alcoholics 
Anonymous (AA) . While this approach appears to have success 
with the general addiction population, it may have limited 
utility with patients with psychiatric disorders and 
cognitive deficits, and who are at increased vulnerability to 
the effects of interpersonal stress. The basic text of AA 
states that many persons with grave emotional and mental 
disorders can recover, if they have the capacity to be honest 
(Alcoholics Anonymous, 1976). However, MICAs are often 
unable to admit to errors or problems or to see connections 
between symptoms, their behavior and the consequences, or 
life situations (Bellack, Mueser, Wade, Sayers, & Morrison, 
1992). That particular characteristic tends to be common 
among alcoholics or addicts in denial. Psychiatric treatment 
traditionally emphasizes tolerance, support, and caring.
These attributes may not be helpful for dealing with 
substance abuse. Substance abuse treatment tends to utilize 
confrontation, reality therapy, "tough love", and highly 
directive and structured approaches. Not all of these 
approaches may be helpful for dealing with the mentally ill.
15
MICAs may require a program that integrates elements of 
psychiatric and substance abuse treatment (Drake, Osher, & 
Wallach, 1991; Lehman, Myers, & Corty, 1989) such as 
supportive and empathic listening, resocialization, social 
skills development as well as a highly structured program of 
recovery and daily living activities.
Rationale
Despite the accumulation of data regarding the 
prevalence of substance use disorders in schizophrenia, there 
are no systematic studies of the neuropsychological 
correlates of substance abuse in psychiatric populations. 
Mueser, Bellack, and Blanchard (1992) suggest that even 
though the cognitive correlates of schizophrenia have 
received considerable investigation, a neglected issue 
concerns the potential role of alcohol and drug use in the 
etiology or exacerbation of cognitive impairment among 
individuals with schizophrenia. Neuropsychological profiles 
of MICAs may be most useful for the development and 
implementation of effective treatment programs.
Purpose
The present study set out to formulate profiles of MICA 
patients based on demographics; medical, substance abuse,
16
legal, and psychiatric histories; performance on 
neuropsychological measures; and, community adjustment 
ratings.
Further, the study set out to examine three specific 
questions. First, it was hypothesized that 
neuropsychological profiles may differentiate three 
diagnostic categories substance-abusers: those with primary
diagnoses of psychotic disorders, affective disorders, and 
personality disorders. It was predicted that participants 
with psychotic disorders would exhibit moderate to severe 
global neuropsychological impairment; whereas participants 
with affective and personality disorders would exhibit mild, 
limited neuropsychological impairment of verbal skills, 
memory, psychomotor speed and analytical thinking.
Second, through the use of multiple regression 
techniques, the development of an equation that would predict 
recidivism among MICAs was proposed.
Third, it was predicted that individuals who followed- 
up with community aftercare would have a profile different 
from those who would not follow-up.
17
Method
Participants
In order to maximize statistical power, minimize both 
structural and functional neurologically-based variance, and 
remain within the logistical constraints imposed by the 
present study, only one sex could be studied. As hospital 
admissions records indicated a male to female ratio of nearly 
3:1, only male subjects were identified to participate in the 
study. A total of 174 patients were approached and asked to 
participate in the study. A total of 26 prospective 
participants refused to participate, including 13 patients 
with psychotic disorders, 9 patients with affective 
disorders, and 4 patients with personality disorders. The 
final sample consisted of 148 participants. Participants 
were randomly selected from hospital admissions. In order to 
reduce interviewer bias, psychiatric diagnoses were obtained 
from chart review following testing sessions. The admission 
diagnosis was not used in participant classification; 
diagnosis at the time of discharge was thought to provide a 
more reliable diagnostic impression. All diagnoses were made 
by three ward psychiatrists using DSM-IV criteria.
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Group one consisted of 40 participants diagnosed with 
psychotic disorders with a second Axis-I diagnosis of 
substance abuse or dependence. Psychotic disorders such as 
schizophrenia, schizophreniform disorder, schizoaffective 
disorder and psychotic disorders were included. Individuals 
with psychotic disorder secondary to substance abuse were 
excluded from this classification, as the primary interest 
was in differences in the long-term neuropsychological 
functioning of participants, and substance-induced psychotic 
disorders are believed to not neurophysiologically resemble 
chronic organic psychotic disorders. In order to be 
sensitive to ethical concerns in the conduct of research with 
mentally ill persons, only those persons who were believed to 
be competent were considered for participation in the study. 
The methods used to screen out incompetent individuals are 
more thoroughly discussed in the procedures section. Group 
two consisted of 42 participants diagnosed with affective 
disorders comorbid with substance abuse. Group three 
consisted of 66 participants with personality disorders 
comorbid with substance abuse. The sample size of the three 
groups approximates the proportion of the respective 
disorders among male admissions to this hospital during the 
testing period.
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Materials
A participant demographics form was developed to record 
relevant background information used for project management. 
Relevant information was obtained from participant charts, 
including: admission number, date of birth (and age), race,
admission and discharge dates, Axis-I, II, and V diagnoses, 
urinalysis results, discharge address, and agencies to which 
participants were referred at discharge. A copy of the 
demographics form can be found in Appendix A.
Each participant was given three consent forms. The 
general research participation consent form described the 
study and requested the participant's permission to 
participate in the study. The clinical consent form 
requested the participant's permission to share the results 
of the neuropsychological assessment with the hospital 
clinical staff. The follow-up consent form requested the 
participant's permission to contact them and the community 
follow-up agency to which they would be referred in order to 
obtain post-discharge follow-up information. A copy of the 
three consent forms can be found in Appendix B.
A neuropsychological history questionnaire was 
developed to identify relevant background variables that 
could confound the neuropsychological testing, such as head 
injuries; cardiovascular accidents (CVAs); neuropsychological
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risk factors such as meningitis, encephalitis, and sexually 
transmitted diseases; cancer; degenerative disorders such as 
HIV or AIDS, Alzheimer's disease, and Parkinson's disease; 
and, seizure disorders. Information on education, grades and 
hand dominance were recorded. In addition, the form was used 
to record and summarize test scores and normative scores. A 
copy of the neuropsychological history questionnaire can be 
found in Appendix C.
The first question on the neuropsychological history 
questionnaire regarded the participant's history of head 
injuries. Participants were asked, using an open-ended 
interview format, to describe any incidents in which he 
experienced a head injury. Participant responses were 
categorized into four classifications. The first 
classification, "0”, was assigned when participants reported 
no history of head injury. A "1" was assigned when 
participants reported mild head injury. A "2" was assigned 
for moderate head injury. A "3" was assigned for severe head 
injury. The severity of head injury was determined by the 
interviewer based on frequency of head injuries, loss of 
consciousness, hospitalization and symptom severity. The 
credibility of participant responses was considered when 
interviewers assigned participant responses to the above 
categories. For example, one psychotic participant reported 
that he had received a head injury when his persecutors
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electrocuted him and chopped off his head. In such cases, 
participant responses were treated as missing data.
Participants were asked several background questions. 
Years of education was recorded. Fractions of years were 
often reported but were not recorded. The completion of the 
General Equivalency Diploma (GED) was recorded but was not 
used in determining educational level.
Participants reported grades received at their last 
educational institution. Participants, thus, reported their 
grades for elementary, junior/middle, high school, college, 
or graduate school. An 'A' was recorded as 4.0, a 'B' was 
recorded as 3.0, a XC' was recorded as 2.0, and a XD' was 
recorded as 1.0 point. A response of XC+' was recorded as 
2.33 and a response such as xBs and Cs' was recorded as 2.50.
The hand dominance of participants was observed. When 
participant report was inconsistent with interviewer 
observation, he was asked about the discrepancy. For 
purposes of the present study, hand dominance was defined as 
the hand which he tended to use while writing. When the 
dominant hand had been amputated, in a cast, or otherwise 
nonfunctioning, hand dominance was treated as missing data.
Additional clinical observations were made, as cases 
warranted. If a participant had difficulty seeing the words 
on a particular test, it was noted. If a participant was too 
psychotic or too inattentive to complete tests, it was also
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noted. Further, interpersonal and psychological attributions 
for poor test performance were periodically recorded.
The first test administered as part of the 
neuropsychological battery was the Wechsler Memory Scale - 
Revised, Logical Memory and Visual Reproduction scales.
These measures provide indices of both verbal and visual 
memory on immediate and delayed recall bases. The WMS-R 
Logical Memory scale consists of two short stories which 
participants were asked to repeat immediately and on a 
delayed basis. A copy of the WMS-R Logical Memory scale can 
be found in Appendix D. The WMS-R Visual Reproduction
consists of the presentation of four stimulus pictures.
Participants were asked to reproduce the pictures immediately 
and on a delayed basis. A copy of the four stimulus pictures 
provided in the WMS-R Visual Reproduction scale can be found
in Appendix E. The WMS-R has a fair amount of normative data
(Wechsler, 1987). Scoring of the Visual Reproduction scale 
was performed by a licensed clinical neuropsychologist.
Next, the Shipley Institute of Living (SIL) test was 
administered. The Shipley consists of a scale for verbal 
abilities and a scale for abstraction abilities. It also 
yields a total score for combined verbal and analytical 
ability and an estimate of intelligence. The SIL provides 
indices of frontal cerebral functioning, (premorbid) verbal 
ability, and an estimate of intelligence. Normative data are
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available (Shipley, 1940; Heaton, Grant, & Matthews, 1991).
A copy of the Shipley Institute of Living, verbal and
analytical scales, can be found in Appendix F.
The Trail Making Tests A and B were administered. The
Trail Making tests provide indices of cognitive rigidity,
psychomotor speed and spatial problem-solving. It is a 
component of the Halstead-Reitan neuropsychological battery, 
and as such, considerable normative data are available 
(Heaton, Grant, & Matthews, 1991). A copy of the Trail 
Making Test A and Trail Making Test B can be found in 
Appendix G.
The Wender Utah Rating Scale provides an indication of 
the level of attention-deficit. The subscale of 25 items that 
have been found by Wender to most unambiguously identify 
attention deficit disorder was used. Normative data are 
available (Ward, Wender, & Reimherr, 1993) but severely 
deficient. A copy of the Wender Utah Rating Scale - 25 can 
be found in Appendix H. As individuals with severe levels of 
attention deficit were unable to attend to the complete 
questionnaire, the questionnaire was believed to inaccurately 
identify levels of attention deficit. In order to adjust for 
this deficiency, the scoring methodology was modified. All 
participants began with an assumed maximum score of 125 (25 
questions x 5 points). Each 1 point response reduced the
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maximum by 4 points. Each 3 point response reduced the 
maximum by 2 points. Thus, an individual who attended to the 
task for only 3 questions and who provided 1 point responses 
would receive a score of 113.
The Reitan-Indiana Aphasia Screening measures 
characteristics of aphasia. As a component of the Halstead- 
Reitan neuropsychological battery, considerable normative 
data are available (Heaton, Grant, & Matthews, 1991). A copy 
of the Reitan-Indiana Aphasia Screening answer sheet can be 
found in Appendix I. The stimulus materials booklet is not 
provided in the Appendices.
The Addiction Severity Index (ASI) scales on drug and 
alcohol background, legal background and psychiatric 
background were used. The ASI scale on drug and alcohol use 
identifies the number of days in the 30 prior to 
hospitalization during which participants used various 
substances, the number of years of use during the lifetime 
during which various substances were used, the major 
substance abuse problem, the number of times one has 
overdosed or experienced the delirium tremens, expenditures 
on alcohol and drugs, as well as severity and accuracy 
ratings.
The ASI scale on legal issues identifies whether the 
admission was prompted by the criminal justice system, 
whether the participant is on probation or parole, the number
25
of times charged with various criminal offenses, imprisonment 
history, pending charges, tendency to commit illegal acts, as 
well as severity and accuracy ratings.
The psychiatric history section identifies the number 
of psychiatric hospitalizations, whether the participant 
receives a pension for a psychiatric disability, whether the 
participant has experienced select psychiatric 
symptomatology, as well as severity and accuracy ratings. A 
copy of the three ASI subscales used in this study can be 
found in Appendix J.
The Rating of Medication Influences (ROMI) was 
administered to participants who were prescribed a 
psychotropic medication prior to hospitalization (Weiden, 
Raphin, Mott & Zygmunt, 1994). For purposes of 
simplification and data reduction, the open-ended interview 
questions on the first page of the ROMI were not 
administered. The ROMI consists of two scales. The first 
scale is composed of 7 questions regarding reasons for 
medication compliance. The second scale is composed of 13 
questions regarding reasons for medication administration 
reluctance. A copy of the ROMI can be found in Appendix K.
The Premorbid Adjustment Scale (Cannon-Spoor, Potkins,
& Wyatt, 1982) was completed for participants. The Premorbid 
Adjustment Scale (PARS) consists of 25 questions organized 
developmentally. It is composed of sections on childhood,
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early adolescence, late adolescence, adulthood, and general. 
Questions in each section focus on function in various life 
domains, such as friendships, interpersonal relations, 
education, sexual development, housing, and employment. A 
copy of the Premorbid Adjustment Scale can be found in 
Appendix L.
Brief questionnaires were developed for completion by 
patients and by community aftercare agency staff. 
Questionnaires consisted of four questions designed to elicit 
whether the patient had attended his first aftercare 
appointment, whether he was taking prescription medication, 
whether he was participating in on-going outpatient 
treatment, and his estimated global assessment of functioning 
(GAF). A copy of the questionnaires sent to patients and 
aftercare agencies can be found in Appendix N.
Apparatus
The Grooved Pegboard was included as a measure. The 
Grooved Pegboard is a component of the Halstead-Reitan 
neuropsychological test battery. The Grooved Pegboard 
provides indices of psychomotor speed, oculomotor 
coordination, and hemispheric injuries. Normative data are 
available (Heaton, Grant, & Matthews, 1991). A copy of the 
Grooved Pegboard manual can be found in Appendix M.
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Research Design
A quasi-experimental between subjects design was 
employed. Interviewers were blind to participant diagnosis 
at the time of interviews.
Research Procedures
Three graduate psychology students were trained to 
administer the research protocol. A licensed clinical 
neuropsychologist provided training on standardized 
administration of neuropsychological measures. A licensed 
clinical psychologist provided training on interview 
techniques and ASI administration. Each graduate student 
completed hospital-offered training in patient management 
skills. Interviewers were trained on the assignment of 
scores so that inter-rater reliability was acceptable (rk.70) 
prior to interviewing participants.
Research participants were selected using the 
randomized sampling procedure described previously. 
Participants consisted of 148 male patients who were admitted 
to Eastern State Hospital between September 1994 and July 
1995.
In order to ensure that prospective participants 
understood their rights in participating in the research,
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prospective participants had to meet an inclusion test. The 
first phase of the screening entailed asking ward staff to 
identify new patients and to relate behavioral observations. 
Patients described with severe behavioral problems or who did 
not appear to be functioning sufficiently to understand 
simple directions were not tested on that day but were placed 
on a waiting list. When they appeared to be able to 
understand instructions, they were solicited to participate 
in the study. The nature of the study, their rights, 
research procedures and incentives were explained to each 
prospective participant. If the interviewer had any doubt 
that the prospective participant may not have understood the 
above description, the prospect was asked to summarize his 
understanding of what had just been stated. When a 
prospective participant did not understand or summarize what 
had been said to him, he could not participate in the study 
at that time.- Again, the purpose of this procedure was to 
ensure that only participants who were competent to decide 
whether or not to participate were actually recruited for the 
research.
Once the interviewer was certain that prospects were 
competent to decide to participate, then the interviewer and 
the prospective participant went to a private testing area. 
Private testing areas were subject to the typical 
restrictions and variations found in many clinical settings.
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As such, testing was performed in the interviewer's office, 
any one of three private visitors rooms, an empty ward, or 
the participant's private bedroom.
At the beginning of each session, the interviewer 
attempted to establish rapport with the participant and to 
make the participant feel comfortable. A short discussion, 
usually between 5 and 10 minutes, began each session, in 
which the interviewer asked the participant how long he had 
been at the hospital and what brought him to the hospital.
The consent to participate in research form was 
presented to the prospective participant so that he could 
read along as the interviewer provided a verbal summary of 
the study, patient rights, and motivational incentives. The 
interviewer described to the participant the exact nature of 
the study. Participants were told that the research was a 
neuropsychological study that would examine the effects that 
substance abuse, head injuries, seizures, and other risk 
factors had on neuropsychological functions such as memory, 
problem-solving, creativity, vocabulary, motor speed and 
aphasia among persons with different types of psychiatric 
diagnoses. The interview would take between 1.25 and 2.50 
hours during which the participant would complete a series of 
tests that assess memory, vocabulary, analytical skills, 
psychomotor speed, and attention. Further, the participant 
was informed that he would be asked a series of questions
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about substance abuse, legal and psychiatric history, head 
injuries, diseases, and school. In addition, by 
participating, the participant would give the interviewer 
authorization to review his medical chart and record data on 
diagnoses, medication and background information.
Patient rights were explained to each participant.
Each person was informed that he did not have to participate 
in the study. And, if he decided to not participate, there 
would be no consequences of any kind - it would not affect 
either his stay at the hospital nor his discharge from the 
hospital. Further, if he decided to participate in the 
project, he could quit at any time without any consequences. 
If at any time he wanted to take a break between tests, he 
could feel free. And, if the interviewer were to ask any 
question that he may interpret to be offensive or that he did 
not wish to answer, he did not have to answer it.
An attempt was made to provide participants with 
motivation to complete the study. Participants were informed 
that the results of the research would confidentially be made 
available to the hospital and that it was hoped that their 
participation in the research project would contribute to the 
continuing improvement in services for future patients. In 
addition, prospective participants were offered a soft drink 
at the beginning of the session. All participants who 
consented to participate in the study were informed that six
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dollars would be deposited the next day in their patient 
account and would be available for their withdrawal within a 
few days. And finally, participants were told that they 
would receive a certificate of appreciation for their 
participation in research.
The protocol consisted of neuropsychological testing 
and a structured interview. Neuropsychological testing was 
administered in accordance with standardized administration 
procedures as described in the respective test administration 
manuals. The testing protocol included the administration of 
the WMS-R, Logical Memory, part I and the WMS-R, Visual 
Reproduction, part I. Part II was to be administered 30 
minutes following part I. Thus, during the intervening 
minutes, the Shipley Institute of Living, Grooved Pegboard, 
and Trail Making Tests A and B were typically administered. 
Following the administration of the WMS-R, Logical and Visual 
Reproduction scales, part II, the Reitan-Indiana Aphasia 
Screening and the WURS-25 were administered. At the 
completion of the neuropsychological testing, participants 
were asked for their permission to share the results of their 
neuropsychological testing with the clinical staff of the 
hospital. If they did not, they were told it would not 
affect their stay or discharge at the hospital. The consent 
was placed at this location in the protocol for two reasons. 
First, at the time that the testing was completed, the
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participant would know exactly of what the neuropsychological 
tests consisted and his performance on the tests and, thus, 
whether or not he would want the results shared with the 
hospital staff. Second, as interview questions regarding 
such topics as substance abuse and criminal history would 
remain confidential, placing the consent to share clinical 
testing results anywhere other than between the testing and 
interviewing phases would tend to confuse participants about 
what information would remain confidential and what would be 
shared with the hospital staff.
The structured interview began with the 
neuropsychological history. The three scales of the 
Addiction Severity Index were completed using an open-ended 
interview format. The Rating of Medication Influences (ROMI) 
was administered to participants who had been prescribed a 
psychotropic medication prior to their admission and who had 
not decompensated or fatigued. The Premorbid Adjustment 
Scale was then completed.
At the completion of the interview, the interviewer 
completed a certificate of participation and presented it to 
the participant. Participants were debriefed and asked if 
they had any questions about the research, the testing or the 
interviews. Participants who expressed an interest in the 
results of their testing were told that the neuropsychologist 
would be available to interpret the test results to them, if
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they would like them interpreted. About 10% of participants 
(generally those with higher functioning) requested that 
their testing results be interpreted to them. The 
interviewer referred each request to the neuropsychological 
service. Participants were told that their assistance was 
greatly appreciated. Before the end of each interview, the 
interviewer made certain that the participant understood how 
he could access his six dollar payment. When the interview 
was completed, the interviewer walked each participant back 
to his ward and, again, thanked him for his participation.
Following the interview, participant charts were 
reviewed. Demographic information such as race, date of 
birth, date of admission, number of admissions, diagnoses, 
medications, and urinalysis results were recorded.
Following patient discharge, the chart was again 
reviewed to identify relevant follow-up information such as 
patient address, community aftercare agency referral, 
appointment dates, and point of contact at the agency.
Between two and four months following discharge, 
follow-up questionnaires were mailed to patients and agency 
staff.
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Analysis Strategy 
Descriptive statistics were performed in reviewing 
neuropsychological profiles. In order to assess the first 
hypothesis, MANOVAs were performed examining the three 
diagnostic categories with performance on neuropsychological 
tests and background data. Pearson's Product-moment 
correlations were performed between admissions and other 
variables. Those variables identified to correlate most 
strongly with recidivism were utilized in the calculation of 
backward, step-wise multiple regression equations in order to 
determine the degree to which recidivism could be predicted 
for each diagnostic group. In order to determine factor 
loadings of the neuropsychological tests, a principal 
components factor analysis with varimax rotation was used.
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Results
Participant Demographics
Demographic variables were identified. These included: 
age, number of documented hospitalizations; educational 
level; grades; racial composition; history of head injuries; 
neuropsychological risk factors such as cardiovascular 
accidents (CVAs), infectious diseases such as encephalitis, 
meningitis, and sexually transmitted diseases; degenerative 
diseases including Alzheimer's disease, Parkinson's disease 
and HIV; seizure disorders; hand dominance; and alertness at 
the time of the testing protocol.
The mean age of the sample was 35.64 {SD = 9.42) and 
ranged from 19 to 60. The mean age of the Psychotic 
Disorders Group (PDG) was 35.53 (SD = 9.96). The mean age of 
the Affective Disorders Group (ADG) was 36.50 (SD = 11.11). 
Among the personality disorders group (PDOG), the mean age 
was 35.17 (SD = 8.07). Differences in age between groups 
were not significant.
The number of documented hospitalizations was recorded. 
The mean number of hospitalizations recorded was 4.03 (SD =
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4.73) and ranged from 1 to 25. Among the PDG, the mean 
recorded hospitalizations was 6.59 (SD = 6.00) and ranged 
from 1 to 25. Among the ADG, the mean was 4.47 {SD = 5.36) 
and ranged from 1 to 23. Among the PDOG, the mean was 2.27 
{SD = 2.10) and ranged from 1 to 10. Refer to Figure 1.
The mean educational level of the sample was 11.17 {SD 
= 2.68) and ranged from 4 to 18 years. The PDG averaged 
10.44 {SD - 1.92) years of education. The ADG averaged 11.88
{SD = 2.63) years. The PDOG averaged 11.12 (SD = 2.97)
years. Refer to Figure 2.
The mean reported grade point average (GPA) of the 
sample for their most recent educational institution was 2.40 
(SD = .75) with a full range (0 to 4). The mean reported GPA
among the PDG was 2.01 (SD = .81) and ranged from 0 to 3.50.
The mean reported GPA among the ADG was 2.64 (SD = .63) and 
ranged from 1.7 0 to 3.90. The mean reported GPA among the 
PDOG was 2.47 (SD = .65) and ranged from 1.50 to 4.00. Refer 
to Figure 3.
The racial composition of the sample was 39.9% 
Caucasians, 58.0% African Americans and 2.2% other. Among 
the PDG, 37.1% were Caucasian and 62.9% were African 
American. Among the ADG, 52.6% were Caucasian, 42.1% were 
African American and 5.3% were other. Among the PDOG, 33.8% 
were Caucasian, 64.6% were African American, and 1.5% was
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Asian. The difference in diagnosis by race should be noted. 
Refer to Figure 4.
Participants' reported history of head injuries were 
recorded. No head injuries were reported by 63 (41.7%) 
participants. Minor head injuries were reported by 44 
(29.1%) participants. Moderate head injuries were reported 
by 23 (15.2%) participants. Severe head injuries were 
reported by 13 (8.6%) participants. No information was 
obtained on 5 participants. Among the PDG, 19 (47.5%) 
reported no head injuries, 12 (30.0%) reported minor head 
injuries, 4 (10.0%) reported moderate head injuries, and 1 
(2.5%) reported severe head injuries. Among the ADG, 17 
(40.5%) reported no head injuries, 13 (31.7%) reported mild 
head injuries, 5 (11.9%) reported moderate head injuries and 
6 (14.3%) reported severe head injuries. Among the PDOG, 27 
(40.9%) reported no head injuries, 19 (28.8%) reported minor 
head injuries, 14 (21.2%) reported moderate head injuries and 
6 (9.1%) reported severe head injuries.
Participant history of select neuropsychological risk 
factors was recorded. Among all participants, 2 (1.3%) 
reported CVAs, 16 (10.6%) reported infectious diseases, 5 
(3.3%) reported degenerative disorders, 13 (8.6%) reported a 
history of non-substance-induced seizures, and no 
participants reported cancer. Among the PDG, 1 (2.5%) 
reported CVAs, 3 (7.5%) reported infectious diseases, 2 (5.5) ;
38
reported degenerative disorders, and 5 (12.5%) reported 
seizures. Among the ADG, 2 (4.8%) reported CVAs, 4 (9.5%) 
reported infectious diseases, 2 (4.8%) reported degenerative 
disorders, and 5 (11.9%) reported seizures. Among the PDOG,
0 reported CVAs, 9 (13.6%) reported infectious diseases, 1 
(1.5%) reported a degenerative disorder and 3 (4.5%) reported 
seizures. Refer to Figure 5.
Hand dominance was observed. Right-hand dominance was 
observed and confirmed by 118 (81.9%) participants. Left-
hand dominance was observed and reported by 2 6 (18.1%) 
participants. Hand dominance was unavailable on 4 
participants. Hand dominance rates were found to be 
approximately the same across the three diagnostic 
conditions.
Interviewer observations of participants* alertness 
were recorded. Alertness characterized 121 (80.1%) 
participants. Fatigue characterized 11 (7.3%) participants. 
Inattentive characterized 3 (2.0%) participant. Confusion 
characterized 10 (6.6%) participants. Of the 24 participants 
who were not characterized as alert, 13 were from the PDG, 5 
were from the ADG and 6 were from the PDOG.
Substance Abuse Pattern Description
Urinalysis testing was performed and available on 8 6
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participants. Results were negative for all substances among 
45 (52.3%) participants. Opiates were detected in 2 (1.3%) 
participants. Barbiturates were detected in 4 (4.7%)
participants. Benzodiazapines were detected in 21 (23.3%) 
participants. Because barbiturates and benzodiazapines are 
frequently administered for medical reasons to the mentally 
ill and substance abusers in withdrawal, further analysis of 
these two substances were not performed. Cocaine was 
detected in 18 (21.0%) participants. Cannabis was detected
in 9 (10.5%) participants. Among the PDG, no opiates, 
cocaine or cannabis were detected in any participants. Among 
the ADG, opiates were detected in 1 (4.2%) participant, 
cocaine was detected in 5 (20.8%) participants, and cannabis
was detected in 2 participants (8.3%). Among the PDOG, 
opiates were detected in 1 (2.1%) participant, cocaine was 
detected in 13 (27.6%) participants, and cannabis was 
detected in 7 participants (14.9%). Refer to Figure 6.
Recent substance abuse was identified, having been 
defined as the number of days during the 30 which preceded 
hospital admission. The mean number of days that 
participants reported that they consumed alcoholic beverages 
in the 30 days prior to treatment was 11.59 (SD * 12.22) and 
ranged from 0 to 30. The PDG (M  = 10.69, SD = 12.14) and ADG 
(M  = 8.55, SD = 10.53) reported consuming alcohol less
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frequently than the PDOG (M  = 14.00, SD = 12.88). Refer to 
Figure 7.
The mean number of recent days that participants 
reported that they consumed alcoholic beverages to the point 
of intoxication was 6.87 (SD = 11.05). The PDG averaged 7.03 
(SD = 11.53) days of intoxication. The ADG averaged 6.12 (SD 
= 10.15). The PDOG averaged 7.28 (SD = 11.49). Refer to 
Figure 8.
The mean number of years which participants reported 
that they consumed alcoholic beverages was 19.79 (SD = 10.09) 
and ranged from 0 to 50 years. The PDG, on average, reported 
consuming alcoholic beverages 19.29 (SD = 11.36) years. The 
ADG reported, on average, 21.10 (SD = 10.33) years. The 
PDOG, reported, on average, 19.18 (SD = 9.3 6) years. Refer 
to Figure 9.
The mean number of years in which participants reported 
consuming alcoholic beverages to the point of intoxication 
was 17.36 (SD = 11.34) and ranged from 0 to 50. The PDG, on 
averaged, reported 17.30 (SD = 12.33) years. The ADG 
reported, on average, 20.08 (SD - 11.09) years. The PDOG, 
reported, on average 15.45 (SD = 10.95) years. Refer to 
Figure 10.
Heroin was reported to have been used an average of
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0.26 (SD = 2.54) days during the recent 30 days prior to 
admission. However, heroin was reported to be used by only 5 
participants during the 30 days prior to treatment 
distributed across the diagnostic groups. Refer to Figure 
11. Methadone was reported by 1 participant to have been 
used on 1 day during the 30 days prior to treatment. Other 
opiates were reported to have been used by 2 participants 
during the 30 days prior to treatment.
Lifetime heroin use was reported to average 1.07 years 
(SD = 3.34). It was reported by 38 (28.1%) participants. 
Among the PDG, 4 (12.5%) participants reported use. Among 
the ADG, 12 (28.6%) participants reported use. Among the
PDOG, 22 (33.3%) participants reported use. Lifetime 
methadone use was reported by 8 participants. Among the PDG, 
2 (6.3%) participants reported use. Among the ADG, 4 (9.5%) 
participants reported use. Among the PDOG, 2 (3.0%) reported 
use. Lifetime non-medicinal use of other opiates was 
reported by 2 8 participants. Among the PDG, 5 (15.2%) 
participants reported lifetime use. Among the ADG, 10 
(23.8%) participants reported lifetime use. Among the PDOG, 
13 (19.7%) reported lifetime use. Refer to Figure 12.
Recent barbiturate use averaged .08 days in the 
previous 30. days. Barbiturate use was reported by only 2 
participants, who averaged 5.5 days of use during the 30 days
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prior to treatment. Lifetime use of barbiturates was 
reported by 23 participants. Among the PDG, 4 (12.1%) 
participants reported lifetime use. Among the ADG, 7 (16.7%) 
participants reported lifetime use. Among the PDOG, 12 
(18.2%) participants reported lifetime use. Refer to Figure 
13.
The average number of days of sedative use in the 
previous 30 days was reported to be 0.92 (SD = 4.90) . The 
recent use of sedatives or tranquilizers was reported by 5 
participants, including 1 from each the psychotic and ADGs 
and 3 from the PDOG. The lifetime use of sedatives or 
tranquilizers was reported by 2 6 participants. Among the 
PDG, 5 (15.3%) reported lifetime use. Among the ADG, 10 
(23.8%) reported lifetime use. Among the PDOG, 11 (16.7%) 
reported lifetime use. Refer to Figure 14.
Recent cocaine use was reported to have been used on an 
average of 4.75 days. It was reported to have been used 
during this time by 61 (43.3%) participants. Among the PDG, 
the mean days of cocaine use was 2.82 (SD = 8.73). A total 
of 6 (18.2%) participants reported recent cocaine use. Among 
the ADG, the mean days of use was 4.38 (SD = 7.95). A total 
of 17 (40.5%) participants reported recent cocaine use.
Among the PDOG, the mean days of use was 5.95 (SD — 8.46). A 
total of 38 (57.6%) participants reported recent cocaine use.
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Refer to Figure 15 for prevalence of use summary. Refer to 
Figure 16 for mean days of use summary.
The mean number of years of use of cocaine reported by 
participants was 4.94 (SD = 6.09) and ranged from 0 to 32 
years. Lifetime use was reported by 104 (73.8%) 
participants. Among the PDG, the mean was 2.68 (SD = 4.70) 
years. A total of 18 (54.5%) participants reported use.
Among the ADG, the mean was 5.85 (SD = 7.90) years. A total 
of 2 9 (69.0%) participants reported use. Among the PDOG, the 
mean was 5.49 (SD = 5.13). A total of 57 (86.4%) 
participants reported use. Refer to Figure 17 for prevalence 
of use summary. Refer to Figure 18 for mean number of years 
summary.
The route of cocaine administration has important 
diagnostic implications and was identified among 87 
participants who reported using cocaine. Primary nasal 
administration was reported by 12 (13.8%) participants.
Primary smoking administration was reported by 62(71.3%) 
participants. Intravenous injection was reported by 10 
(11.4%) participants. Ingestion was reported by 3(3.4%) 
participants. Among those who reported cocaine route of 
administration, the PDG and ADG reported smoking and nasal 
administration at about the same rate; the PDOG was more 
likely to report smoking cocaine. Refer to Figure 19.
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Amphetamines were reported to have been used by 1 
psychotic participant 4 times recently. Amphetamines were 
reported to have been used an average of 1.58 (SD = 4.91) 
years. Lifetime use of amphetamines was reported by 3 9 
(27.7%) participants. Among the PDG, 7 (21.2%) participants 
reported lifetime use. Among the ADG, 14 (33.3%) 
participants reported lifetime use. Among the PDOG, 18 
(27.3%) reported lifetime use. Refer to Figure 20.
Cannabis was reported to have been used an average of 
2.83 (SD = 7.39) days in the 30 days prior to admission. 
Recent cannabis use was reported by 34 (23.9%) participants. 
Among the PDG, 5 (14.7%) reported recent use. Among the ADG, 
14 (33.3%) reported recent use. Among the PDOG, 15 (22.7%)
reported recent use. Lifetime cannabis use was reported by 
114 (80.9%) participants. Among the PDG, 19 (57.6%) reported 
use. Among the ADG, 38 (90.5%) reported use. Among the 
PDOG, 57 (86.4%) reported use. Refer to Figure 21.
Hallucinogens were reported to have been used by 4 
(2.8%) participants during the 30 days prior to treatment. 
Lifetime hallucinogen use averaged 2.11 (SD = 5.18) years and 
was reported by 53 (37.9%) participants. Among the PDG, 10 
(31.3%) reported lifetime use. Among the ADG, 20 (47.6%) 
reported use. Among the PDOG, 23 (34.8%) reported use.
Refer to Figure 22.
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Inhalant use during the 30 days prior to treatment was 
denied by all participants. The average length of inhalant 
use was 0.5 6 {SD = 2.48) years. Lifetime inhalant use was 
reported by 23 (16.3%) participants. Among the PDG, 4 
(12.1%) reported lifetime use. Among the ADG, 10 (23.8%) 
reported use. Among the PDOG, 9 (13.6%) reported use. Refer 
to Figure 23.
Recent polysubstance use was defined as the number of 
days on which they consumed more than one substance. 
Polysubstance use averaged 5.08 {SD = 9.00) days and was 
reported by 64 (45.1%) participants. Among the PDG, 8 
(22.9%) reported recent polysubstance abuse. Among the ADG, 
21 (50.0%) reported recent polysubstance abuse. Among the 
PDOG, 35 (53.0%) reported recent polysubstance abuse.
Lifetime polysubstance abuse averaged 10.43 {SD = 9.56) years 
and was reported by 105 (74.5%). Among the PDG, 20 (60.6%) 
reported lifetime polysubstance abuse. Among the ADG, 31 
(73.8%) reported lifetime polysubstance abuse. Among the 
PDOG, 58 (87.9%) reported lifetime polysubstance abuse.
Refer to Figure 24.
The combined recent substance abuse score (CRSAS) was 
determined by summing the number of days of use for each 
substance. On average, participants' CRSAS was 32.05 (SD = 
35.12). This means that, on average, participants reported
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using about 1.07 mind-altering substances per day. Among the 
PDG, the average CRSAS was 23.97 (SD = 38 .08) . Among the
ADG, the average CRSAS was 28.93 (SD = 31.22). Among the
PDOG, the average CRSAS was 37.97 (SD - 35.49). Refer to 
Figure 25.
The reported number of years of use of alcohol and each 
drug were combined to yield a summed lifetime substance abuse 
score (SLSAS). On average, participants' SLSAS was 72.63 (SD 
= 47.98). The average SLSAS of the PDG was 63.20 (SD =
42.2 6) years. The average of the ADG was 8 3.15 (SD = 58.54)
years. The average of the PDOG was 68.60 (SD = 40.5 9) years.
Refer to Figure 26.
The primary substance of abuse, or the major problem, 
was identified. Alcohol abuse or dependence was the primary 
problem among 20 (13.2%) participants, including 5 (14.3%) in 
the PDG, 9 (21.4%) in the ADG, and 6 (9.1%) in the PDOG. 
Barbiturate abuse was the primary problem for 1 (0.7%) 
participant in the ADG. Cocaine abuse or dependence was the 
primary problem among 12 (8.4%) participants, including 2 
(5.7%) in the PDG, 2 (4.8%) in the ADG, and 8 (12.1%) in the 
PDOG. Cannabis abuse or dependence was the primary problem 
for 2 (1.4%) participants in the ADG. Alcohol and drug
dependence was the primary problem for 17 (11.9%) 
participants, including 3 (8.6%) in the PDG. 5 (11.9%) in the
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ADG, and 9 (13.6%) in the PDOG. Polysubstance abuse was the 
primary problem for 83 (58.0%) participants, including 19 
(54.3%) in the PDG, 22 (52.4%) in the ADG, and 42 (63.6%) in 
the PDOG. Refer to Figure 27.
Substance Abuse Pattern Analysis
Six substance abuse pattern variables were believed to 
be important between groups discriminator variables, based on 
clinical observation, interviews with clinical staff, and 
review of descriptive data. These variables were: (1) the
number of days of cocaine use during the 30 days preceding 
hospital admission, (2) the number of days on which multiple 
substances were used during the recent 30 day period, (3) the 
combined recent substance abuse score, (4) the number of 
years of lifetime cocaine use, (5) the number of years during 
which multiple substances were used, and (6) the combined 
lifetime substance abuse score.
These six variables were submitted to multivariate 
analysis of variance (MANOVA). Using Wilks' lambda, between 
groups differences were not found to be significant (F =
1.23048, p = .255). Group differences in years of lifetime 
cocaine use approached significance (F = 2.7715, p = .067). 
Refer to Table 1. Thus, differences in substance abuse 
patterns across diagnostic groups were not significant.
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Substance Abuse Consequences Description
The length of the last period of abstinence was 
recorded. The mean number of months of abstinence reported 
by participants was 9.24 (SD = 20.56). Among the PDG, the 
mean months of abstinence was 16.53 (SD = 34.77). Among the 
ADG, the mean was 4.18 (SD = 6.10). Among the PDOG, the mean 
was 9.32 (SD = 17.74). Refer to Figure 28.
The mean number of months ago that the last period of 
abstinence ended was recorded. This is an inverted method of 
identifying how long participants have been using substances 
in the recent past. The mean number of months in which 
abstinence ended for participants was 16.08 (SD = 34.54). 
Among the PDG, the mean months was 12.22 (SD — 26.58). Among 
the ADG, the mean was 9.54 (SD = 17.02). Among the PDOG, the 
mean was 21.52 (SD = 43.48. Refer to Figure 29.
The frequency of delirium tremens, or DTs, were 
recorded. Participants were asked whether they have had the 
DTs and, if so, how often. DTs were reported an average of
1.57 (SD = 8.71) times. Among the PDG, DTs were reported an 
average of 0.90 (SD = 2.79) times. Among the ADG, DTs were 
reported an average of 1.07 (SD = 2.14) times. Among the 
PDOG, DTs were reported an average of 2.2 0 (SD = 12.35) 
times. Refer to Figure 30.
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The number of incidences in which one reported to have 
overdosed was recorded. The average number of overdose 
incidents was 0.77 (SD = 2.42). Among the PDG, the average 
was 0.81 (SD = 1.12). Among the ADG, the average was 1.32 
(SD = 4.14). Among the PDOG, the average was 0.41 (SD = 
0.96). Refer to Figure 31.
The number of substance abuse treatments were reported. 
The mean number of treatments was 3.65 (SD = 5.42), ranging 
from 1 to 41. Among the PDG, the average was 2.33 (SD =
4.82) . Among the ADG, the average was 3.48 (SZ? * 3.25) .
Among the PDOG, the average was 4.35 (SD = 6.56). Refer to 
Figure 32.
The mean expenditure of participants in a recent, 
typical 30 day period on alcohol was $91.29 (SD - $160.02), 
ranging from $0 to $1,000. The mean expenditure among the 
PDG was $61.95 (SD = $107.92), ranging from $0 to $360. The 
mean among the ADG was $8 6.14 (SD = $183.57), ranging from $0 
to $1,000. The mean among the PDOG was $105.21 (SD = 
$160.51), ranging from $0 to $750. Refer to Figure 33.
The question on drug spending was modified to reflect 
the economic influences of drug dealing and the barter 
economy on the consumption/cost ratio. The question was 
rephrased to "how much was the street value of the drugs 
consumed during this period?" The mean reported street
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value of drugs consumed by participants in a typical 3 0 day 
period was $410.43 (SD = $958.12), ranging from $0 to $8,000. 
The mean expenditure among the PDG was $77.77 (SD = $219.47), 
ranging from $0 to $1,000. The mean among the ADG was 
$344.05 (SD = $618.04), ranging from $0 to $3,000. Among the 
PDOG, the mean was $578.95 (SD — $1,238.85), ranging from $0 
to $8,000. Refer to Figure 34.
Combined monthly spending on alcohol and drugs was 
calculated. The average spending was $513.54 (SD = $994.40). 
The average among the PDG was $143.43 (SD = $244.04). The 
average among the ADG was $442.08 (SD = $625.13). The 
average among the PDOG was $695.02 (SD - $1,281.25). Refer 
to Figure 35.
Combined spending on drugs and alcohol appeared to be 
rather high in a population many of whom are on a fixed 
government disability pension. Thus, further analyses were 
performed. Among 8 6 participants who reported not receiving 
a pension, the mean combined spending was $619.28 (SD = 
$1,115.61). Among 24 participants who reported receiving a 
pension, the mean combined spending was $157.29 (SD =
187.73). The combined substance use spending between those 
receiving and not receiving a pension was submitted to an 
analysis of variance. The difference between these groups 
was significant (F = 4.06, p = .046).
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The accuracy of participant self-report due to 
misrepresentation of substance abuse history as well as 
misunderstanding was recorded, based on interviewer 
observation. Among all participants, 43 (30.9%) participants 
were believed to have engaged in misrepresentation regarding 
their substance abuse history, as reported by the 
interviewer. Among all participants, 34 (24.3%) participants 
were believed to provide inaccurate information due to 
misunderstanding.
Based on clinical observation, interviews with clinical 
staff, and review of preliminary data, six variables were 
identified that might serve as useful between groups 
discriminator variables. These variables were: (1) the
length of the participant's last abstinence, (2) the number 
of times the participant experienced the delirium tremens,
(3) the number of times the participant overdosed, (4) 
spending on alcohol in a typical, recent 30 day period, and 
(5) the street value of drugs consumed in a typical, recent 
30 day period.
These variables were submitted to a mulitivariate 
analysis of variance. Using Wilks' lambda, this group of 
variables was not found to be statistically significant (F =
1.11366, p = .351). Only the length of the last period of 
abstinence approached significance (F(2,107) = 2.6471, p =
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.075), suggesting that participants in the PDG may report 
longer periods of recent abstinence than participants in 
either the personality disorders or the ADGs. Refer to Table 
2. Thus, differences on substance abuse consequences 
variables were not significant across diagnostic conditions.
Criminal History Description
Participants were asked whether their current admission 
was prompted by the criminal justice system. Only 22 (17.7%)
reported that it had been. Participants were then asked 
whether they were currently on probation or parole. Again,
2 2 participants reported that they were currently on 
probation or parole.
Participants were asked whether they had ever been 
charged with various crimes. It is noteworthy that 20 
(15.4%) participants reported no history of felony, 
misdemeanor or summary offense arrests. A total of 110 
(84.6%) participants reported a total estimate of 1,099 
felony, misdemeanor or summary offense arrests.
Shoplifting charges were reported by 30 (21.6%) 
participants a total of 64 times. Probation or parole 
violations were reported by 12 (8.7%) participants a total of
14 times. Drug charges were reported against 21 (18.7%) 
participants a total of 31 times. Forgery charges were
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reported against 5 (3.6%) participants a total of 6 times. 
Weapons-related charges were reported against 20 (14.4%)
participants a total of 30 times. Breaking and entering, 
burglary or larceny charges were reported against 32 
participants a total of 4 0 times. Robbery charges were 
reported against 9 (6.5%) participants a total of 11 times. 
Assault charges were reported against 38 (27.3%) participants
a total of 114 times. Arson charges were reported against 4 
(2.9%) participants a total of 8 times. Rape charges were 
reported against 2 (1.4%) a total of 2 times. Homicide or 
manslaughter charges were reported to have been filed against 
4 participants a total of 5 times. Prostitution charges were 
reported against 1 participant twice. Contempt charges were 
reported against 16 (11.6%) participants a total of 51 times. 
Disorderly conduct, drunk in public and vagrancy were 
combined as a single variable on the ASI. A total of 63 
(45.7%) participants reported such charges a total of 596 
times. DWI charge were reported against 50 (36.0%)
participants a total of 97 times with DWI. Refer to Figure 
36.
The overall average length of time in which 
participants served in jail was 12.2 4 {SD = 27.54) months. A 
total of 74 (54.0%) participants reported that they had 
served time in jail. The overall average length of the last
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jail term was 5.12 (SD = 16.54) months. Participants were
asked whether they were awaiting charges or sentencing. A
total of 21 (15.2%) participants reported that they were 
awaiting charges or sentencing. A total of 15 participants 
reported that they had been incarcerated at some time in the
30 days prior to hospital admission. A total of 22 
participants admitted to engaging in some form of illegal 
activity for profit in the typical month prior to hospital 
admission.
Interviewers' perceptions of participant 
misrepresentation to legal questions were recorded. It was 
believed that 19 (13.8%) participants engaged in 
misrepresentation to legal questions. Observations of 
participant misunderstanding over legal questions were 
recorded. It was believed that 2 0 (14.5%) participants had 
some misunderstanding regarding legal questions.
Criminal History Analysis
The following variables were submitted to multivariate 
analysis of variance: times charged with crimes, the sum
arrests variable, whether the current admission was prompted 
by the criminal justice system, years in jail during 
lifetime, the number of days in the previous 30 in which the 
participant was in jail, and the total estimated number of
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crimes committed in a recent, typical 30 day period. These 
criminal history variables were found to be significant using 
Wilks' lambda (F = 1.46658, p = .048). The number of charges 
for robbery approached significance (F(2,110) = 2.71588, p = 
.071). Refer to Table 3. Generally, the PDOG reported 
somewhat more arrests than the other two groups.
Psychiatric Status Description
Participants were asked to recall the number of 
inpatient psychiatric admissions. The mean number of 
admissions reported of all participants was 5.02 (SD — 8.24), 
and ranged from 1 to 70. Participant reports of admissions 
correlated .5631 (p = .000) with computerized statewide 
psychiatric admission records. The average reported 
psychiatric admissions by the PDG was 8.07 (SD = 6.15), and 
ranged from 1 to 21. The average reported by the ADG was 
6.98 (SD = 12.82), and ranged from 1 to 70. The average 
reported by the PDOG was 2.38 (SD = 2.99), and ranged from 1 
to 15. Refer to Figure 37.
Receipt of a psychiatric disability pension was 
reported by 36 (27.1%) participants. Among the PDG, 19 
(63.3%) participants report receiving a psychiatric pension. 
Among the ADG, 12 (30%) participants reported receiving a
psychiatric pension. Among the PDOG, 5 (7.9%) participants
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reported receiving a psychiatric pension. Refer to Figure 
38.
Participants were asked whether they had experienced a 
number of psychiatric symptoms in the previous 30 days. 
Depressed feelings were reported by 101 (74.8%) participants. 
Depressed feelings were reported by 18 (58.1%) PDG 
participants. Depressed feelings were reported by 31 (75.6%) 
ADG participants. Depressed feelings were reported by 52 
(82.5%) PDOG participants. Refer to Figure 39.
Anxiety was reported by 102 (75.6%) participants in the
previous 30 days. Among the PDG, 18 (58.1%) reported 
anxiety. Among the ADG, 33 (80.5%)reported anxiety. Among 
the PDOG, 51 (81.0%) reported anxiety. Again, refer to 
Figure 39.
A total of 44 (32.6%) participants reported 
hallucinations in the previous 30 days. Among the PDG, 13 
(41.9%) reported hallucinations. Among the ADG, 18 (43.9%)
reported hallucinations. Among the PDOG, 13 (20.6%) reported 
hallucinations. Again, refer to Figure 39.
A total of 8 9 (65.9%) participants reported that they 
had recently experienced memory problems and related 
cognitive problems. Among the PDG, 23 (74.2%) reported such
problems. Among the ADG, 2 6 (63.4%) reported such problems. 
Among the PDOG, 40 (63.5%) reported such problems. Again, 
refer to Figure 39.
57
When asked whether they have had difficulty controlling 
violent behavior in the past 30 days, 35 (25.9%) reported 
such difficulty. Among the PDG, 5 (16.1%) reported such 
difficulty. Among the ADG, 12 (29.3%)reported such 
difficulty. Among the PDOG, 18 (28.6%)reported such
difficulty. Refer to Figure 39.
A total of 68 (50.4%) participants admitted that they
had seriously thought of committing suicide in the previous 
30 days and 31 (29.5%) participants admitted to an attempt. 
Among the PDG, 14 (45.2%) admitted suicidal thoughts and 5 
(16.1%) admitted to an attempt. Among the ADG, 21 (51.2%) 
admitted suicidal thoughts and 11 (26.8%) admitted to an 
attempt. Among the PDOG, 33 (52.4%) admitted suicidal 
thoughts and 23 (36.5%) admitted to an attempt. Refer to 
Figure 39.
A  total of 26 (20.2%) participants were suspected of 
engaging in misrepresentation on their psychiatric status. A 
total of 22 (17.1%) of participants were believed by
interviewers to have misunderstood portions of the 
psychiatric status interview.
Psychiatric Status Analysis
The following psychiatric status variables were 
selected for submission to multivariate analysis of variance:
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number of psychiatric hospital admissions, whether the 
participant received a pension for a psychiatric disability, 
as well as interviewer and participant self-reports of 
depression, anxiety, hallucinations, impaired cognitive 
functioning, violent outbursts, suicidal thinking, suicidal 
behavior, and psychotropic medication administration were 
selected for submission to multivariate analysis of variance. 
Between groups differences were observed using Wilks' lambda 
(F = 3.24946, p = .000). Between groups differences were 
found to be significant on the reported number of psychiatric 
hospital admissions (F(2,114) = 10.85908, p  = .000), receipt 
of a psychiatric pension (F(2, 114) = 25.54104, p = .000), 
recent anxiety (F(2,114) = 3.33103, p = .039), recent 
hallucinations (F(2,114) = 4.22296, p = .017), psychotropic 
medication administration (F(2,114) = 12.50519, p = .000), 
interviewer observations of psychotic behavior (F(2,114) = 
11.41181, p = .000), and interviewer observations of 
cognitive impairment (F(2,114) = 3.12811, p = .048). In 
addition, recent depression was found to approach 
significance (F(2,114) = 2.63015, p_ = .076). Refer to Table 
4.
Neuropsychological Functioning
The results of the neuropsychological measures reported
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below are summarized in one table. The interested reader is 
referred to Table 5.
Neuropsychological Functioning on the WMS-R
The Wechsler Memory Scale - Revised, Logical Memory 
Scale was administered to participants. The mean score on 
the WMS-R Logical Memory I was 15.5 9 (SD — 6.52). Scores 
ranged from 0 to 32. The mean corresponding WMS-R Logical 
Memory I percentile score was 17.79 (SD = 16.44), indicating 
mild impairment. Percentile scores ranged from 1 to 81.
Among the PDG, the mean score on the WMS-R Logical Memory I
was 10.35 (SD = 6.44). Scores ranged from 2 to 29. The mean
corresponding WMS-R Logical Memory I percentile score was 
8.61 (SD = 14.6), indicating mild impairment. Percentile 
scores ranged from 1 to 62. Among the ADG, the mean score on 
the WMS-R Logical Memory I was 17.81 (SD = 5.40). Scores 
ranged from 6 to 27. The mean corresponding WMS-R Logical 
Memory I percentile score was 21.13 (SD = 17.44), indicating 
mild impairment. Percentile scores ranged from 2 to 59. 
Among the PDOG, the mean score on the WMS-R Logical Memory I
was 17.11 (SD = 5.64). Scores ranged from 0 to 32. The mean
corresponding WMS-R Logical Memory I percentile - score was
20.14 (SD = 15.20), indicating mild impairment. Percentile 
scores ranged from 1 to 81. For a summary of raw scores,
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refer to Figure 40. For a summary of percentile scores, 
refer to Figure 41.
The WMS-R Logical Memory II was administered to all 
participants. The mean score on the WMS-R Logical Memory II 
was 11.14 (SD = 6.57). Scores ranged from 0 to 25. The mean 
corresponding WMS-R Logical Memory II percentile score was 
18.37 (SD — 15.90), indicating mild impairment. Percentile 
scores ranged from 1 to 61. Among the PDG, the mean score on 
the WMS-R Logical Memory II was 6.78 (SD = 6.72). Scores 
ranged from 0 to 25. The mean corresponding WMS-R Logical 
Memory II percentile score was 10.91 (SD = 15.51), indicating 
mild impairment. Percentile scores ranged from 1 to 61.
Among the ADG, the mean score on the WMS-R Logical Memory II 
was 12.86 (SD = 5.75). Scores ranged from 0 to 24. The mean 
corresponding WMS-R Logical Memory II percentile score was
20.30 (SD = 15.66), indicating mild impairment. Percentile 
scores ranged from 1 to 59. Among the PDOG, the mean score 
on the WMS-R Logical Memory II was 12.48 (SD = 5.94). Scores 
ranged from 0 to 23. The mean corresponding WMS-R Logical 
Memory II percentile score was 20.86 (SD = 15.33), indicating 
mild impairment. Percentile scores ranged from 1 to 56. For 
a summary of raw scores, refer to Figure 42. For a summary 
of percentile scores, refer to Figure 43.
The WMS-R Visual Memory I was administered to all
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participants. The mean score on the WMS-R Visual Memory I 
was 26.22 (SD = 8.7 6). Scores ranged from 2 to 41. The mean 
corresponding WMS-R Visual Memory I percentile score was 
32.90 (SD = 30.91), indicating generally no impairment. 
Percentile scores ranged from 1 to 99. Among the PDG, the 
mean score on the WMS-R Visual Memory I was 19.11 (SD =
9.82). Scores ranged from 2 to 38. The mean corresponding 
WMS-R Visual Memory I percentile score was 17.77 (SD =
27.97), indicating mild impairment. Scores ranged from 1 to 
90. Among the ADG, the mean score on the WMS-R Visual Memory 
I was 2 8.95 (SD — 1.28) . Scores ranged from 13 to 41. The 
mean corresponding WMS-R Visual Memory I percentile score was 
41.20 (SD = 32.88), indicating no impairment. Percentile 
scores ranged from 1 to 99. Among the PDOG, the mean score 
on the WMS-R Visual Memory I was 28.46 (SD = 6.66). Scores 
ranged from 9 to 38. The mean corresponding WMS-R Visual 
Memory I percentile score was 34.87 (SD — 28.72), indicating 
generally no impairment. Percentile scores ranged from 1 to 
96. For a summary of raw scores, refer to Figure 44. For a 
summary of percentile scores, refer to Figure 45.
The WMS-R Visual Memory II was administered to all 
participants. The mean score on the WMS-R Visual Memory II 
was 21.67 (SD = 10.62). Scores ranged from 0 to 41. The 
mean corresponding WMS-R Visual Memory II percentile score
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was 30.42 (SD = 29.15), indicating generally no impairment. 
Percentile scores ranged from 1 to 99. Among the PDG, the 
mean score on the WMS-R Visual Memory II was 13.11 (SD = 
10.75). Scores ranged from 0 to 34. The mean corresponding 
WMS-R Visual Memory II percentile score was 12.00 (SD = 
20.35), indicating mild impairment. Scores ranged from 1 to 
69. Among the ADG, the mean score on the WMS-R Visual Memory 
II was 24.29 (SD = 9.55) . Scores ranged from 0 to 41. The 
mean corresponding WMS-R Visual Memory II percentile score 
was 36.93 (SD - 30.22), indicating generally no impairment. 
Percentile scores ranged from 1 to 99. Among the PDOG, the 
mean score on the WMS-R Visual Memory II was 2 4.83 (SD = 
8.48). Scores ranged from 2 to 38. The mean corresponding 
WMS-R Visual Memory II percentile score was 35.44 (SD — 
28.72), indicating generally no impairment. Percentile 
scores ranged from 1 to 95. For a summary of raw scores, 
refer to Figure 46. For a summary of percentile scores, 
refer to Figure 47.
Analysis of Neuropsychological Functioning on the WMS-R
The raw scores on the Wechsler Memory Scale - Revised, 
Logical Memory Scale I and II as well as the Visual 
Reproduction Scale I and II were submitted to multivariate 
analysis of variance. Between groups differences were found
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to be significant using Wilks' lambda, (F = 6.76590, p = 
.000). Between groups differences on each of the four 
variables were found to be significant: Logical I (F(2,138)
= 19.57420, p = .000), Logical II (F(2,138) = 11.94966, p  = 
.000), Visual Reproduction I (F(2,138) = 20.36195, p = .000), 
and Visual Reproduction II (F(2,138) = 20.01054, p = .0000). 
Refer to Table 6.
The percentile scores on the Wechsler Memory Scale - 
Revised, Logical Memory I and II as well as Visual 
Reproduction I and II were submitted to multivariate analysis 
of variance. Using Wilks' lambda, the group differences in 
percentile scores were found to be significant (F = 3.11362, 
p  = .002). Between groups differences were found to be 
significant on the four variables: Logical I (F(2,128) = 
6.59078, p  = .002), Logical II (F(2,128) = 4.04675, p  =
.020), Visual Reproduction I (F(2,128) = 5.53912, p = .005) 
and Visual Reproduction II (F(2,128) = 8.42293), p = .000). 
Refer to Table 7.
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Neuropsychological Functioning on the Shipley
Institute of Living
The Shipley Institute of Living (SIL) was administered 
to participants. The SIL consists of a verbal scale, an 
abstraction scale, a total score, and an estimated 
intelligence quotient.
The SIL verbal scale was administered to participants. 
The mean score was 21.49 (SD = 7.75) . Scores ranged from 0 
to 40. The mean corresponding T-score on the SIL verbal 
scale was 35.81 (SD — 13.03), indicating mild impairment. T- 
scores ranged from 10 to 69. Among the PDG, the mean SIL 
verbal scale score was 17.50 (SD = 8.78). Scores ranged from
0 to 30. The mean corresponding T-score on the SIL verbal 
scale was 30.32 (SD = 13.71), indicating mild-to-moderate 
impairment. T-scores ranged from 10 to 52. Among the ADG, 
the mean SIL verbal scale score was 23.14 (SD = 7.75).
Scores ranged from 6 to 37. The mean corresponding T-score 
on the SIL verbal scale was 39.67 (SD = 13.41), indicating 
no-to-mild impairment. T-scores ranged from 11 to 62. Among 
the PDOG, the mean SIL verbal scale score was 22.21 (SD = 
7.46). Scores ranged from 7 to 40. The mean corresponding 
T-score on the SIL verbal scale was 35.70 (SD = 12.00), 
indicating mild impairment. Scores ranged from 11 to 69.
For a summary of raw and T-scores, refer to Figure 48.
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The SIL abstraction scale was administered to 
participants. The mean score was 16.55 (SD = 9.54). Scores 
ranged from 0 to 40. The mean corresponding T-score on the 
SIL abstraction scale was 43.88 (SD = 10.45), indicating no 
impairment. T-scores ranged from 14 to 67. Among the PDG, 
the mean SIL abstraction scale score was 11.3 6 (SD — 6.90). 
Scores ranged from 0 to 26. The mean corresponding T-score 
on the SIL abstraction scale was 38.52 (SD = 7.81), 
indicating mild impairment. T-scores ranged from 1 to 56. 
Among the ADG, the mean SIL abstraction scale score was 19.22 
(SD = 9.31). Scores ranged from 4 to 40. The mean 
corresponding T-score was 46.09 (SD = 11.12), indicating no 
impairment. T-scores ranged from 14 to 67. Among the PDOG, 
the mean SIL abstraction scale score was 17.12 (SD = 9.91). 
Scores ranged from 0 to 40. The mean corresponding T-score 
was 44.53 (SD = 10.37), indicating no impairment. T-scores 
ranged from 27 to 66. For a summary of raw and T-scores, 
refer to Figure 49.
The SIL Total Score combines the raw scores of the 
verbal and abstraction scales. The mean score was 38.21 (SD 
= 15.50). Scores ranged from 8 to 77. The mean 
corresponding T-score on the SIL Total was 39.51 (SD =
11.41), indicating no to mild impairment. T-scores ranged 
from 17 to 66. Among the PDG, the mean SIL Total Score was
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29.16 {SD = 12.92). Scores ranged from 8 to 55. The mean 
corresponding T-score on the SIL Total was 33.14 (SD =
10.09), indicating mild impairment. T-scores ranged from 17 
to 53. Among the ADG, the mean SIL Total Score was 42.74 {SD 
= 15.98). Scores ranged from 10 to 77. The mean 
corresponding T-score on the SIL Total was 42.97 {SD =
11.33), indicating no impairment. T-scores ranged from 21 to 
66. Among the PDOG, the mean SIL Total Score was 3 9.33 {SD 
= 14.89). Scores ranged from 9 to 70. The mean 
corresponding T-score on the SIL Total was 3 9.84 {SD =
11.12), indicating no to very mild impairment. T-scores 
ranged from 18 to 63. For a summary of raw and T scores, 
refer to Figure 50.
The SIL Total Score provides an estimate of the 
participant’s intelligence. The mean SIL estimated IQ of 
participants was 83.35 {SD = 16.01). Estimated IQ scores 
ranged from 47 to 119. Among the PDG, the mean SIL estimated 
IQ was 74.24 {SD = 14.81). Estimated IQ scores ranged from 
49 to 100. Among the ADG, the mean SIL estimated IQ was
87.15 {SD = 16.04). Estimated IQ scores ranged from 47 to 
119. Among the PDOG, the mean SIL estimated IQ was 84.51 
{SD = 15.39). Estimated IQ scores ranged from 50 to 115. 
Refer to Figure 51.
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Analysis of Neuropsychological Functioning
on the Shipley Institute of Living
SIL verbal and abstract raw scores were submitted to 
multivariate analysis of variance. Between groups 
differences were significant using Wilks' lambda (F =
3.20629, p = .014). Between group differences were 
significant on each the verbal raw scale (F(2,117) = 4.18740, 
p  = .018) and the abstraction scale (F(2,117) = 5.88575, p = 
.004). Refer to Table 8.
SIL T scores and estimated IQ scores were submitted to 
multivariate analysis of variance. Between groups 
differences were significant using Wilks' lambda (F(2, 108) = 
2.28667, p = .023). Between group differences were 
significant on the SIL abstraction T score (F(2, 108) = 
5.04977, p = .008), the total T score (F(2, 108) = 5.16914, p 
= .007), and the SIL estimated IQ (F(2, 108) = 4.79128, p = 
.01). Refer to Table 9.
Neuropsychological Functioning on the
Trail Making Test A and B
The Trail Making Test A was administered to 
participants. The grand mean was 52.51 (SD = 42.04). Scores 
ranged from 16 to 302. Among the PDG, the mean score on the
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Trails A was 82.17 (SD - 66.81) . Scores ranged from 19 to 
302. Among the ADG, the mean score on the Trails A was 44.19 
(SD = 21.72). Scores ranged from 17 to 143. Among the PDOG, 
the mean score on the Trails A was 42.08 (SD = 2 4.50) .
Scores ranged from 16 to 152. Refer to Figure 52.
The Trail Making Test A corresponding T-scores were 
recorded. The grand mean T-score was 3 6.80 (SD = 12.51), 
indicating mild impairment. The range was from 10 to 68. 
Among the PDG, the mean of the Trails A T-scores was 27.75 
(SD = 11.17), indicating moderate impairment. The range was 
from 10 to 59. Among the ADG, the mean of the Trails A T- 
scores was 37.20 (SD = 9.56), indicating mild impairment.
The range was from 18 to 68. Among the PDOG, the mean of the 
Trails A T-scores was 40.52 (SD = 12.84), indicating no 
impairment. The range was from 14 to 67. Refer to Figure 
52 .
The Trail Making Test B was administered to 
participants. The overall mean was 118.36 (SD = 65.13). The 
range was from 23 to 315. Among the PDG, the mean Trails B 
score was 172.93 (SD = 11.72) . The range was from 66 to 322. 
Among the ADG, the mean Trails B score was 104.63 (SD =
51.84) . The range was from 3 6 to 233. Among the PDOG, the 
mean Trails B score was 103.08 (SD = 53.74). The range was 
from 23 to 2 65. Refer to Figure 53.
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The Trail Making Test B T-scores were recorded. The 
overall mean was 40.15 (SD = 12.56), indicating generally no 
impairment. The range was from 10 to 82. Among the PDG, the 
mean Trails B T-score was 32.50 (SD - 9.13), indicating mild 
impairment. The range was from 14 to 50. Among the ADG, the 
mean Trails B T-score was 41.58 (SD = 11.57), indicating no 
impairment. The range was from 23 to 69. Among the PDOG, 
the mean Trails B T-score was 41.98 (SD = 13.31), indicating 
no impairment. The range was from 10 to 82. Refer to Figure
53.
Neuropsychological Functioning on the Grooved Peghoard
The Grooved Pegboard was administered to participants. 
Using the dominant hand, the grand mean was 101.93 (SD — 
43.21). Scores ranged from 54 to 322. Corresponding T- 
scores were recorded for each score. The mean T-score was 
30.82 (SD = 12.94). T-scores ranged from 2 to 61. Among the 
PDG, the mean GPB-Dominant score was 140.47 (SD = 58.45) . 
Scores ranged from 66 to 322. The mean T-score was 19.86 (SD 
= 9.75) indicating, on average, severe impairment. T-scores 
ranged from 2 to 37. Among the ADG, the mean GPB-Dominant 
score was 90.65 (SD = 23.57) . Scores ranged from 62 to 176. 
The mean t-score was 32.34 (SD = 10.56). T-scores ranged
from 11 to 55. Among the PDOG, the mean GPB-Dominant score 
was 87.85 (SD — 28.31). Scores ranged from 54 to 198. The 
mean T-score was 35.03 (SD = 12.56). T-scores ranged from 9 
to 61. For a summary of raw and T-scores, refer to Figure
54.
The Grooved Peg Board was administered to participants 
using their nondominant hand. The overall mean was 104.94 
(SD = 36.85). Scores ranged from 58 to 292. Corresponding 
T-scores were recorded for each score. The mean T-score was 
30.75 (SD = 11.16), indicating mild to moderate impairment. 
T-scores ranged from 3 to 60. Among the PDG, the mean GPB- 
Nondominant score was 127.66 (SD — 38.60). Scores ranged 
from 75 to 22 9. The mean corresponding T-score was 22.91 
(SD = 9.72), indicating moderate impairment. T-scores ranged 
from 3 to 41. Among the ADG, the mean GPB-Nondominant score 
was 97.02 (SD = 26.23). Scores ranged from 65 to 205. The 
mean T-score was 32.58 (SD = 10.56), indicating mild 
impairment. T-scores ranged from 11 to 55. Among the PDOG, 
the mean GPB-Nondominant score was 99.59 (SD = 38.09).
Scores ranged from 58 to 292. The mean T-score was 32.56 (SD 
= 10.91), indicating mild impairment. Scores ranged from 10 
to 60. For a summary of raw and T-scores, refer to Figure
55.
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Analysis of Neuropsychological Functioning on the 
Trail Making Tests A and B and the Grooved Pegboard 
The raw scores on the Trail Making Tests A and B and 
the Grooved Pegboard, Dominant and Nondominant trials were 
submitted to multivariate analysis of variance. Significant 
group differences were found using Wilks' lambda (F =
4.40318, p = .000). Between group differences were found on 
the Trails A (F(2,116) = 3.46289, p  = .035), Trails B 
(F(2,116) = 9.07862, p = .000), Grooved Pegboard - Dominant 
(F(2,116) = 14.65487, p = .000), and the Grooved Pegboard -
Nondominant (F(2,116) = 4.61354, p = .012). Refer to Table
10.
The T-scores on the Trail Making Tests A and B and the 
Grooved Pegboard, Dominant and Nondominant trials were 
submitted to multivariate analysis of variance. Significant 
group differences were found using Wilks' lambda (F =
3.17407, p  = .002). Between group differences were found on 
the Trails A (F(2,107) = 3.35146, p = .039), Trails B 
(F(2,107) = 3.52186, p = .033), Grooved Pegboard - Dominant 
(F(2,107) = 10.36059, p = .000), and the Grooved Pegboard -
Nondominant (F(2,107) = 3.71238, p = .028). Refer to Table
11.
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Neuropsychological Functioning on the Aphasia Screening
The Reitan-Indiana Aphasia Screening was administered 
to participants. The mean of the total aphasia score was 
3.74 (SD = 4.24). The corresponding T-scores were recorded 
for each total score. The mean of aphasia T-score was 53.95 
(SD - 10.47), indicating normal functioning. Among the PDG, 
the mean number of aphasia errors was 6.40 (SD = 6.07) . The 
mean aphasia T-score was 47.91 (SD - 12.83), indicating no 
impairment. Among the ADG, the mean number of aphasia errors 
was 2.91 (SD = 3.40). The mean aphasia T-score was 55.36 (SD 
= 9.7 6), indicating normal functioning. Among the PDOG, the 
mean number of aphasia errors was 2.84 (SD = 2.80). The 
mean aphasia T-score was 55.83 (SD = 8.78), indicating 
normal functioning. For a summary of raw scores, refer to 
Figure 71. For a summary of T-scores, refer to Figure 56.
Raw and T scores on the Reitan-Indiana Aphasia 
Screening were submitted to a multivariate analysis of 
variance. Significant between group differences were found 
(F = 3.77347, p = .006). Group differences were found in 
both the raw scores (F(2,101) = 7.69232, p = .001) and the T- 
scores (F(2,101) = 5.35022, p = .006). Refer to Table 12.
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Neuropsychological Function and the Wender Utah Rating 
Scale of Childhood Attention Deficit Disorder 
The Wender Utah Rating Scale (WURS-25) was administered 
to participants. The overall mean score was 64.20 (SD =
22.7 9). The range of scores was 25 to 125. Among the PDG, 
the mean score was 64.52 (SD = 23.61). The range was from 25 
to 111. Among the ADG, the mean score was 66.92 (SD =
23.30). The range was from 33 to 125. Among the PDOG, the 
mean score was 62.37 (SD = 22.27) . The range was from 2 6 to 
118. Due to the similarity of scores on this measure, it was 
not submitted to analysis of variance.
Factor Analysis of Neuropsychological Measures
Raw scores on the WMS-R Logical Memory I, Visual 
Reproduction I, Shipley Verbal and Abstraction scales, Trail 
Making Tests A and B, Grooved Pegboard - dominant and 
nondominant, The Reitan Indiana Aphasia Screening, and the 
Wender Utah Rating Scale were submitted to a principal 
components analysis with varimax rotation. An Eigenvalue 
greater than or equal to one was identified as the minimum 
criterion for factor identification. Three factors were 
identified which explained 71.3% of the variance on all 
neuropsychological measures.
Factor 1 loaded heavily on the WMS-R, logical memory as
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well as the Shipley verbal and abstraction scales and appears 
to be a cognitive factor. Factor 2 loaded heavily on the two 
Trail Making and two Grooved Pegboard measures and appears to 
be a psychomotor factor. Factor 3 loaded heavily on the 
Wender Utah Rating Scale and appears to be an attention- 
deficit / freedom from distractibility factor. Refer to 
Table 13.
Rating of Medication Influences (ROMI)
The Rating of Medication Influences (ROMI) was 
administered to participants who reported that they were 
prescribed medication. The mean responses on the compliance 
section questions were: #1 was 1.73 (SD = 1.12), #2 was
1.30 (SD = 1.14), #3 was 0.93 (SD = 1.16), #4 was 1.61 (SD = 
1.29), #5 was 1.59 (SD = 1.09), #6 was 1.20 (SD = 0.94), and 
#7 was 1.22 (SD = 1.01). The grand mean score on the 
medication compliance section was 1.48 (SD = 0.67). The 
range was from 0 to 2.71. Among the PDG, the mean on the 
compliance section was 1.35 (SD = 0.72). The range was from 
0 to 2.71. Among the ADG, the mean was 1.44 (SD = 0.68).
The range was from 0.2 9 to 2.29. Among the PDOG, the mean 
was 1.65 (SD = 0.68). The range was from 0.8 6 to 2.43.
The mean responses on the reluctance section questions 
were: #8 was 1.74 (SD = 0.99), #9 was 0.75 (SD = 0.69), #10
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was 0.50 (SD = 0.54), #11 was 0.29 (SD = 0.46), #12 was 0.81
(SD = 0.70), #13 was 1.18 (SD = 0.86), #14 was 1.35 (SD =
0.80), #15 was 1.15 (SD = 0.89), #16 was 1.46 (SD = 0.91),
#17 was 1.38 (SD = 1.02), #18 was 1.51 (SD = 1.02), #19 was
1.85 (SD = 0.93), and #20 was 1.48 (SD = 0.83).
The grand mean score on the ROMI medication reluctance 
section was 1.18 (SD = 0.36) . The range was from 0 to 1.85. 
Among the PDG, the mean on this section was 1.19 (SD = 0.31). 
The range was from 0.54 to 1.62. Among the ADG, the mean was 
1.29 (SD = 0.29). The range was from 0.85 to 1.85. Among 
the PDOG, the mean was 1.04 (SD = 0.47). The range was from 
0 to 1.58.
The mean of the ROMI compliance section was subtracted 
from the mean of the reluctance section to provide the ROMI 
composite score. The grand mean of the ROMI composite score 
was -0.29 (SD = .73). The range was from -1.18 to +1.31. 
Among the PDG, the mean composite score was -0.12 (SD =
0.77). The range was from -1.18 to +1.31. Among the ADG, 
the mean composite score was -0.19 (SD = 0.70). The range 
was from -1.13 to +1.10. Among the PDOG, the mean composite 
score was -0.53 (SD = 0.65). The range was from -1.07 to 
+0.54. Comparison of means testing was not performed on ROMI 
variables. A summary of mean section responses can be found
in Figure 57.
Responses to the 20 ROMI questions were submitted to 
multivariate analysis of variance. Between group differences 
were not found using Wilks7 lambda (F = 1.02821, p = .465).
Of the 20 questions, only question #15 resulted in 
significant between groups differences (F(2,39) = 4.25964, p 
= .021) and question #18 approached significance (F(2,39) = 
3.16863, p  = .053). This is not unlikely due to error.
The Premorbid Adjustment Scale
The Premorbid Adjustment Scale (PAS) was completed on 
participants. Mean scores for the PAS-childhood questions 
were: A was 1.80 (SD = 1.72), B was 1.97 (SD = 1.63), C was
2.7 9 (SD = 1.40), and D was 1.99 (SD = 1.27). The grand mean 
PAS-childhood score was 8.59 (SD = 4.97). The range was from 
0 to 21.
Mean scores on the PAS-early adolescence section were:
A was 1.93 (SD = 1.79), B was 2.13 (SD = 1.58), C was 3.09 
(SD = 1.62), D was 2.43 (SD = 1.78), and E was 1.34 (SD = 
1.45). The grand mean PAS-early adolescence score was 10.86 
(SD = 6.36) . The range was from 0 to 25.
Mean scores on the PAS-late adolescence section were:
A was 2.13 (SD =1.81), B was 2.19 (SD =1.66), C was 3.61
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(SD = 1.95), D was 3.11 (SD = 2.22), and E was 1.43 (SD =
1.55). The grand mean PAS-late adolescence score was 12.23 
(SD = 7.11). The range was from 0 to 27.
Mean scores on the PAS-adulthood section were: A was
2.21 (SD = 1.90), B was 2.51 (SD = 1.81), and C was 2.07 (SD 
— 1.67). The grand mean PAS-adulthood score was 6.80 (SD = 
4.44). The range was from 0 to 17.
Mean scores on the PAS-general section were: A was 2.25 
(SD = 1.40), B was 2.65 (SD = 1.94), C was 4.42 (SD = 1.88),
D was 3.51 (SD =2.02), E was 1.60 (SD =1.87), F was 2.23 
(SD =1.63), G was 2.61 (SD = 1.48), H was 3.07 (SD = 1.75), 
and I was 2.8 9 (SD = 1.97). The grand mean PAS-general 
score was 25.58 (SD = 11.13). The range was from 6 to 51.
The PAS childhood, early adolescence, late adolescence, 
adulthood and general section scores were combined to produce 
the composite PAS score. The mean composite PAS score was 
65.58 (SD = 28.52). The range was from 12 to 125.
Individual PAS variables were submitted to a 
multivariate analysis of variance. Between groups 
differences were significant (F = 1.48512, p = .045) using 
Wilks' lambda. It is noted that group differences on 20 of 
the 2 6 variables were significant and 2 additional variables 
approached significance.
78
Recidivism
The number of documented hospital admissions for the 
total sample was 4.03 {SD = 4.73), ranging from 1 to 25. The 
average among the PDG was 6.5 9 {SD = 6.00). The average
among the ADG was 4.47 {SD = 5.36). The average among the
PDOG was 2.27 {SD = 2.10). Refer to Figure 2.
The average number of substance abuse treatments was 
3.65 {SD = 5.42), ranging from 1 to 41. The average among 
the PDG was 2.33 (SD = 4.82). The average among the ADG was 
3.48 {SD = 3.25). The average among the PDOG was 4.35 {SD =
6.56). Refer to Figure 34.
Participants were asked to recall the number of 
inpatient psychiatric admissions. The mean was 5.02 {SD = 
8.24), and ranged from 1 to 70. Participant reports of 
admissions correlated .5631 (p = .000) with computerized 
state psychiatric admission records. The average reported 
admissions among the PDG was 8.07 {SD = 6.15). The average 
among the ADG was 6.98 {SD = 12.82) . The average among the
PDOG was 2.38 {SD = 2.99), and ranged from 1 to 15. Refer to
Figure 39.
The recorded number of hospital admissions, as well as 
participant self-reports of substance abuse and psychiatric 
treatment were submitted to multivariate analysis of
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variance. Group differences were found to be significant (F 
= 5.02292, p = .000). Between group differences were 
significant on number of hospital admissions (F(2,117) = 
9.33873, p = .000) and psychiatric hospitalization self- 
report (F(2,117) = 7.82598, p = .001). Between group 
differences were not significant on substance abuse treatment 
admissions. Refer to Table 15.
A Pearson's Product-moment correlation was performed 
between the number of recorded hospital admissions and the 
participant report of psychiatric hospital admissions. The 
correlation was significant (r = .5631, p  = .000).
As the purpose of developing a prediction equation was 
for clinical use and was not driven by a theoretical model, 
Pearson's Product-moment correlations were performed between 
the number of recorded hospital admissions and selected 
variables. The purpose of this analysis was to identify 
those variables that most highly correlate with admissions, 
thereby providing an initial list of variables to enter into 
a regression equation. In addition to participant self 
report of psychiatric hospitalizations, those variables that 
most highly correlated with admissions were: qualification
for a psychiatric pension (r = .5864, p  = .000), age (r = 
.1954, p = .028), raw score on the WMS-R Logical Memory I (r 
= -.2338, p = .007), percentile score on the WMS-R Logical
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Memory I (r = -.2224, p = .013), raw score on the WMS-R 
Logical Memory II (r = -.2372, p ~ .006), raw score on the 
WMS-R Visual Reproduction I (r = -.37 65, p = .000), 
percentile score on the WMS-R Visual Reproduction I (r = - 
.2685, p = .003), raw score on the WMS-R Visual Reproduction 
II (r = -.3654, p = .000), percentile score on the WMS-R 
Visual Reproduction II (r = -.2894, p = .001), raw score on 
the SIL Abstraction scale (r = -.2089, p = .026), T-score on 
the SIL Abstraction scale (r = -.2004, p = .040), raw score 
on the total SIL scale (r = -.2162, p = .022), T-score on the 
Trail Making Test A (r = -.2119, p  = .020), raw score on the 
Trail Making Test B (r = .1976, p = .030), T-score on the 
Trail Making Test B (r = -.1988, p  = .036), T-score on the 
Grooved Pegboard-Dominant (r = -.1968, p = .036), raw score 
on the Aphasia Screening (r = .4083, p = .000), T-score on 
the Aphasia Screening (r = -.4175, p = .000), and the PAS 
composite score (r = .4338, p = .000).
Those variables that most strongly correlated with the 
number of hospital admissions along with those variables of 
clinical interest were entered into a regression equation. A 
backwards stepwise regression was performed. The initial 
regression examined all participants and included the 
following four variables: (1) participant report of number
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of psychiatric hospitalizations, (2) receipt of a psychiatric 
pension, (3) raw score on the Aphasia Screening, and (4) the 
combined total number of days in the previous 30 during which 
drugs were consumed. The equation yielded a multiple R of 
.6509, an F2 of .42367, an adjusted F2 of .40755 and was 
significant (F(4,143) = 26.28010, p = .0000). However, due 
to the differing profiles of the three diagnostic groups, 
regression equations were performed on each group in order to 
identify those variables which most contribute to recidivism 
within each group. Refer to Table 14.
A backward stepwise regression was performed which 
examined the psychotic group. The final regression equation 
included the following six variables: (1) the number of years
of cocaine use, (2) participant report of number of 
psychiatric hospitalizations, (3) receipt of a pension, (4) 
raw score on the WMS-R Visual Memory I, (5) combined spending 
on drugs and alcohol during a typical, recent 30 day period, 
and (6) the combined , total days of consumption of drugs 
during the previous 30 days. The equation yielded a multiple 
R of .79329, an F2 of .62930, an adjusted R2 of .56190 and 
was significant (F(6,33) = 9.33685, p = .0000). Refer to 
Table 15.
A backward stepwise regression was performed which 
examined the ADG. The final regression equation included the
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following ten variables: (1) the number of years of cocaine
use (negatively), (2) participant report of number of 
psychiatric hospitalizations, (3) the number of years of 
education (negatively), (4) age, (5) the percentile score on
the WMS-R Logical I (negatively), (6) the raw and (7) 
percentile scores on the WMS-R Visual Reproduction I, (8) the 
percentile score on the WMS-R Visual Reproduction II, (9) T- 
score on the Trail Making Test A, and (10) the raw score on 
the Trail Making Test B. The equation yielded a multiple R 
of .77808, an R2 of .60541, an adjusted R? of .47812, and was 
significant (F(10,31) = 4.75617, p = .0004). Refer to Table 
16.
A backward stepwise regression was performed which 
examined the PDOG. The final regression equation included 
the following five variables: (1) participant report of
number of psychiatric hospitalizations, (2) the number of 
years of education, (3) the raw score on the Trail Making 
Test B, (4) the combined, total number of days of substance 
use in the previous 30, and (5) the composite ROMI score.
The equation yielded a multiple R of .55341, an I?2 of .30626, 
an adjusted R2 of .24845, and was significant (F(5,60) = 
5.29754, p = .0004). Refer to Table 17.
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Community Aftercare and Patient Follow-up
As patient discharge addresses were not uniformly 
provided in patient charts and some patients did not wish to 
be contacted following discharge, questionnaires were mailed 
to 106 of the 148 participants. The postal service returned 
32, indicating that participants had moved and left no 
forwarding address. Of the remaining 74, 52 did not respond 
and 22 participants did respond.
Participants were asked whether they had attended their 
first aftercare session. Of the 22 respondents, 17 indicated 
that they had, 4 indicated they had not, and 1 did not 
respond. In response to the question of whether they were 
taking their psychotropic medication, 16 indicated that they 
were and 6 indicated that they were not. In response to the 
question of whether they were participating in treatment or a 
12-step program, 15 indicated that they were and 7 indicated 
they were not. The last question asked patients to indicate 
how they were feeling today, on a scale of 1 to 100, where 1 
was really bad and 100 was really good. The 22 responses 
ranged from 1 to 100 and averaged 55.55 (SD = 32.45).
As numerous patients refused follow-up services, left 
the hospital against medical advice, or did not authorize our 
contacting the community aftercare agency to which they would 
be referred, questionnaires were mailed to agencies
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requesting information on 90 of the 148 participants. The 
postal service returned one letter from an out-of-state 
agency. Of the remaining 89, 44 did not respond and 45 did 
respond.
Agency staff were asked whether the patient had 
attended his first aftercare session. Of the 45 respondents, 
22 indicated that he had and 23 indicated he had not. In 
response to the question of whether he was taking his 
psychotropic medication, 16 indicated that he was and 28 
indicated that he was not. In response to the question of 
whether he was participating in treatment or a 12-step 
program, 11 indicated that he was, 32 indicated he was not, 
and 1 was missing. The last question asked staff to identify 
the patient's level of functioning, using the global 
assessment of functioning scale of 1 to 100. The 19 
responses ranged from 1 to 80 and averaged 47.32 (SD =
20.52).
The group of participants who followed-up was different 
from that group who did not on a number of important 
variables, such as crime (4.95 and 9.44), ROMI-Compliance 
Section (11.58 and 7.75), ROMI-Reluctance Section (17.17 and 
14.00), combined recent substance abuse score (26.41 and 
36.27), summed lifetime substance abuse score (56.41 and 
70.06), neuropsychological functioning factor 2 or
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psychomotor functioning (93.86 and 104.75), and spending on 
drugs and alcohol ($199.29 and $312.22). None of these 
differences approached significance.
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Discussion
Study Limitations
One limitation of the study is the design. By studying 
only substance abusing psychotic, affective and personality 
disorders groups, the ability to make inferences regarding 
etiology has been limited. A more informative design would 
include non-substance abusing controls. This limitation was 
given consideration during the early design phase of the 
study. The decision to use the simple design without the 
non-substance abusing control group was based on the belief 
that: (1) the benefits of a 2 x 3 design would have been
offset by a substantial reduction in statistical power, and 
(2) there would not have been a sufficient number of patients 
admitted within each diagnostic category who were non­
substance abusing.
The generalizability of the study is limited by several 
factors. Foremost, the greatest limitation is the frequent 
reliance upon participant self-report. The validity of 
reports by participants with psychotic behavior are often 
suspect, due to misunderstanding and their periodic inability 
to respond nontangentially and meaningfully to specific 
stimulus questions. By adhering to the inclusion criteria
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originally developed for ethical purposes, most of those 
individuals were not included whose delusional states would 
most substantially interfere with the interview process. 
Certainly, this had the effect of restricting the psychotic 
sample to those less impaired. Further, an attempt was made 
to validate participant responses wherever possible by chart 
review.
A second reason to question the validity of self-report 
is due to secondary and characteristics of participants that 
may confound their reporting. For example, it would not be 
unexpected for individuals with an affective disorder to tend 
to provide more socially acceptable responses than 
individuals with antisocial personality disorder. Another 
example is that those individuals with higher
neuropsychological functioning would be expected to be better 
able to understand the concept of confidentiality and, thus, 
they may be less likely to provide socially desirable 
responses.
A third limitation of the study is interviewer biases. 
Although interviewers did not review participant charts until 
following the interview, and thus were not certain of 
participants' diagnoses, the interactive nature of the 
protocol often provided interviewers with sufficient 
information to make a tentative diagnosis. This may have 
resulted in some biasing of results.
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A fourth limitation of the study is the lack of 
representativeness of the sample and the subsequent 
generalizability to the general MICA population. For 
example, over half of participants were African American and 
nearly all were referred from an urban area. Thus, 
demographics, historical background, neuropsychological 
performance and community adjustment may be influenced by the 
over-sampling of minorities. Further, the screening of 
psychotics using inclusion criteria reduced representation of 
those with more severe psychotic symptomatology. Further, 
psychotics had a higher rate of refusal. This had the effect
of all but eliminating those psychotics with paranoid 
symptoms from participating in the study.
A fifth limitation is that generalization may not be 
appropriate due to the nonrepresentative nature of the 
sample. Normative data for most of the neuropsychological 
measures were developed on samples more characteristic of the 
general population. In the absence of normative data 
specifically for African American individuals, the general 
norms were used. This may have magnified the appearance of
impairment using the normative scores. A MANOVA was
performed to determine whether racial differences were 
significant. Racial differences were not significant (F = 
1.15705, p = .441) in this sample. This suggests that it may
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be acceptable, in the current study, to use normative data 
that underrepresented minorities, providing that score 
interpretation is made with caution.
General Findings: Demographics
A large number of background variables were examined. 
These included general demographic; substance abuse, legal 
and psychiatric historical data.
On average, the PDOG had the least documented number of 
admissions (2.27), followed by the ADG (4.47) and the PDG 
(6.59). Such individual service utilization patterns are 
within normal expectations.
Differences in education were nonsignificant. The ADG 
reported the highest mean education (11.88) whereas the PDG 
reported the lowest (10.44). The same pattern was observed 
in reported grades. The ADG reported the highest mean grade 
(2.64) whereas the PDG reported the lowest (2.01). One might 
expect that early attention difficulties might have most 
severely impaired the academic performance of the PDG. 
Likewise, various personality and behavioral factors might 
have most negatively influenced the academic performance or 
evaluation of the PDOG. Further, major depressive disorders 
are not typically characterized by premorbid impaired 
academic performance. Thus, this pattern is not unexpected.
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About half of the sample were African American. As the 
hospital serves an urban region with a large African American 
constituency, such a distribution was expected. Of 
particular interest is what appears to be a difference in the 
rates of diagnosis by race. The majority of psychotic 
(62.9%) and personality disorders (64.6%) participants were 
African American, whereas the majority of those with 
affective disorders were Caucasian (52.6%) and only a 
minority (42.1%) were African American. This finding may 
reflect a difference in diagnostic prevalence in the general 
population. The difference may also be explained by sampling 
error or by a performance bias among the diagnosing 
psychiatrists. Further study may be warranted.
The prevalence of head injuries, infectious diseases, 
degenerative disorders and seizures among participants was 
very high. Statistical control of such covariates is not as 
useful with categorical data as it is with ordinal data. One 
alternative method of dealing with these confounds was the 
post-hoc removal of the data on these participants. However, 
this would have substantially reduced the statistical power, 
and, further, it was believed that they represented the 
general MICA population in prevalence and were, therefore, 
useful for making generalizations.
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General Findings: Substance Abuse
The majority of participants tested negative for recent 
non-prescription drugs, as measured by urinalysis. The drug 
for which participants most commonly tested positive was 
cocaine. It is noteworthy that no one in the PDG had a 
positive urine screen. Urinalysis may be a useful clinical 
tool, particularly in the differential diagnosis of psychotic 
disorders with organic etiology and the various substance- 
induced psychotic disorders.
It appears that, for the most part and under the 
conditions of the research protocol, participant self-report 
of recent substance use tends to be confirmed by urinalysis 
findings. Discrepancies were noted in only a few cases. One 
limitation of this assertion is that the interview requested 
the participant to identify the number of days in the past 30 
during which he used a given substance. For most substances, 
this poses no problem. Alcohol and cocaine, the two most 
commonly reported substances of abuse, posed problems.
Unless an individual is involved in an automobile accident, 
it appears that most hospitals that serve as state detention 
facilities do not regularly obtain or report blood alcohol 
levels or breathalyser results. Due to the high comorbidity 
of alcohol use with suicide and various mental disorders, it 
seems as though alcohol levels should routinely be measured
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and reported. Cocaine, on the other hand, is a drug for 
which individuals are generally tested. The body typically 
disposes of cocaine within 24 to 96 hours. As 26 to 28 days 
go unconfirmed or validated by urinalysis, a considerable 
number of false negatives would be expected.
On most substance abuse variables, the PDG tended to 
report the fewest abuse indicating responses. The ADG tended 
to report more abuse indicating responses. The PDOG tended 
to report the most abuse indicating responses. Exceptions to 
this pattern and variables of particular clinical or research 
relevance are individually discussed below.
Recent cocaine use was reported by the majority (57.6%) 
of those with personality disorders but only a minority 
(18.2%) of psychotics. This same pattern was found in the 
mean days of recent cocaine use as well as the prevalence of 
lifetime cocaine use. The pattern was slightly different 
when looking at mean years of lifetime cocaine use: those
with affective disorders reported an average of 5.85 years, 
those with personality disorders reported an average of 5.49 
years, and those with psychotic disorders reported an average 
of 2.68 years. It is suggested that one explanation of this 
pattern change is the number of participants with personality 
disorders with primary cocaine dependence who reported only 
recently beginning to smoke crack cocaine and, due to its 
alleged accelerated addictive process, they "hit bottom"
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within a year.
The most common route of administration reported by 
MICAs was by smoking (71.3%). The frequency of smoking was 
less common prior to the introduction into the market of 
crack cocaine. This shift in administration from nasal to 
smoking may result in decreased incidence of nasal - septum 
damage. However, smoking may increase vulnerability to 
respiratory disorders. This increased respiratory 
vulnerability coincides with an increased nationwide 
incidence of tuberculosis. The neurological and 
neuropsychological sequelae of different routes of 
administration merit further study.
No participants reported recent inhalant use. However, 
the distribution of those reporting lifetime inhalant abuse 
was of particular interest. Only 12.1% of psychotic and 
13.6% of personality disorders participants reported lifetime 
inhalant use, whereas 23.8% of affective disorders 
participants reported such. Inhalant abuse may lead to 
increased vulnerability of subcortical structures to toxic 
insult. Further, the hypothalamus and other subcortical 
structures may function in the regulation of affective 
states. Thus, the higher prevalence of inhalant use among 
the ADG may suggest that impairment of affect regulation may 
be related with inhalant abuse. The only indicators of 
affect regulation were participant self-reports of
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depression, anxiety and difficulty controlling violent 
behavior. A chi-square was performed to determine the 
likelihood that this distribution may have occurred by
chance. The results were not significant (x2 (2) = 2.500, p
= .28648), suggesting that this distribution may have been 
coincidental. Due to the limitations of the present study, 
the question of the potential relationship between inhalant 
abuse and affect regulation disturbances may deserve further 
examination.
The major identified problem for over half of 
participants was polysubstance abuse. About one-eighth 
reported alcohol was the major problem. About one-tenth of 
participants reported alcohol and one drug as the major 
problem. Less than 10% reported that the primary problem was 
cocaine, cannabis or barbiturates. It is suggested that the
ASI criteria need to be fully delineated.
Psychotic participants tended to report a longer 
average length of their last abstinence (16.53 months) than 
the personality disorders (9.32) or affective disorders 
(4.18) participants. Relatedly, the length of the last 
period of use was longest for personality disorders (21.52 
months), followed by psychotic (12.22) and affective 
disorders (9.54) participants.
Those in the psychotic group tended to report, on
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average, more incidences of delerium tremens (1.57) than the 
personality disorders (1.07) or affective disorders (0.90) 
groups. The results are suspect, as the definition of the 
DTs included hallucinations. Psychotics may have confused 
these with hallucinations of an organic etiology; although 
interviews made an effort to explain and tease out 
differences. Another explanation is that participants in the 
other two groups may have been more reluctant to report DT 
hallucinations while in a state hospital.
The prevalence of overdoses were most common among the 
ADG (1.32 times), followed by the PDG (0.81) and PDOG (0.41) 
groups. Responses to this question are believed to have 
included considerable noise. The intent of this question was 
to identify those who have used drugs in such quantities and 
frequency that they pushed the upper limits of abuse.
However, suicide attempts by overdose are relatively common 
among patients in a state hospital. Thus, some depressed 
participants may have consumed too much of a drug with the 
intent of committing suicide and not in order to "get really 
high". It is believed that such a motivation more accurately 
describes the participant's psychological state at that time 
than it describes their substance abuse tendencies. However, 
individuals who choose to attempt suicide by substance 
overdose may be more likely, as a group, to have substance 
use disorders than those who attempt suicide by other means.
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Future studies using the Addiction Severity Index with MICA 
populations need to tease out these two motivations.
The PDOG tended to report the most spending on and 
consumption of alcohol and drugs. The ADG reported the next 
highest. The PDG reported the least. The reported spending 
and consumption of drugs and alcohol varied by whether or not 
they received a psychiatric pension. Those participants who 
reported receiving a pension for a psychiatric disability 
reported significantly less spending on average ($71.15) on 
drugs than those who did not receive a pension ($517.7 6) (F 
(1,108) = 3.98960, p = .048).
Between groups differences on select substance abuse 
variables appeared to be of clinical relevance; however, 
between groups differences were not statistically 
significant.
General Findings: Legal
Of the nearly 1,100 criminal charges reported by 
participants, over half were for drunk-in-public, disorderly 
conduct, or vagrancy. Over 100 were assault charges. Almost 
100 were DWI charges. Between group differences on criminal 
variables were not reliably significant. The between group 
differences,on robbery approached significance, suggesting 
that those with personality disorders may be more likely to
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admit to committing robbery.
One disturbing observation was that although black 
participants reported, on average, slightly fewer arrests 
than white participants (6.53 6 and 9.458, respectively)(F
(1.114) = .633, p = .428), the average number of months that 
participants reported in jail was greater for black 
participants (16.455) than white participants (6.337) (F
(1.114) = 3.21169, p = .076 .
General Findings: Psychiatric
Participant self-reported number of previous 
psychiatric hospital admissions was found to positively and 
significantly correlate with the number of admissions 
recorded in the Virginia state health department database.
Of the seven symptoms (depression, anxiety, 
hallucinations, cognitive problems, difficulty controlling 
violent behavior, suicidal thoughts and suicidal acts) on 
which participants were asked to self-report, the PDOG 
reported higher prevalence on four. The psychotic group 
reported more frequent problems with cognition than the other 
groups. The ADG reported slightly more frequent problems 
with controlling violent behavior and more hallucinations 
than the other groups. The PDOG was found to report 
depression more frequently than the psychotic group. This
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difference approached significance. The personality and ADGs 
reported anxiety significantly more often than the psychotic 
group. The affective and PDGs reported hallucinations 
significantly more often than the PDOG. Other between 
groups differences on symptoms were not found to be 
significant. Participant reports of recent symptomatology 
are of questionable validity. Some participants exhibiting 
severe psychotic behavior reported no symptoms and appeared 
to display some motivation to minimize. Some participants 
who were not exhibiting psychiatric symptomatology and who 
admitted that their lawyer suggested that they seek treatment 
due to pending criminal charges, thus displaying a potential 
motivation to maximize, responded affirmatively to all 
questions but that dealing with difficulty controlling 
violent behavior.
On most psychiatric severity variables, the PDG tended 
to report the most symptom - confirming responses. The ADG 
tended to report the next most symptom - confirming 
responses. The PDOG tended to report the least symptom - 
confirming responses.
General Findings: Neuropsychological Testing
Participant scores on the WMS-R Logical I suggest that 
the psychotic group performance was significantly more
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impaired than that of the affective or PDOGs on both raw and 
percentile scores. Participants in all three groups 
generally demonstrated mild impairment.
Participant scores on the WMS-R Logical II suggest that 
the psychotic group performance was significantly more 
impaired than that of the affective or PDOGs on both raw and 
percentile scores. Participants in all three groups 
generally demonstrated mild impairment. The stability of the 
general level of impairment in performance, suggests that 
most impairment on the delayed recall task may have been due 
to initial encoding.
Participant scores on the WMS-R Visual I suggest 
that the psychotic group performance was significantly more 
impaired than that of the affective or PDOGs on both raw and 
percentile scores. Only the PDG demonstrated mild 
impairment. The affective and PDOGs performed within the 
normal range.
Participant scores on the WMS-R Visual II suggest that 
the psychotic group performance was significantly more 
impaired than that of the affective or PDOGs on both raw and 
percentile scores. Only the PDG demonstrated mild 
impairment. The affective and PDOGs performed within the 
normal range. The stability of the general level of 
impairment in performance, suggests that most impairment on 
the delayed recall task may have been due to initial
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encoding.
Participant normative scores on the two visual measures 
were generally better than normative scores on the two 
logical measures. This suggests that patient memory may be 
enhanced by the use of multimedia approaches, especially 
visual images, pictures, graphs and drawings.
Participant scores on the Shipley Institute of Living 
Verbal Scale suggest that the psychotic group performance was 
significantly more impaired than that of the affective or
PDOGs on both raw and normative scores. The psychotic group
demonstrated mild-to-moderate impairment. The affective and 
PDOG demonstrated mild impairment. These results lend 
support to previous findings of mild verbal impairment among 
substance abusers.
Participant performance on the SIL Abstraction Scale 
suggests that the psychotic group performance was
significantly more impaired than that of the affective or
PDOGs on the raw score but not significantly different on the 
normative scores. The psychotic group demonstrated mild 
impairment. Considerably more people in this sample 
attempted the first three problems than did the normative 
sample. Either this sample was more highly motivated or they 
demonstrated less frontal lobe impairment than the normative 
sample.
Participant scores on the SIL Total Scale suggest that
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the psychotic group performance was more impaired than that 
of the affective or PDOGs on both raw and T scores. The 
psychotic group demonstrated mild impairment. The PDOG 
demonstrated no-to-mild impairment. The SIL Total Scale was 
used to estimate intelligence. The SIL estimated IQ was 
nonsignficantly higher among the affective and PDOGs than the 
PDG.
Participant scores on the Trail Making Test A suggest 
that the psychotic group performance was significantly more 
impaired than that of the affective or PDOGs on both raw and 
T scores. The psychotic group demonstrated moderate 
impairment. The ADG demonstrated mild impairment.
Participant scores on the Trail Making Test B suggest 
that the psychotic group performance was significantly more 
impaired than that of the affective or PDOGs on both raw and 
T scores. The psychotic group demonstrated mild impairment.
Participant scores on the Grooved Pegboard - Dominant 
suggest that the psychotic group performance was 
significantly more impaired than that of the affective or 
PDOGs on both raw and T scores. The psychotic group 
demonstrated severe impairment. The affective and PDOGs 
demonstrated mild impairment.
Participant scores on the Grooved Pegboard - 
Nondominant suggest that the psychotic group performance was 
significantly more impaired than that of the affective or
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PDOGs on both raw and T scores. The psychotic group 
demonstrated moderate impairment. The affective and PDOGs 
demonstrated mild impairment.
Participant scores on the Reitan - Indiana Aphasia 
Screening suggest that the psychotic group performance was 
significantly more impaired than that of the affective or 
PDOGs on the number of raw errors committed and on the T 
score. The performance of all three groups was within the 
normal range. There was no reason to expect an elevated 
prevalence of aphasia. Therefore, this finding confirmed 
previous expectations.
Participant scores on the Wender-Utah Rating Scale - 25 
suggest no between groups differences. Further, on average, 
all three groups* reports of childhood symptomatology are 
within the range of attention deficit disorder, as defined by 
Wender and colleagues (1994). Thus, all three groups are 
well beyond the range which Wender reports as asymptomatic. 
One possible explanation is that there may have been an 
administration error that accounts for the high rate across 
all three conditions. It is also possible that the norms for 
this very new instrument may benefit from further refinement. 
Another explanation is that these substance abusers tended to 
have childhood attention deficits.
In summary, there were no significant differences in 
neuropsychological performance between the affective and
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PDOGs. Both groups performed with no to mild impairment on 
each measure. There were significant differences in 
neuropsychological performance between the psychotic group 
and the other two groups. The psychotic group performed with 
mild to severe impairment on all but one measure.
The neuropsychological measures were submitted to a 
principal components analysis with varimax rotation. Seven 
factors were identified that loaded primarily on: (1) all
seven SIL measures, (2) the four WMS-R Logical measures, (3) 
the four WMS-R Visual measures, (4) the four Grooved Pegboard 
measures, (5) the four Trail Making measures, (6) the two 
Aphasia measures, and (7) the WURS-25. Factor 1 (SIL) also 
loaded on Trails B T score. Factor 5 (Trails) also loaded on 
the Grooved Pegboard - Dorn Raw. Factor 6 (Aphasia) also 
loaded negatively on Trails A Raw. These findings suggest 
that each instrument was measuring something usually quite 
different from each other measure. It lends support to the 
validity of these measures.
General Findings: Community Adjustment
Participant responses on the ROMI suggest that 
participants may be slightly more compliant than reluctant to 
take their psychotropic medication. Participant responses to 
individual questions did not yield significant findings.
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Group differences were nonsignificant on individual questions 
or on section averages. Several alternative explanations are 
posited to explain this absence of findings. The ROMI was 
administered at the end of the protocol and, thus, 
participants may have experienced fatigue effects. It is 
suggested that the validity of many participants' responses 
was suspect as command characteristics may have been 
operational. Further, the ROMI was only administered to 
participants who reported having a psychotropic prescription 
prior to their admission and who did not appear to have 
decompensated or fatigued significantly. And finally, the 
instrument itself is believed to have contributed to the 
finding of no relationships. The scale used is essentially a 
3 point categorical measure rather than a dimensional scale. 
It allowed participants limited freedom in their selection of 
responses and, therefore is believed to have provided 
inadequate statistical power. Future measures of patient 
attitudes toward medications should use no less than a 7 
point Likert-like scale.
The Premorbid Adjustment Scale reflected significant 
differences between the affective and PDOGs with the 
psychotic group. The psychotic group tended to have poorer 
functioning at an earlier age than the affective or PDOGs.
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General Findings: Recidivism
A regression equation that would predict recidivism was 
developed. Due to the unique nature of each of the three 
groups, separate regression equations were developed. Across 
conditions, participant report of the previous number of 
admissions was always a predictor of recidivism.
Among the PDG, in addition to self-reported admissions, 
receipt of a psychiatric pension, raw score on the WMS-R 
Visual I, recent cocaine use, monthly spending on drugs and 
alcohol and the combined recent substance abuse score 
predicted about 56% of the variance in recidivism among 
psychotics. It is interesting to observe that with 
psychoticism as a given, various substance abuse factors 
contributed considerably to predicting recidivism among the 
psychotic group.
Among the ADG, years of cocaine use, self-reported 
number of previous admissions, education (negatively), age, 
WMS-R Logical I Percentile, WMS-R Visual I Raw, WMS-R Visual 
I Percentile, WMS-R Visual II Percentile, Trail A T score and 
Trails B Raw predicted about 48% of the variance in 
recidivism among those with affective disorders. It would 
appear that memory disorders may play some role in predicting 
recidivism among those with affective disorder. Persons with 
major depression or even bipolar disorder, depressed, would
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be expected to exhibit impairments in memory. Although two 
Trails measures were included in the equation, the absence of 
the Grooved Pegboard is intriguing: psychomotor retardation
is characteristic of depression. But, since the Pegboard was 
not included in the equation while the Trails measures were, 
it suggests that the cognitive component was more predictive 
than psychomotor retardation.
Among the PDOG, self-reported number of previous 
admissions, education, Trails B Raw, Combined Recent 
Substance Abuse Score, and the ROMI Total predicted about 25% 
of the variance in recidivism among those with personality 
disorders. One possible reason for the lower predictive 
power among the PDOG is that their mean number of admissions 
was only about one-third that of the psychotics group. The 
lower mean and mode of 1 considerably reduced the statistical 
power. A much larger group with higher mean admissions would 
be useful to study. A second possible reason for the lower 
predictive power may be that those medical, psychiatric and 
neuropsychological variables identified in the present study 
do not contribute as significantly to recidivism as other 
variables such as personality factors, ability to deal with 
stress in the community, and malingering.
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General Findings: Community Follow-up
In general, it appears that the majority of patients in 
this sample did not follow-through with referrals to 
community aftercare agencies. The majority of those who did 
follow through went on to participate in treatment services 
and take medications. No group differences were found 
between those who followed through and those who did not.
Recommendations for Further Study
It is suggested that future studies would benefit from 
using a more complex design. The clustering of participants 
into three diagnostic categories based on DSM-IV criteria has 
some limitations. Schizoaffective and schizophreniform 
disorders, although quite similar to schizophrenia, are 
distinctly different. Similarly, patients with dependent 
personality disorder usually present quite differently from 
those with antisocial personality disorder. To achieve some 
degree of parsimony, the present design was selected.
Relatedly, the reliance upon the diagnosis of 
psychiatrists using DSM-IV criteria may have been yet another 
limitation of this study. Psychiatric staff may often be 
overworked and not have sufficient time to perform a thorough 
assessment.. Future research might use identified clinicians' 
ratings based on the Diagnostic Research Criteria.
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The use of a questionnaire rather than interview may 
reduce demand characteristics. For the most part, 
participant responses do not generally reflect an attempt by 
participants to provide desirable responses.
Future studies may benefit from careful participant 
inclusion criteria. The over-sampling of minorities may have 
limited the generalizability of this study to the general 
population. Furthermore, the inability to control for the 
effects of head injuries and neuropsychological risk factors 
was a flaw in the current design. This problem is commonly 
discussed throughout the neurological and neuropsychological 
research literature on substance abusing populations. It is 
a population that is predisposed to head injury and other 
neurological insults. Careful control and selection criteria 
are the best method of dealing with these problems. While 
not all noise would be eliminated, it would be expected that 
a substantial amount should be eliminated.
Most instruments used appeared to provide very useful 
information. The Addiction Severity Index provides a 
substantial amount of information. Some of the information 
provided by the ASI is of limited usefulness in 
differentiating the demographic backgrounds of participants. 
Several sections of the ASI provided some difficulty. One 
example in which a question may have had less utility with 
psychotics was the question regarding whether they had
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experienced alcohol delerium tremens (DTs). This is 
primarily due to overlapping symptomatology between DTs and 
psychosis. Another problem was encountered on the section on 
substance abuse history. The interview calls for the 
identification of the number of days in the last 30 and the 
number of years of use of various categories of drug.
Several additional measures that perhaps ought to be used in 
future research is the quantity of a drug or alcohol 
consumed, on average, for each day of use; age of first use; 
age of last use; and, the history of progression, if 
applicable. Asking participants how many days in the 
previous 30 they engaged in illegal activities is one 
question believed to have elicited a large proportion of 
false-negatives. Further, participant and interviewer 
ratings of severity did not appear to have any relationship 
nor did they seem to have predictive utility. It was not an 
uncommon clinical impression that many psychotic participants 
tended to underreport current and observable psychiatric 
symptoms whereas some personality disorders participants 
tended to over report current psychiatric symptoms. Future 
research with psychiatric patients using the ASI ought to 
modify several sections.
The cursory finding that inhalant use prevalence is 
higher among those with affective disorders than those with 
psychotic or personality disorders deserves further study.
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The difficulties encountered with the Ratings of 
Medication Influence (ROMI) are believed to be considerable. 
The difficulties encountered may have been an artifact of 
the administration procedure. However, it would be 
recommended that substantial modifications to the instrument 
design be performed prior to re-administration.
Clinical Implications
The high relationship between patient self-reported 
recent drug use and urinalysis results lends some support to 
the belief that MICAs tend to be honest in their reporting of 
substance abuse. However, the fact that cocaine use could 
only be confirmed by urinalysis for three days prior to 
admission severely restricts the confidence with which this 
finding is reported.
The observation that hospitals that serve as community 
detention facilities often do not collect or report 
urinalysis results to the state hospitals is a weakness in 
the state mental health service system. Early urinalysis and 
laboratory results of alcohol use are critical components of 
the diagnostic process and should be available to 
diagnosticians at the time the patient is transferred to the 
state hospital.
All groups demonstrated some level of impairment on
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neuropsychological measures. It was found that participants 
in the PDG exhibited more impaired performance on 
neuropsychological measures than either the affective or 
PDOGs. As all groups seemed to have some impairment in the 
verbal domain, it is suggested that intervention efforts make 
use of multimedia designs. The use of films, graphics, 
drawings and other sources of nonverbal communication may 
lead to improved information processing, storage and 
retrieval. Given that patients possess sufficient 
prerequisite motivation, it would be expected that such 
efforts would lead to more effective intervention outcomes. 
The highly differentiated loading patterns on the 
neuropsychological measures lends support to the individual 
contributions of each test in the screening package.
The development of regression equations predicting 
recidivism yielded two very important pieces of information. 
First, given all of the demographic, medical, 
neuropsychological, and historical information collected 
still only predicted between 25 and 56% of the variance in 
readmission rates. This suggests that certain non-medical 
personality and community variables may play a significant 
role in recidivism. Second, different factors may predict 
recidivism between the three groups. The factor that most 
differentiated high and low recidivistic psychotics was 
related to substance use. The factors that most
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differentiated high and low recidivistic participants with 
affective disorder are believed to be substance use and 
slowed cognitive processes (a symptom of major depressive 
disorder). And, the factors that most differentiated high 
and low recidivistic participants with personality disorder 
include 5 very unrelated variables.
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Summary
This study set out to develop profiles of MICA 
patients. As the findings suggest, MICAs report a high 
prevalence of substance abuse, especially polysubstance and 
cocaine use. Those with psychotic disorders reported lower 
levels of substance abuse. It appears as though MICA self- 
report of recent substance abuse is usually accurate, as 
compared with urinalysis. MICAs very often report previous 
criminal charges, although the majority of these are related 
to the substance abuse. About one-half of MICAs accurately 
report a lengthy history of multiple admissions to 
psychiatric facilities. Each diagnostic group reported a 
differentiated cluster of psychiatric symptoms. Generally, 
those participants with personality disorders reported more 
severe psychiatric symptoms.
MICAs were found to have relatively high impairment 
scores using the Premorbid Adjustment Scale. Psychotics 
appeared to have a lower level of functioning at earlier ages 
than other MICAs.
As a whole, MICAs reported a high prevalence of head 
injuries, infectious diseases and seizure disorders. Being 
substance abusers with psychiatric disorders, many MICAs are
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at increased risk of receiving head injuries and developing 
seizure disorders. Such disorders, in turn, often exacerbate 
substance abuse.
MICAs as a whole demonstrated mild to moderate 
neuropsychological impairment. MICAs especially demonstrated 
impairment in psychomotor speed, memory and verbal skills. 
Those with psychotic disorders were most impaired on all 
measures. The development of treatment intervention programs 
may benefit from the incorporation of these findings. It was 
also found that each neuropsychological instrument measured a 
factor of its own and that redundancy of measures was 
limited.
Recidivism was predicted within each of the three 
diagnostic groups. The development of recidivism prediction 
equations may be helpful for the differential allocation of 
limited resources, the identification of individuals with 
different types of need, and the targeting of prevention and 
intervention efforts.
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Table 1
Multivariate Analysis of Variance 
Substance Abuse Pattern Analysis
Multivariate Test F
Wilks' lambda 1.23048
Univariate F-tests df 2, 109
Variables M e a n  S c o 
Psychotic Affective
r e s
Personality
F
Cocaine use in 
recent 30 days 2.82 4.38 5. 95 0.55668
Polysubstance use 
in recent 30 days 4.20 4.00 6.25 1.24984
Combined recent 
substance abuse score 23.97 28.93 37.97 0.71767
Cocaine use 
in years 2.68 5.85 5.49 2.77150 *
Polysubstance 
use in years 7.91 10.74 11.50 0.70689
Combined lifetime 
substance abuse score 63.20 83.15 68.60 1.73146
* p < .10 ** p < .05 *** p < .01 *★★★ p < .001
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Table 2
Multivariate Analysis of Variance 
__________________ Substance Abuse Characteristics Analysis
Multivariate Test F
Wilks' lambda 1.11366
Univariate F-tests df 2, 107
Variables M e 
Psychotic
a n  S c o  
Affective
r e s
Personality
F
Length of 
last abstinence 16.53 4.18 9.32 2.64710
Delerium Tremens 0.90 1.07 2.20 0.29827
Overdoses 0.81 1.32 0.41 1.87079
Number of substance 
abuse treatments 2.33 3.48 4.35 0.10429
Recent alcohol spending 61.95 86.14 105.21 0.31768
Street value of drugs 
used in 30 days 77.77 344.05 578.95 1.89668
* p < .10 **p < .05 < .01 ****p < .001
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Table 3
Multivariate Analysis of Variance 
_________ Criminal History_________
Multivariate Test F
Wilks' lambda 1.46658
Univariate F-tests df 2, 110
Variables Total Number of Reported Incidences 
Psychotic Affective Personality
F
Prompted by justice 9 3 10 1.29966
Shoplifting 7 26 31 1.48821
Probation Violations 2 2 10 0.66663
Drug Charges 5 14 12 1.28686
Forgery 1 1 4 0.51470
Weapons Offenses 5 11 14 0.55194
Burglary 10 9 21 0.20995
Robbery 1 6 4 2.71588*
Assault 7 40 67 0.89614
Arson 6 0 2 2.11809
Rape 2 0 0 3.18244**
Murder 0 1 4 1.54721
Prostitution 2 0 0 1.53228
Contempt of Court 1 17 33 1.06692
Other 7 3 21 1.38651
Drunk in Public 51 181 374 0.47641
Mos in jail 407 402 868 0.03612
Days in jail 109 91 62 0.69612
Illegal acts in mo 36 97 263 1.27922
* p < .10 ** p < . 05 *** p < .01 **+* p < .001
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Table 4
Multivariate Analysis of Variance 
_____________________________ Psychiatric Interview_______
Multivariate Test 
Wilks' lambda 
Univariate F-tests df 2, 114
F
3.24946
Variables
Psychiatric Treatments
Psychotic
8.07
M e a n s
Affective
6.98
Personality
2.38
F
10.85908****
Psychiatric Pension 63.3% 30.0% 7.9% 25.54104****
Depression 58.1% 75.6% 82.5% 2.63015*
Anxiety 58.1% 80.5% 81.0% 3.33103**
Hallucinations 41.9% 43.9% 20.6% 4.22296**
Cognitive problems 74.2% 63. 4% 63.5% 0.42829
Problems controlling 
violent behavior 16.1% 29.3% 28.6% 1.07490
Suicidal thoughts 45.2% 51.2% 52.4% 0.14553
Suicidal acts 16.1% 26.8% 36.5% 1.52421
Psychotropic meds 94.0% 80.0% 49.0% 12.50519****
p < .10 ** p < .05 *** p < .01 ★ * * * p  < .001
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Table 6
Multivariate Analysis of Variance 
________________ WMS-R Logical and Visual Raw Scores Analysis
Multivariate Test 
Wilks' lambda
Univariate F-tests df 2, 138
F
6.76590****
Variables M e a n  S c o r e s F
Psychotic Affective Personality
WMS-R Logical I Raw 10.35 17.81 17.11 19.57420****
WMS-R Logical II Raw 6.78 12.86 12.48 11.94966****
WMS-R Visual I Raw 19.11 28.95 28.46 20.36195****
WMS-R Visual II Raw 13.11 24.29 24.83 20.01054****
* p < .10 ** p < .05 *** p < .01 **** p < .001
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Table 7
Multivariate Analysis of Variance 
_______________________ WMS-R Percentile Scores Analysis
Multivariate Test F
Wilks' lambda 3.11362***
Univariate F-tests______ df 2, 128________________________________________ _____
Percentile Variables M e 
Psychotic
a n  S c o  
Affective
r e s
Personality
F
WMS-R Logical I 8.61 21.13 20.14 6.59078***
WMS-R Logical II 10.91 20.30 20.86 4.04675**
WMS-R Visual I 17.77 41.20 34.87 5.53912***
WMS-R Visual II 12.00 36.93 35.44 8.42293****
* p < .10 ** p < .05 *** p < .01 **** p < .001
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Table 8
SIL
Multivariate Analysis of 
Verbal and Abstraction Raw
Variance 
Score Analysis
Multivariate Test 
Wilks' lambda
Univariate F-tests df 2, 117
F
3.20629***
Raw Variables M e a n S c o r e s F
Psychotic Affective Personality
SIL Verbal 17.50 23.14 22.21 4.18740**
SIL Abstraction 11.36 19.22 17.12 5.88575***
* p < .10 ** p < .05 *** p < .01 ★★★★ p < .001
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Table 9
Multivariate Analysis of Variance 
___________________ SIL T Scores and IQ Scores Analysis
Multivariate Test 
Wilks' lambda
Univariate F-tests
F
2.28667
Variables M e a n  S c o r e s F
Psychotic Affective Personality
Variables F
SIL Verbal T 30.32 39.67 35.70 2.90729*
SIL Abstraction T 38.52 46.09 44.53 5.04977***
SIL Total T 33.14 42.97 39.84 5.16914***
SIL Estimated IQ 74.24 87.15 84.51 4.79128***
* p < .10 ** p < .05 *** p < .01 **** p < .001
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Table 10
Multivariate Analysis of Variance 
___________________ Trails and Pegboard Raw Scores Analysis
Multivariate Test 
Wilks' lambda
Univariate F-tests df 2, 116
F
4.40318****
Raw Variables M e a n  S c o r e s F
Psychotic Affective Personality
Trail Making Test A 82.17 44.19 42.08 3.46289**
Trail Making Test B 172.93 104.63 103.08 9.07862****
Pegboard - Dom 140.47 90.65 87.85 14.65487****
Pegboard - Non 127.66 97.02 99.59 4.61354**
* p < .10 ** p < .05 *** p < .01 **** p < .001
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Table 11
Multivariate Analysis of Variance 
____________________Trails and Pegboard T Score Analysis
Multivariate Test 
Wilks' lambda
Univariate F-tests df 2, 107
F
3.17407***
Variables M e
Psychotic
a n  S c o  
Affective
r e s
Personality
F
Trails A  T Score 27.75 37.20 40.52 3.35146**
Trails B T Score 32.50 41.58 41.98 3.52186**
Pegs - Dom T Score 19.86 32.34 35.03 10.36059****
Pegs - Non T Score 22.91 32.58 32.56 3.71238**
* p < .10 ** p < .05 *** p < .01 **★* p < .001
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Table 12
Multivariate Analysis of 
Aphasia Analyis
Variance
Multivariate Test 
Wilks' lambda
Univariate F-tests df 2, 101
F
3.77347***
Variables M e a n S c o r e s F
Psychotic Affective Personality
Variables F
Aphasia Errors 6.40 2.91 2.84 7.69232****
Aphasia T Score 47.91 55.36 55.83 5.35022***
* p < .10 ** p < .05 *** p < .01 ★★★★ p < .001
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Table 14
Summary of Backward Regression Analysis 
for Variables Predicting Recidivism (N = 147)
Variable B SE B Beta
Patient reported number 
of psychiatric admissions 0.201314 .039582 .345499****
Psychiatric pension 3.544188 .775540 .330580****
Aphasia Errors 0.298760 .079246 .253666****
Recent Combined 
Substance Abuse Score 0.014845 .008741 .110266*
* p < .10 ** p < .05 *** p < .01 **** p < .001
Note. R2 = .42367
Adjusted R2 = .40755
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Table 15
Summary of Backward Regression Analysis for Variables Predicting
Recidivism among Patients with Psychotic Disorders (N = 40)
Variable B SE B Beta
Recent Cocaine Use 0.271060 .109828 .372152**
Patient reported number 
of psychiatric admissions 0.303080 .140567 .274195**
Psychiatric pension 4.004185 1.614944 .293701**
WMS-R Visual I Raw -0.141122 .072033 -.227916*
Spending on Drugs and Alcohol -0.016637 .004807 -.504580***
Combined Recent 
Substance Abuse Score 0.060132 .025445 .348490**
* p < .10 ** p < .05 *** p < .01 **** p < .001
Note: R2 = .62930
Adjusted R2 - .56190
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Table 16
Summary of Backward Regression Analysis for Variables Predicting 
Recidivism among Patients with Affective Disorders (N = 42)__________
Variable B SE B Beta
Years of Cocaine Use -0.222991 .078195 -0.355668***
Patient reported number 
of psychiatric admissions 0.380827 .066382 0.962011****
Education -0.437854 .255902 -0.229622*
Age 0.187796 .070725 0.410848**
WMS-R Log I Per -0.108987 .041210 -0.374505**
WMS-R Vis I Raw 0.693183 .230847 1.019040***
WMS-R Vis I Per -0.191202 .057596 -1.238598***
WMS-R Vis II Per 0.092608 .041586 0.551344**
Trails A T Score 0.266236 .077023 0.501398***
Trails B Raw 0.057370 .016462 0.585830***
* p < . 10 ** p < . 05 *** p < .01 p < .001
Note: JR2 = .60541
Adjusted R2 = .47812
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Table 17
Summary of Backward Regression Analysis for Variables Predicting 
Recidivism among Patients with Personality Disorders (N  = 66)________
Variable B SE B Beta
Patient reported number 
of psychiatric admissions 0.272728 .077338 .389230****
Education 0.233727 .087406 .336421**
Trails B Raw 0.008241 .004850 .212998*
Combined Recent 
Substance Abuse Score 0.015542 .006862 .265258**
ROMI Total 0.268928 .111781 .268477**
* p < .10 ** p < .05 *** p < .01 *★★★ p < .ooi
Note: JR* = .30626
Adjusted R2 « .24845
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Appendix A 
MICA RESEARCH DEMOGRAPHICS SHEET
N am e Last
Social Security Num ber 
Sex: M F
Marital S ta tu s:________
Pre-ad m ission  address:
H istory o f  Previous Treatment, A dm ission and D ischarge Dates and D iscnarge D iagnosis:
A g e  o f  O nset or First Psychiatric H ospital A dm ission:
G eneral Functioning:
P re-A dm ission  H ousing Status:
Frequency o f  contact w ith family o f  origin
Social support system  (Financial and em otional)
Recent Em ploym ent H istory. W hen availab le, include em ployer, cates, responsibilities:
First M iddle Patient Chart N um ber
__________________  D O B :__________ :__________ /
Race: ____________________________
  Length o f  Status:____________________________
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R isk  Assessment:
V iolence R ecent/Long Term
Threatening Behavior Recent/Long Term
Originating CSB: _ _ _____________________________ Originating hospital:
Discharging CSB: _________________________________ P O C :_____________
PO C  Telephone: __________________________________
PO C A d d r e ss:_______________  ____
Patient D ischarge A d d r e ss :__________
Patient D ischarge T e le p h o n e :________
D ischarge Date: __________/__________/
D ischarge D iagnosis: A x is - I :_____
A x is -I I :___
A xis-Ill: _ _
A xis-I V : __
D ischarge M edication Information:
Aftercare A p p t:__________ (_ _________ i
A xis-V :
Other:
191
A p p e n d ix  B 
N EU R O PSY C H O LO G IC A L ASSESSM ENT STUDY
RESEA R C H  PA R TIC IPA N T CONSENT FO R M
I, _____________  . hereby agree to participate in a neuropsychological
research project, conducted by Robert Smith. I understand that all information obtained by or about me will be held 
in strict confidence and no information will be given that will identify me. I also understand that how I do on these 
tasks will not affect my stay in this facility or after release.
I understand that during the study, [ will participate in the administration of a series o f interviews and short 
psychological tests. This will take between two and one-half and three hours. The tests will present questions or 
behavioral tasks which will assess areas such as attention, memory, problem -solving, perseveration, creativity, 
movement, and attribution. I understand that participation in this study will have no potential risks, discomforts, 
or inconveniences to me as a participant. Also, there is no cost to this study other than my time.
I understand that I will be assigned a number which will be used to record my answers on the testing forms in order 
to protect my confidentiality.
I understand that my participation in this research project is entirely voluntary. I may withdraw at any time during 
the session and, if  I have any questions, I may ask them at any time during the study. There will be no 
consequences for stopping at any time and I may refuse to answer any questions at any time.
I agree :o give Robert Smith permission to obtain the following information from my records:
Date o f birth, relevant diagnoses, educational and intellectual testing and background information, 
medication history, information from clinical notes from my file with the Department o f Mental 
Health, Mental Retardation, and Substance Abuse Services.
I further give Robert Smith permission to obtain information from aftercare agencies to which I may be referred 
at the time o f my discharge. I expressly authorize these agencies to release information on my attendance. I 
understand that specific information which I share with the staff o f aftercare agencies will remain confidential and 
will not be shared with M r. Smith.
I agree >o participate in this study with full knowledge of the information presented above. I understand that I may 
withdraw at any time and that any questions 1 have will be answered by Mr. Smith. If I wish to have the results 
o f  this test, I may request that Mr. Smith release the results to an authorized psychologist to give to me. Further, 
if  I request, M r. Smith will provide me with a copy o f the report of the researc h project. 1 understand that if I have 
any questions or problems about these procedures. I can direct them to Dr. Michael Ito, Director ot Research, at 
(804) 2153-52 82. Robert Smith will also be available to answer any questions.
Patient Research Assistant
Witness Date
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AUTHORIZATION TO R E L E A SE  CONFIDENTIAL IN F O R M A T IO N
I , ________________________________ , expressly provide authori/aiion to:
the community aftercare program to which i was referred at discharge from Eastern State Hospital, to release 
the following information to Robert Warren Smith, Department o f Psychology, College ot W illiam and Mary, 
and to Dr. Gerald Boynton, Psychologist-Supervisor, Eastern State Hospiiai. 1 understand that all information 
will be held in complete confidence. This means that no one else will be aide to read this information. This 
■iiiOmiation will be coniuluuiiiuiy it.sbemmed ior use in a study on tiie neuropsychology and recidivism of MICA 
patients. This study is funded by the Virginia Department of Mental Health. Mental Retardation and Substance 
Abuse Services.
The information tor which I authorize release includes my attendance in therapeutic activities, general 
assessment of community functioning, assessment of psychiatric and substance abuse history, medical 
compliance and any pertinent follow-up information since my discharge from Eastern State Hospital. I 
understand that this release of information is effective for six months from the authorization date below.
If at any time 1 have any questions, 1 understand that 1 may ask Robert Warren Smith, (804) 221-3891, 
Dr. Gerald Boynton. (804) 253-423'.’.. or Dr. Michael Ito, (804) 253-5282.
Patient Authorization Date Witness Signature Date
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A U T H O R IZ A T IO N  TO  R E L E A S E  N E U R O P S Y C H O L O G IC A L  T E S T IN G  R E S U L T S
F O R  C L IN IC A L  P U R P O S E S
I h ereb y  authorize Robert Sm ith and/or designated  research  associates to release th e resu lts o f  clinical
neuropsychological testin g  performed on (d a te )_____________ . I understand th a t only neuropsychological
testin g  resu lts will be released and that all other information w ill rem ain strictly  confidential.
I understand  that th ese  results shall be re leased  t o _______________________________ for clinical treatm ent
p urposes only.
I f  I h ave any questions, I understand that I  m ay direct them  to  R obert Sm ith or Dr. M ichael Ito, D irector 
o f  R esearch, a t (804) 253*5282.
P atien t R esearch  A ssistant
W itness D ate
A p p e n d i x  C 1 9 4
M IC A  R E S E A R C H  P R O JE C T  
N E U R O P S Y C H O L O G IC A L  H IS T O R Y  A N D  IO T E R V IE W
I. C H A R T  R E V IE W
N am e Last F irst M .I. Identification Num ber
A dm ission  D iagn osis:
A xis-I  
A xis-I I 
A x is-I ll
A xis-I V  A xis-V
Current M edication Orders:
R ecent C hanges in M edication Adm inistration:
H . N E U R O P S Y C H O L O G IC A L  H IS T O R Y  IN T E R V IE W  
A . N eu rop sych ological-M edical H istory:
1. H ead/Spinal Injuries. Identify location , con cu ssion , lo ss o f  con sc iou sn ess, am nesia,
hospitalization and dates.
2 . Cerebrovascular A ccidents. Identify location , reported im pairm ents and dates.
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3. In fectious Diseases:. Identify w hether patient has p ositive  h istory  o f  M en in g itis , E ncephalitis, 
Sexually  Transmitted D iseases, etc.
4 . Cancer. Identify patient and fam ily history.
5 . D egenerative D isease. Identify w hether patient has p o sitiv e  h istory  o f  H IV  /  A ID S,
Park inson’s D isease , H untington’s D isease, A lzheim ers D ise a se , etc . in clu d ing  fam ily h istory.
6 . Seizure D isorders. Identify type, onset, etio logy  and location .
B . N europsychological-E ducational H istory:
_________________________________________   C heck One:
Years o f  Education
Grades: ______________  ______________  __________________
T otal M ath R eading/E nglish
H igh  S ch o o l D ip lom a
C ertificate
G .E .D .
Y ears o f  T raining  
D evelopm ental D isab ilities:
Training D escription
Learning D isab ilities:
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C hildhood A ttention  D efic it  Disorder:
Standardized T esting  R esu lts
G .E .D .:  ___
M ilitary: ___
S .A .T . - Verbal:_________ ___
S .A .T . - Math:
m .  N E U R O P S Y C H O L O G IC A L  IN T E R V IE W E R  R A T IN G S  
A lertness at Interview : A lert Fatigued Inattentive C onfused
Hand D o m in a n c e :______________
O bservations:
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N E U R O P S Y C H O L O G IC A L  T E S T IN G  S U M M A R Y  
W echsler M em ory Scale - Revised
L ogical M em ory I:________________ _____________
L ogical M em ory II: _____________
V isual Reproduction I: _____________
V isual Reproduction II: _____________
Shipley Institute o f  Living: _____________
Trail M aking Test A:
Trail M aking Test B:
G rooved  P eg  Board:Dominant:
Non-dom inant:
Reitan-Indiana Aphasia:
W ender-U tah Rating Scale:
T im e Errors
T im e Errors
T im e Drops
T im e Drops
Aphasiatic Constructional
Com pleted
Com pleted
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Appendix D
L O G IC A L  M E M O R Y  I A dm in ister both  stories. Score 1 p o in t for each correct item  (:;ee A p p en d ix  A  in  M anual •
 __________________________ for Scoring Criteria)._____________________________ ___________ __________________________
S to r y  A
A n n a  / T h o m p s o n  /  o f  S o u th  /  B o s to n  I, e m p lo y e d  / a s  a  c o o k  /
9
in a 's c h o o l  /  c a fe te r ia  /, re p o r ted  I a t th e  G t y  H a ll / S ta t io n  I___________________ __
th a t s h e  h a d  b e e n  h e ld  u p  / o n  S ta te  S tr ee t  I th e  n ig h t  b e fo r e  /_____________________________________ __
a n d  ro b b ed  I o f  f if ty - s ix  d o lla rs  / .  S h e  h a d  fo u r  I __
sm a il c h ild re n  t, t h e  ren t w a s  d u e  /, a n d  th e y  h a d  n o t e a te n  / _
fo r  tw o  d a y s  L  T h e  p o l i c e / ,  to u c h e d  b y  th e  w o m a n 's  s to r y  / ,  _
to o k  u p  a c o lle c tio n  I for  h e r /.
Max. «  25 
Total Story A
S to r y  B
R ob ert I M iller / w a s  d r iv in g  I a te n -to n  I truck  I
d o w n  a h ig h w a y  / at n ig h t I in  th e  M is s is s ip p i / D e lta  I,
i c a r r y in g e g g s  . to  N a sh v ille  /, w h e n  h is  a x le  / b ro k e  /.
H is  truck s k id d e d  / o ff th e  r o a d / .  in to  a d i t c h / .
H e  w a s  th r o w n  I a g a in st  th e  d a sh b o a r d  / a n d  w a s  b a d ly  sh a k e n  I.
T h e r e  w a s  n o  traffic I an d  h e  d o u b te d  that h e l p  w o u ld  c o m e  /.
lu s t  th e n  h is  tw o -w a y  r a d io  I . b u z z e d  /. H e  q u ick ly  a n s w e r e d  /,
"T his is G r a ssh o p p e r  / .  "
M ax. = 25 
Total S to ry  B
M ax. «= 50 
Total S u m  of S tories A + B
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Appendix F
S H I P L E Y  I N S T I T U T E  O F  L I V I N G  S C A L E  
Vocnbttlarv T e s t  a n d  A b s t r a c t i o n  T e s t
NAM E
In the test below , the first w ord in each  line is printed in c a p itd  letters. O pposite it are four 
other words. D r a w  a line under the one w o r d  which means the s a m e  fJitog, or m ost nearly the sam e thing, 
as the first word. A sample has been worked out for you. If you d e n t  know , guess. Be sure to under*
LARGE
(1) TALK
(2) TERM IT
(3) PAllDON
(4) COUCII
(5) REMEMBER 
(8) TUMBLE  
CO H ID E O U S
(8) C O H DIAL
(9) E V ID E N T
(10) IMPOSTOR
(11) MERIT
(12) FASCINATE
(13) INDICATE
(14) IGNORANT
(15) FORTIFY 
(IS) RENOWN
(17) N A RRA TE
(18) M ASSIVE
(19) H ILA R ITY
(20) SMIRCHED
(21) SQUANDER
(22) CAPTION
(23) FACILITATE
(24) JOCOSE
(25) APPRISE
(26) RUE
(27) DENIZEN
(28) DIVEST
(29) AMULET
(30) INEXORABLE
(31) SERRATED
(32) LISSOM
(33) MOLLIFY
(34) P LA G IA R IZ E
(35) O R IF IC E
(38) QUERULOUS 
(37) PARIAH
(33) ABET
(39) TEMERITY
(40) PRISTINE
that means the 
red .
same thing as the first word.
sample 
big silent wet
draw
begin here 
eat speak sleep
allow sew cut drive
forgive pound divide teU
pin eraser sofa glass
swim recall number defy
drink dress faU think
silvery tilted young dreadful
swift muddy ieafy hearty
green obvious sceptical afraid
conductor officer book pretender
deserve distrust fight separate
welcome fix stir enchant
defy excite signify bicker
red sharp uninformed precise
submerge strengthen vent deaden
length head fame loyalty
yield buy associate tell
bright large speedy low
laughter speed grace malice
stolen pointed remade soiled
tease belittle cut waste
drurr. ballast heading ape
help turn strip bewilder
humorous paltry fervid plain
reduce strew inform delight
eat lament dominate euro
senator inhabitant fish atom
dispossess intrude rally pledge
chann orphan dingo pond
untidy mvolatile rigid sparse
dried notched armed blunt
moldy loose supple convex
mitigate direct pertain abuse
appropriate intend revoke maintain
brush hole bu iid iu g lute
maniacal curious devout complain.
outcast priest lentil locker
waken ensue incite placate
rashness timidity desire kindness
vain sound first level
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Com piete the following. Each dash ( __ ) calls for either a num ber or a letter to be filled in . Every
l i n e  i s  a  s e p a r a t e  i t e m .  T a k e  t h e  i t e m s  i n  o r d e r ,  b u t  d o n 't  s p e n 4  to o  m u c h  t i m e  o n  a n y  o n e .
s t a r t  h e r e
(1 )  1 2 3 4 5 —
(2 )  white black short long down —  —
(3) AB EC CD D —
(<) z n  w  v u _
( 5 )  1 2 3 2 1  2 3 4 3 2  3 4 5 4 3  4 5 6  ------------ '
(6) NE/SW SE/NW E/W N/__
( 7 )  e s c a p e  s c a p e  c a p e  —
( 8 )  o h  h o  r a t  t a r  m o o d  _ _   —
(9) A Z B Y C X D  _
(1 0 )  tot tot bard drab 537  —  —
(11)  mist is wasp as pint in tone —  —
(12)  57326 73265 32657 26573 __________________
(1 3)  knit in spud up both to stay —  —
( 14 )  Scotland landscape scapegoat —  —  —  — ee
(1 5 )  surgeon 1234567 snore 17635 rogue ---------------  -
( 1 6 )  U r n  tan rib rid rat raw hip  — ---------
(1 7 )  tar pitch throw saloon  bar rod fee  tip end plank —  . . .  —  -  - - - m eals
(1 8 )  3124 82 73 154 46 13 __
( 1 9 )  lag leg  pen pin b ig  bog rob — ---------
(2 0 )  two w  four r one o three  
Appendix G
Port A
SAMPLE
End
Begin
Begin
TR AIL  M AKIN G  204
Part B
SAMPLE

Appendix H 
\M JRS-25
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As a child I was (or had):
3. Concentration problems, 
easily distracted
4. Anxious, w orrying
5. Nervous, fidgety
6. Inattentive, daydreaming
7. Hot- or short-tem pered, 
low boiling point
Not at 
all
1
1
1
1
1
M ildly
2
2
2
2
~>
M oderate Quite Very 
or very a bit much 
slightly
3 4 5
3 4 5 
3 4 5 
3 4 5
3 4 5
9. Temper outbursts, 
tantrums 1 2 3 4 5
10. Trouble w ith stick-to- 
it-tiveness, not following 
through, failing to finish 
things started 1 2 3 4 5
11. Stubborn, strong-willed 1 2 3 4 5
12. Sad or blue, depressed, 
unhappy 1 2 3 4 5
15. Disobedient w ith parents, 
rebellious, sassv 1 3 4 5
16. Low opinion o f  m yself 1 2 3 4 5
17. Irritable 1 2 3 4 5
20. Moody, ups and downs 1 2 3 4 5
21. Angry 1 2 3 4 5
24. Acting w ithout thinking, 
impulsive 1 3 4 5
25. Tendency to be immature 1 2 3 4 5
26. Guilty feelings, 
regretful 1 2 3 4 5
27. Losing control o f  myseif 1 2 3 4 5
28. Tendency to be or 
act irrational 1 2 3 4 5
29. Unpopular w ith other 
children, d idn’t keep 
friends for long, d idn’t 
get along w ith other 
children 1 2 3 4 5
40. Trouble seeing things 
from someone else’s point 
of view 1 2 3 4 5
41. Trouble w ith authorities, 
trouble w ith school, 
visits to p rincipal’s 
office 1 2 3 4 5
51. Overall a poor student, 
slow learner 1 2 3 4 5
56. Trouble w ith mathematics 
or numbers I 2 3 4 5
59. Not achieving up to 
potential 1 2 3 4 5
207
Appendix I
REITAN-INDIANA APHASIA SCREENING TEST
Form f o r  Ad u l t s  o n d  O l d e r  C h i l d r e n
N a m e :______________________________________________________ A ge:_________Date:-------------------------Examiner:.
Copy SQUAF.E Repeat TRIANGLE
Name SQUARE Repeat MASSACHUSETTS
Spell SQUARE R epeat METHODIST EPISCOPAL
Copy CROSS Write SQUARE
Name CROSS Read SEVEN
Spell CROSS Repeat SEVEN
Copy TRIANGLE Repeat/Expla n HE SHOUTED THE WARNING.
Name TRIANGLE Write HE SHOUTED THE WARNING.
Spell TRIANGLE Compute 85 -  27  =
Name BABY Compute 1 7 X 3  =
Write CLOCK N am e KEY
Name FORK Demonstrate u se  of KEY
Read 7 SIX 2 Draw KEY
Read MGW Read PLACE LEFT HAND TO RIGHT EAR.
Reading 1 Place LEFT HAND TO RIGHT EAR
Reading II P lace LEFT HAND TO LEFT ELBOW
Copyright ©  1979 by Ralph M. Reitan
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PAST 30 
Davs
LIFETIME USE
Yrs. Riof
adm.
Qj/ Alcohol - Any
© use at ail Alcohol - To Intoxication
Heroin
^  Methadone
©  Other opiates/
© analgesics Barbiturates
(P?) Other secu 
hyp/tranq.
Cocaine
M9J Amphetamines
up) Cannabis
UIJ Hallucinogens
C 2) Inhalants
©  More than one 
substance ptr 
day (IncL 
alcohol).
Note: See msiual for represeraauve examples 
lor each drug class
* Route of Administration: I = Oral. 2 = Nasal 
3 * Smoking. 4 = Non IV inj.. 5 = IV inj.
□
][
Appendix J
DRUG/ALCOHOL USE
Which substance is die major 
prooiem? Please code as 
above or 00-No problem: 
15-Alcohol St. Drug (Dual 
addiction); 16-Polydrug; 
when not clear, ask patient.
15. How long was your last 
period of voluntary 
abstinence trom this 
major substance?
! 00 - never abstinent /
16. How many months ago 
did this abstinence end?
(00 • still abstinent)
• ©  How many times have you: 
Had alcohol dx's 
Overdosed on drugs
Gr­
in
* n8) How many times in your life have you 
been treated for
Alcohol Abuse: 
Drug Abuse:
•f!9jHow many of these were detox oniy?
Alcohol
Dtug
201 H ow  much would you say you spent 
during the past 30 days on:
Alcohol
Drags
a©  How many daya have you been created in an outpatient set­
ting for alcohol or drugs m the 
put 30 days (Include NA. AA).
©  How many days in the put 30 
have you experienced:
Alcohol Problems
Drug Problems
FOR QUESTIONS 23 A 24 PLEASE ASK 
PATIENT TO USE THE PATIENTS 
RATING SCALE
©  How troubled or bothered have you beoi 1 
the put 30 days by these: |
Alcohol Problems
Drug Problems I
( 2 d )  How imp o rtan t to you now  is treatment fo 
these: — _
Alcohol Problems I
Drag Problems \
INTERVTEWFP SEVERITY RATING
© How would you rate the patient’s(rsw H>ool»IWIt fflfneed fortreatmen or:
Alcohol Abuse
Drag Abuse
CONFIDENCE RATINGS
Is the above information significantly 
distorted by:
© Patterns misrepresentation?0 • No 1 Yes
© Patients inability to understand?0 - No I Yes
E
c
c
Comments
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Was this admssion prompted 
or suggested by the cnminai 
justice system (judge, probation; 
paroie officer, etc.)
0 - No I Yes
©  Are you on probation or 
paroie?
0 - No 1 - Yes
How many times in your life have you been 
arrested and chirged with the following:
LF.ftAI. ST.m.-S
How many of these charges 
resulted in convicuons?
□
□
How many times in your life have you Dcen 
charged with the following:
•(OT) • shoplifting/vandalism
* ' paroie/orobation violations
* (j53) • drug clargea
forgery
*(67). weapotis offense
burglary, larceny, fi & E
robbe^ *
*(T5)- assault
*(H)- arson
*(2)- rape
* (0^ . homiciiie. manslaughter
■Qdfr - prosutution
* (fffa) - contempt of court
" ' ot^ er
* Q6j Disorderly conduct, vagrancy.
public intoxication
• ©  Driving while intoxicated
• Qili) Major dnvmg violations
(reckless driving, speeding, 
no license, eta.)
• 0  How many months were you 
incarcerated in your life?
20. How long was your 
Iasi incarceration?
21. What was u for?
(Use code3-14, 16-18.
MOS.
□If multiple charges, code most severei
□(22) Are you presently awaiting charges, tnal or sentence?0 - No 1 Yes
^3)Whai for (If multiple charges, 
use most severe}.
(24) How many days in the past 30 
were you rfeuin—i or
(3) How many days in the past 30 
have you engagea in ulegai 
activities for protii?
□
FOR QUESTIONS 26 & 27 PLEASE ASK 
PATIENT TO USE THE PATIENTS 
RATING SCALE
an
(26) How serious do you feel your 
present legal problems are?
(Exclude ctvii prootanst
How important to you now is 
counseling or referral for these 
legal problems ?
INTERVIEWER SEVERITY RATING
08) How would you rate the patient s j
need for legal services or counseling?!
c
□
□
CONFIDENCE RATINGS
Is the above information significantly 
distorted by:
(9) Patients misrepresentation?
0 - No 1 - Yea
(3M Patient a inability to understand? 
W  0. No 1 - Yea
□
□
c
Comments
FAMILY HISTORY
Have any of your relatives had what you would call a significant drinking, drug use or psych oroblem- one that did or should have led to treaosm?
Mother s Side Father s Side Siblings
Grandmother
Ale
□
Drug
□
Psrch
□ Grandmother
Ale
□
Drug
□
Psych
□ Brother til
Afc
□
Drug
□
Psvcb
□
Gmdfather □ □ □ Grandfather □ □ □ Brother #2 □ □ □
Mother □ □ □ rather □ □ □ Sister Ml □ □ □
Aunt □ □ □ Aunt □ □ □ Sister #2 □ □ □
Uncle □ □ □ Uncle □ □ □ 'l“ where the answer is clearly y« for antDirection: Ph.ce O ' in rciauve category where the answer is clearly 1______________
relative wnhin the category. "X" where the answer is uncertain or ~I don't know' and Tf* vtm there never was a relieve fivhl LflH PBtJWDt* 
Code most iroblemaoc relaove in cases of multiple memoers per category.
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PSYCHIATRIC STATUS
’ (l) How many tunes nave you been treated 
lor any psychological or emotional problems?
In a hospital
As an Opt. or Priv. patient
(2^  Do you receive a pension for a r- |
psychiatric aisaolity? __I
0-No 1 Yes
Have you had a significant period, (that was not 
a direct result ol drug/alcohol use), in which you 
have:
PAST 30 IN 
0 - No 1 - Yes DAYS YOUR
LIFE
^3^ Experienced serious 
depression
M j  Experienced serious 
anxiety or b ms ton
©  Experienced hallucinations
Q  Experienced trouble under­
standing. co.-eencranng or 
remem berm;
(?) Expenenceil trouble control­
ling violent sehavior
Expenenceil serious 
thoughts of .'luicide
Q  Attempted tuicidc
©  Been prescribed
medication fm any psycho­
logical/emotional problem
©  How many days in the past 30 
have you experienced these 
psychological or emotional . ■ 
problems? I
FOR QUESTIONS 12 &. 13 PLEASE ASK 
PATIENT TO USE THE PATIENT ’S 
RATING SCALE
©  How much have you been troubled r——j
or bothered by these psychological I J
or emotional problems in the past 
30 days?
(H) How important to you now is I "J
treaancnt for these psychological I I
problems?
THE FOLLOWING ITEMS ARE TO BE 
COMPLETED BY THE INTERVIEWER
At the time of the interview, is patient;
0-No I-Yes
^  Obviously depressed/withdrawn □
©  Obviously hostile □
^  Obviously anxious/nervous □
©  Having trouble with reality testing | j
thought disorders, paranoid thinking 1 1
Having trouble comprehending. : J
concentrating, remembtxxng. I I
^  Having suicidal thoughts □
Comments
INTERVIEWER SEVERITY RATING
How would you rate the panent's 1 —1 
need for psychiatric/psychological
treatment?
CONFIDENCE RATINGS
Is the above information significantly 
distorted by:
till Patient's misrepresentation 
0 - No I - Yes
Q  Patient's mabiiity to understand? 
0 - No 1 - Yes
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Appendix K
Appendix I: Rating of 
Medication Influences 
(ROMI)
Patient's name:______________________________________________ Date ___________________
Rater's name:  _____________________________________________________________ _ ____
BEGINNING THE INTERVIEW:
< A) SEMI-STRUCTURED INTERVIEW
For interviewing patients with whom you are not well acquainted, it is helpful to begin the interview 
with a few background questions. Reviewing the overall lituation and setting will help you obtain more 
accurate information regarding factors which directly affect compliance.
Suggested prompt:
"I'm trying to ieam about people's attitudes toward taking neuroleptic medication. I'd like to understand 
what makes people willing to take medication and what makes them feel reluctant to take medication. But, 
before I ask you about your opinions. I need tc ask you a iittle background information."
You should ask about the following general areas which may impact on compliance. These topics 
include:
(1) Living situation (:.g., supervised vs. unsupervised, alone vs. family vs. residence).
(2) Treatment setting
(3) Prescribed medica.tion regimen (specific neuroleptic, IM route of medication vs. oral, other non­
neuroleptic medication, dosage, frequency, length of treatment).
(4) Patient's overall attitude toward treatment and meditation (positive vs. negative, voluntary com­
pliance vs. coerced compliance). ------------- - ----------------— — --------- - --
(5) The family's and caregiver's overall attitude toward treatment and medication.
B) STRUCTURED INTERVIEW
"Now I'd like to ask you some questions about why you tike the medication. There are no nght or wrong 
answers, it’s just what you think. I'm only interested in your opinion, not what your doctor or your family 
may think."
Begin the interview with an open ended question, such as, "What is the main reason you are willing to 
take medication?"
"Now 1 am going to read you some reasons other people ire willing to take their medication. Please tell me 
if any of these reasons have influenced your willingness to take your medication over the past month."
If patient has been norcompliant for at least 1 week for any part of the last month or is currently off 
medication, begin with Part II, otherwise begin with Part I.
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PART I: REASONS FOR COMPLIANCE
ARE YOU WILLING TO TAKE YOUR MEDICATION BECAUSE":
DEGREE OF INFLUENCE
1. PERCEIVED DAILY EENEFIT
You believe the medicine helps you feel better?
NA 1
None
2
Mild
3
Strong Not
9
Assessable
2. POSITIVE RELATION WITH PRESCRIBING CLINICIAN 
Your relationship with vour prescnbing doctor influences you?
NA 1
None
2
Mild
3
Strong Not
9
Assessable
3. POSITIVE RELATION WITH THERAPIST 
Your relationship with voar therapist influences yon?
NA 1
None
2
Mild
3
Strong Not
9
Assessable
4. POSITIVE FAMILY BELIEF
Someone tn your family cr a friend believes that you should 
take medicine?
NA i
None
2
Mild
3
Strong Not
9
Assessable
5. RELAPSE PREVENTION
You believe taking medication prevents your illness or symptoms 
from returning?
NA 1
None
2
Mild
3
Strong Not
9
Assessable
6. PRESSURE/FORCE
You are pressured or forced to take medication?
NA 1
None
2
Mild
3
Strong Not
9
Assessable
7. FEAR OF REHOSPITALIZATION 
You are afraid of being renospitalized?
NA 1
None
2
Mild
3
Strong Not
9
Assessable
PART II: REASONS FOR NONCOMPLIANCE
"Even if you always take your medication, there may te times when 
didn't have to. What is the rr.ain reason you felt reluctant or wished 
month?"
you
you
are reluctant to take it or wish you 
didn't have to take the medication this
"Now I am going to tell you some reasons other people are reluctant to take their medication. Please tell me if 
any of these reasons apply to you."
"ARE YOU RELUCTANT TC TAKE YOUR MEDICATION BECA'JSE":
DEGREE OF INFLUENCE
8. NO PERCEIVED DAILY BENEFIT NA 1 2 3 9
You believe medication dots not help you feel better? None Mild Strong Not Assessable
9. NEGATIVE RELATION WITH CLINICIAN
Your bad relationship with your prescribing doctor influences NA 1 2  3 9
you? None Mild Strong Not Assessable
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10. NEGATIVE RELATION WITH THERAPIST
Your bad relationship wit.t your therapist influences you?
11. PRACTITIONER OPPOSED TO MEDS
One of your practitioners does not believe you should be taking 
the medication?
12. FAMILY/FRIEND OPPOSED TO MEDS
Someone whose opinion is important to you is against your 
talcing the medication?
13. ACCESS TO TREATMENT PROBLEMS
You have difficulty getting to your appointments, and/or 
difficulty getting meds?
14. EMBARRASSMENT OR STIGMA OVER MEDS/ILLINESS 
You feel embarrassed about taking medication?
15. FINANCIAL OBSTACLES
You don't have enough money to pay for treatment or 
medication?
16. SUBSTANCE ABUSE
You would rather take other drugs or alcohol?
17. DENIAL OF ILLNESS
You don't believe you have a mental illness?
18. MEDICATION CURRENTLY UNNECESSARY
You don't believe that you currently need the medication?
19. DISTRESSED BY SIDE EFFECTS
The side effects of the medicine are too upsetting to you?
NA 1 2 3 9
None Mild Strong Not Assessable
NA 1 2 3 9
None Mild Strong Not Assessable
NA 1 2 3 9
None Mild Strong Not Assessable
NA I 2 3 9
None Mild Strong Not Assessable 
Symptom Related Problems □
Logistical Problems G
NA I 2 3 9
None Mild Strong Not Assessable
NA 1 2 3 9
None Mild Strong Not Assessable
NA 1 2 3 9
None Mild Strong Not Assessable
NA I 2 3 9
None Mild Strong Not Assessable
NA 1 2 3 9
None Mild Strong Not Assessable
NA 1 2 3 9
None Mild Strong Not Assessable
Current Side Effects O
Fear of Future Side Effects G
20. DESIRES REHOSPITALIZATION 
You feel more comfortable in the hospital?
NA 1 2 3 9
None Mild Strong Not Assessable
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C H IL D H O O D  (0-111________________
A . Sociability nnd withdrawal
0 N ot w ithdraw n, activeiy  and frequent 
ly seeks out socia l contacts.
1
2 M ild  w ithdraw al, enjoys socia liza tion  
w hen in v o lv e s , o ccasion a lly  seek s  
opportunities to socia lize .
3
4 M oderately withdrawn, g iven  to 
d aydream ing and e x c e ss iv e  fantasy , 
may p a ss iv e ly  a llow  s e lf  to b e  draw n  
into con tact with others but d o es  not 
seek  it.
5
6 U nrelated  to e thers, w ithdraw n and 
isolated. A vo  ds contacts.
B. Peer relationships
0 M any friends, c lo se  re lation sh ips w ith  
severa l.
1
2 C lo se  relationships with a few  friends  
(I  o r  2 ) , casual friendships w ith  oth  
ers.
3
4  D evian t friencship  patterns: friendly  
with ch ildren  younger o r  o ld er  o n ly , or  
relatives on ly , or casual re lation sh ips  
on ly .
5
6 S ocia l iso la te , no in en d s . not ev en  
superficia l relationships.
C. Scholastic performance
0 E xce llen t student
1
2 G ood student
3
4 Fair student
5
6 Failing  all c la ise s
D. Adaptation io school
0 G ood  adaptation, enjoys s c h o o l, no or  
rare d isc ip lin e  prob lem s, has friends at 
sch o o l, likes rrost teachers.
1
2 Fair adaptation, occasion a l d isc ip lin e  
problem , not very interested  in sch o o l,  
but no truancy, or rare. H as friends  
in sch o o l, but d ees  not often  take part 
in extracurricular activ ities.
3
4 Poor adaptation, d islik es s c h o o l, frc 
quent truancy, frequent d isc ip lin e  
problem .
5
6 R efu ses to have anything to do with  
sch oo l - dciinq icn cy  or  vandalism  
directed  against sch ool.
Appendix L 
PREMORBID ADJUSTMENT SCALE
EARLY ADOLESCENCE (12-15)
A. S o c ia b ility  and  w ith d ra w a l
0 N ot w ithdrawn.
1
2 M ild w ithdraw al, enjoys socialization  
w hen in vo lved , occasion ally  seeks  
opportunities io  socia lize .
3
4 M oderately w ithdrawn, g iven  to 
daydream ing and ex c ess iv e  fantasy, 
may passively  a llow  se lf  to be drawn 
into contact w ith others. k>ut d oes not 
seek it.
5
6  Unrelated to others, w ithdraw n and 
isolated. A void s contact.
B. Peer relationships
0 M any friends, c lo se  relationships  
with severa l.
1
2 C lose  relationships with a few  fnends  
(1 or  2 ) . casual friendships w ith  oth 
era.
3
4 D eviant friendship patterns: friendly 
with children younger or ild er  on ly , or 
relatives on ly , or casual relationships 
on ly .
5
6 Socia l isolate, no iriends. not even  
superficial relationships.
C . S ch o la stic  p erfn riiiiin ct
0 E xcellent student.
1
2 G ood student.
3
4 Fair student.
5
6  Failing ail c la sses .
I). Adaptation to school
0 G ood adaptation, enjoys sch o o l, no or 
rare d iscip lin e p rob lem s. lias friends a', 
sch oo l, likes m ost teaclicr.i.
1
2 Fair adaptation, occasional d iscip line  
problem , not very interestrd in school 
but no truancy, or rare. H as friends 
in sch o o l, but d ocs not ottcn  take part 
in extracurricular a c tiv ities .
3
4 Poor adaptation, d islikes .*ciu>ol. Ire 
quent truancy, frequent d iscip lin e  
p rob lem .
5
6 R efuses io  have anything o do with, 
sch ool-d eh nq u cn cy or vandalism  di 
reeled against sch ool.
E. Social-sexual Aspects of Life
0 Started d atin g , sh ow ed  a healthy 
in ter es t ' in th e o p p o s ite  sex . m ay have 
g o n e  'steady."  m ay include som e sexu ­
al activ ity .
1 A ttachm ent and interest in o thers, may 
be sa m c-scx  a ttachm ents, may be a 
m em oer  o f  a grou p , interested m the 
o p p o s ite  s e x . a lthough  may not nave 
c lo se , em otion a l relutiunshm  wuh  
s o m eo n e  o f  the op p osite  sex . crush es' 
and flirtations.
2 C on sisten t d eep  in terest in sam e-sex  
attachm ents w ith  restricted  or no inter­
e st in  th e o p p o site  s e x .
3 C asu al sa m e-sex  attachm ents, with  
inadequate attem pts at relationships  
w ith  the o p p osite  s e x . C asual contacts  
w ith  both sex es .
4  C asu al con tacts w ith  th e sam e s e x . no 
interest in the o p p o s ite  sex .
5 A  lon er , no or rare contacts with  
cith er  b o y s  or  g ir ls.
6  A n tiso c ia l, avo id s or  avoided  by 
p eers. (D iffers  from  ab ove m that an 
activ e  a vo id an ce  o f  o thers rather than 
p a ss iv e  w ithdraw al is im plied ;
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LATE ADOLESCENCE (16-1X)
A . S o c ia b ility  n n d  w ith d r a w a l
0 N ot withdrawn
1
2 M ild w ithdraw al, en joys socia liza tion  
w hen in v o lv e * , occasion a lly  seek s op  
port uni ties to tocia lizc .
3
4 M oderately w ithdraw n, g iv en  to day  
dream ing and e x c e ss iv e  fantasy, m ay  
p assive ly  a llow  s e lf  to be draw n into  
contact w ith  o th ers, but d o es  not seek  
it.
5
6 U nrelated  to oth ers, w ithdraw n and 
isolated. A vo id s contact.
B. Peer relatio.uhips
0 M any friends, c lo se  relationships w ith  
several.
1
2  C lo se  relationships w ith a few  friends 
(1 o r  2 ) , casual friendships w ith  oth  
ers.
3
4 D evian t frien csh ip  patterns: friendly  
with children yo u n g er  or  o ld er  o n ly , or  
relatives o n ly , o r  casu a l relationships  
only.
5
6  S ocia l iso la te , no friends, not even  
sup erficia l relationships.
C. Scholastic performance
0  E xcellent student
1
2 G ood student
3
4  Fair student
3
6  Failing all c la sses
D. Adaptation o School
0  G ood  adaptation, en joys sc h o o l, no or  
rare d isc ip lin e  p rob lem s, has friends at 
sch oo l, likes m ost teach ers.
1
2 Fair adaptation, o cca sio n a l d isc ip lin e  
problem , not very interested  in ..school, 
but n o truancy, or rare. H as friends in 
sch o o l, but d oes  not o lten  take p a n  in 
extracurricular activ ities.
3
4 P oor adaptation, d islik es s c h o o l, fre 
quent truancy, frequent d isc ip lin e  
problem .
5
6  R efu ses to h ave anything to do w ith  
sch oo l • d elinq u en cy  or  vandalism  di 
reeled  against s ch o o l.
E. Social Aspwt.s of Sexual Life
0 A lw ays snow ed  a healthy interest i i  
the op posite sex . dating, las gone
stead y, en gaged  m som e scxu ai 
activity tnot n ecessarily  in tercourse!.
1 D ated regularly. Had on ly  o n e  friend 
o f  the op posite  sex  with w h om  the pa 
ticnt w ent "steady ' for a long tim e. 
(Includes sexu al asp ects o f  a relation  
sh ip , although not n ecessarily  inter 
cou rse: im plies a tw osom e , pairing on" 
into cou p ics . as d istingu ished  from  
b e lo w .)
2 A lw a y s m ixed  c lo se ly  w-i h b o y s  and 
g ir is . (Invo lves m em bersh ip  in a 
crow d , interest in and attachm ent to 
o th ers , no co u p le s .)
3 C onsisten t d eep  interest 11 sam c-scx  
attachm ents w ith  restricted o r  no inter­
e s t in the op p osite  sex .
4 C asual sa m c-scx  attachm ents w ith  
inadequate attem pts at adjustm ents to 
g o in g  out with the op p o si.e  s e x .
C asual contacts w ith b ovs and girls.
5 C asual con tacts w ith sam e s e x  with 
lack o f  interest m op p osite  sex . O c ca ­
s ion a l con tacts w ith the o p p osite  sex .
6  N o  d esire to be with b oys and girts, 
n ev er  w ent out with o p p n h tc  sex .
ADULTHOOD (19 AM) ABOVE)
A. Sociability and withdrawal
0 N ot w ithdraw n, actively  i.nd frequent 
Iv seek s out socia l contact.
1
2 M ild w ithdraw al, en joys socia lization  
w hen  in vo lved , n ccasion a  iy seek s op  
portunities to soc ia lize .
3
4 M oderately w ithdraw n. g:ven  to day 
d ream ing and e x c e ss iv e  fantasy, may 
p a ssiv e ly  a llow  s e lf  to be draw n into 
con tact with others but d oes  not seek
it.
5
6  U nrelated  to o th ers, w ithdraw n and 
isolated. Avoids contacts.
B. Peer relationships
0  M any friends, cio.se relationships with 
severa l.
1
2 C lo se  relationships with a few- friends 
(1 or  2). casual friendships with oth 
ers.
3
4 D ev ian t iricndsh ip  patterns: friendly 
w ith  children you nger or o ld er on ly , or 
relatives o n ly , or casual relationships  
o n ly .
5
6 S o c ia l iso late , no friends, not even  
sup erficia l relationships.
C. Aspects of Adult Social- 
Sexual Life
a M arricu. present or  form erly
0 M arn eo . on iv  on e m arriage tor remar­
ried as a result o f  death o f  spouse), 
liv ing  as a unit, adequate scxuai rela 
lion s.
1 Currently m arried with history o f  low  
sexual d rive , periods o f  d ifficult sexual 
relations, or extram arital affair.
1 M arried, m ore than on e tim e, current­
ly rem arried. A dequate scxuai rcia 
(ions during at least on e m arriage.
2 M a m c a . o r  d ivorced  ana remarried, 
w ith ch ron ica lly  inadequate sex  life.
2 M arried, and apparently permanently 
separated o r  d ivorced  w ithout remar 
riage, but m aintained a h om e in one  
m arriage for at least 3 years.
3 Sam e as a b o v e , but: d ivorce  occurred  
o v er  3 years a g o . and. w hile  m am ed . 
m aintained a h om e lor less than 3 
years.
b N ever m a m ed . ov er  3U:
2 H as b een  en gaged  on e or m ore times 
or has had a long-term  relationship tat 
least 2  vcars) in vo lv in g  heterosexual or 
h om osexual re lations, or apparent evi 
duiMM o f  a lava  affair w ith  on e person, 
hut unable tu ach iev e  a long-term  com ­
mitment such as m arriage.
3 Long-term  h eterosexu al or hom osexual 
relationship lasting over  6 months but 
less than 2 years, il l  stable, long- 
lasting h om osexu al relationship, over 2 
years, sco re  as ’3." I
4 B rief, or short-term  dating experiences  
(heterosexu al or hom osexual) with one  
or m ore partners, but no long-lasting  
sexu al ex p er ien ce  with a sin g le  part 
ner.
5 S exu al and/or socia l relationships rare 
or infrequent.
6  M inim al sexu al or socia l interest in
c i th e r  m e n  o r  w o m e n ,  is o la te d .
c . N ever  m a m ed . age 20-29
0  H as had at least on e long-term  love- 
affair (m inim um  o f  6  months) or on 
gagem em . even  though religious or 
other prohibitions or inhibitions may 
have prevented actual scxuai union. 
M ay have lived together
1 Has dated actively , had several boy 
friends nr girifriends. som e reia 
lionsh ips have lasted a lew  m onths, hut 
no long-term  relationships. Relation  
ships mav have b een  "serious, but a 
long-term  com m itm ent such as mar 
riage w as not understood to be an 
eventuality
3 Brief, short-term  dating exp erien ces or 
affa irs" with on e or m ore partners, 
but no long-lasting  scxuai experiences  
with a sin g le  partner
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4 Casual sexua. or social relationships 
wuh persons o f either sex with no deep 
emotional bords.
5 Sexual and/or social relationships rare 
or infrequent.
6 Minimal scxuai o r social interest in 
either men or women, isolated.
GENERAL_____________
A. Education
0 Completed college ana/or graduate 
school, or professional school (Law. 
for example).
1 Completed high school and some 
college or vocational training school or 
business schocl (such as secretarial or 
computer programming schools).
2 Completed high school.
3
4 Completed eighth grade.
5
6 Did not get beyond fifth grade.
B. During a period of 3 rears up to 6 
months before first hospitalization or 
onset of first episode, patient was 
employed for piy or functioning in 
school
0 All the tune.
1
2 Half the tune.
3
4 Briefly, about 25 percent of the time.
5
6 Never.
C. Within a period of a year up to 6 
months before first hospitalization or 
first episode change in work or school 
performance occurred
0 Abruptly.
1
2 Within 3 mont.ts.
3
4 Within 6 months.
5
6 Imperceptibly, difficult or notpossiblc 
to determine onset o f  deterioration.
D. During a period of 3 years up to i 
months before first hnspiialization or 
first episode, frequency of jo b  chang-.*. 
if w orking, o r in terrup tion  of school 
attendance was
0 Same job held, or remained in schoo..
1
2 Job change or school interruption 
occurred two to three times.
3
4 Kept the same job more ilian 8 months 
but less than a year, or remained 
continuously in school lot the same 
period.
5
6 Less than 2 weeks at a job or in 
school.
E. Establishm ent of independence 
0 Successfully established residence
away from family home, inanctally 
independent of parents.
2 Made unsuccessful attempts to csiab 
iish independent residence, lives in 
parents' home, but pays pirents room 
and board, otherwise financially inde 
pendent.
4 Lives in parents' home, receiving an 
allowance from parents which patient 
budgets to pay for entertainment, 
clothes, etc.
6 Made no attempts to leave home or be 
financially independent.
F. Global assessment of highest level 
of functioning achieved in patient's life 
0 Fully able to function successfully in
and take pleasure from < I ) school or 
job; (2) friends; (3) intimate sexual 
relationships; (4) church, hobbies, etc. 
Enjoys life and copes with it well.
2 Able to function well in and enjoys 
some spheres o f life, but has a definite 
lack of success in at least one area.
4 Minimum success and picasucc m 
three areas of life.
6 Unable to function in or enjoy any 
aspect of life.
G. Social-personal adjustment
0 A leader or  o fficer  in form ally d esig  
nated grou p s, c iu b s. organ ization s, or 
athletic team s in sen ior  high sch o o l, 
vocational sch o o l, c o i ie g e . or you ng  
adulthood. Involved in intim ate, c lo se  
relationship with others
1 An a ctiv e  and interested  participant, 
but did not play a leading role in 
groups o i friends, clubs, organ ization s, 
or athletic team s, but w as in vo lved  in 
c lo se  relationships w un others a lso .
2 A nom inal m em ber, cut nad no m 
vo lvem en t in or com m itm ent to. 
groups o f  friends, c lu o s . organ ization s, 
etc. Had c lo se  relationships w ith  a 
few  friends.
3 From a d o le sce n c e  through early  adult 
hood had a few  casu a i m en d s.
4  From a d o le sce n c e  through early  adult 
hood had no real frien ds, on ly  superfi 
cia l relationships.
5 From a d o lescen ce  through early  adult 
hood ( i .e . .  after ch ild h ood ), quiet, 
s ec ltu iv c . preferred to be by se lf , 
m inim al efforts to m aintain any contact 
at all w ith  o thers.
6 N o d esire  to be w ith  peers or  others, 
e ith er  a so c ia l or an u soeia i.
(I. Degree of interest in life
0 K een, am bitious interest in som e o f  
the fo llow in g , h om e, tam ily. friends, 
w ork, sports, art. p ets, garden ing, 
social activ ities, m u sic, and dram a.
2 M oderate d egree  oi interest in several 
activities including socia l gatherings, 
sports, m u sic , and op p osite  sex .
4 M ild interest m a few  things such  as 
job . fam ily , q u id  soc ia l gatherings  
T he interest is barely sustain ing.
6 W ithdrawn and indifferent tow ard life 
interests o f  average individual. N o  
d eep  interests o f  any sort.
I. Energy level
0 Strong d rive , k een , a ctive , alert inter 
cst in life . Liked life and had en ergy  
enough to enjoy it. O utgoing and adc 
quale in m eeting life.
2 M oderately adequate d rive, en erg y , 
interest, as described  ab ove.
4 M oderately inadequate energy level. 
Tended tow ard su b m issive , p assive  
reactions. S how ed  som e potential to 
face life's  prob lem s, but w ould  rather 
avoid them  than exp en d  the n ecessary  
energy
6 S ub m issive , inadequate, p assive  reac 
lions. W eak grasp on life, dues not go 
out to m eet life's  p rob lem s, d o es  not 
participate actively , but p assive ly  ac­
cepts his lot without having the energy  
to help se ll.
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Appendix M
I N S T R U C T I O N S  F O R  T H E  3 2 0 2 5  
G R O O V E D  P E G B O A R D  T E S T
I N T R O D U C T I O N
T h e  f o l l o w i n g  a d m i n i s t r a t i v e  i n s t r u c t i o n s  a n d  a g e  c u r v e  d at a  a r e  t 2 k e n  f r o m  
t h e  N e u r o p s y c h o l o g i c a l  T e s t  M a n u a l  d e v e l o p e d  by D r. R o n a l d  T r i t e s ,  P.oyal 
O t t a w a  h o s p i t a l ,  O t t a w a .  O n t a r i o ,  C a n a d a .
T h r e e  b a t t e r i e s  o f  t e s t s  h a v e  b e e n  d e f i n e d  f o r  t h e  n o r m a t i v e  d a t a  o b t a i n e d  b y  
T r i t e s .
A d u l t :  A g e  15 y e a r s  0 m o n t h s  a n d  a b o v e
A d o l e s c e n t :  A g e  9 y e a r s  0 m o n t h s  to 14 y e a r s  12 m o n t h s
K i d d i e :  A g e  5 y e a r s  0 m o n t h s  to 8 y e a r s  12 m o n t h s
D E S C R I P T I O N
T h e  G r o o v e d  P e g b o a r d  is a m a n i p u l a t i v e  d e x t e r i t y  t e s t .  T h i s  u n i t  c o n s i s t s  or 
25 h o l e s  w i t h  r a n d o m l y  p o s i t i o n e d  s l o t s .  P e g s ,  w h i c h  h a v e  a k e y  a l o n g  o n e  
s i d e ,  m u s t  b e  r o t a t e d  to m a t c h  t h e  h o l e  b e f o r e  t h e y  c a n  be i n s e r t e d .  T h i s  
t e s t  r e q u i r e s  m o r e  c o m p l e x  v i s u a l - m o t o r  c o o r d i n a t i o n  t h a n  m o s t  p e g b o a r d s .
I N S T R U C T I O N S  TO T H E  T E S T
T h e  p e g b o a r d  is p l a c e d  in m i d - l i n e  w i t h  t h e  s u b j e c t  s o  that t h e  b o a r d  is at 
t h e  e d g e  of t h e  t a b l e  a n d  c e g  t r a y  i m m e d i a t e l y  a b o v e  the b o a r d .  T he  e x a m i n e r  
e x p l a i  ns t he  t e s t :
T H I S  IS A P E G B O A R D  A N D  T H E S E  A R E  T HE  P E G S .  ( T h e  e x a m i n e r  p o i n t s  o u t  e a c h  a n a  
t h e n  p i c k s  u p  o n e  o f  t he  p e g s  a n d  c o n t i n u e s . )
A L L  T H E  P E G S  A R E  T H E  S A M E .  T H E Y  H A V E  A G R O O V E .  T H A T  IS,, A R O U N D  S I D E  A N D  A 
S Q U A R E  S I D E  A N D  S O  D O  T H E  H O L E S  IN T H E  B O A R D S .  W H A T  Y O U  M U S T  D O  IS M A T C H  T H E  
G R O O V E  OF T H E  P E G  W I T H  T H E  G R O O V E  OF T H E  B O A R D  A N D  P U T  T H E S E  P E G S  I N T O  T HE  
H O L E S  L I K E  T H I S .  ' ( T h e  e x a m i n e r  d e m o n s t r a t e s  by f i l l i n g  the t o p  r o w . )
( R e m o v e  t h e  p e g s ,  p u t t i n g  t n e m  b a c k  i n t o  t h e  t r a y . )
W H E N  I S A Y  G O ,  B E G I N  H E R E  A N D  P U T  T H E  P E G S  I N T O  T H E  B O A R D S  AS F A S T  AS Y O U  C A N .  
U S I N G  O N L Y  Y O U R  ( D O M I N A N T )  H A N D .  F I L L  T H E  T O P  R O W  C O M P L E T E L Y  F R O M  T H I S  S I D E  
TO T H I S  S I D E .  D O  N O T  S K I P  A N Y ,  F I L L  E A C H  R O W  T H E  S A M E  WAY Y O U  F I L L E D  T H E  T O P  
R O W .  A N Y  Q U E S T I O N S ?  R E A D Y .  AS F A S T  Y O U  C A N ,  GO.
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S U P P L E M E N T A R Y  I N S T R U C T I O N S ( A D U L T ,  A D O L E S C E N T )
F o r  t h e  r i g h t  h a n d  t r i a l ,  t h e  e x a m i n e r  d e m o n s t r a t e s  t h a t  t h e  p e g s  a r e  p l a c e a  
f r o m  s u b j e c t ' s  l e f t  to r i g h t ,  a n d  f r o m  r i g h t  to l e f t  f o r  t he l e f t  h a n d  t r i a l .  
T h e  G c m i n a n t  h a n d  t r i a l  is a d m i n i s t e r e d  f i r s t ,  f o l l o w e d  by the n o n d o m i n a n t  
hand trial.
T h e  e x a m i n e r  e n c o u r a g e s  t h e  s u o j e c t  to p e r f o r m  t h e  t a s k  as q u i c k l y  as 
p o s s i o l e ,  t e l l i n g  h i m  or h e r  to s p e e a  up if n e c e s s a r y .  The p e g s  m u s t  be p u t
in t h e  b o a r d  in t h e  e x a c t  o r d e r  a n d  in t h e  c o r r e c t  d i r e c t i o n .  F r e q u e n t l y ,  it 
w il l  be n e c e s s a r y  to p o i n t  o u t  t h e  f i r s t  h o l e  of a n e w  r ow .  p a r t i c u l a r l y  
d u r i n g  t h e  n o n d o m i n a n t  h a n d  t r i a l .  O n l y  o n e  p e g  is to be p i c k e d  up at a t i m e  
a n d  t h e  s u b j e c t  s h o u l d  i m m e d i a t e l y  be t o l d  if m o r e  t h a n  o ne  is p i c k e d  u p .
A l s o ,  o n l y  o n e  h a n d  is to be u s e d .  O c c a s i o n a l l y ,  a s u b j e c t  will a t t e m p t  to 
u s e  h i s  o r  h e r  o t h e r  h a n d  to h e l p  t u r n  t h e » p e g  a r o u n d .  It m a y  be n e c e s s a r y  to 
t e l l  t h e  s u b j e c t  to k e e p  t h e  h a n d  o n  h i s  or h e r  l a p ,  o r  f o r  t h e  e x a m i n e r  to 
h o l d  it. If n e c e s s a r y ,  t he  b o a r a  s h o u l d  be h e l d  s t e a d y  f o r  t h e  p a t i e n t .  In 
t h e  c a s e  of s e v e r e  m o t o r  i m p a i r m e n t ,  t h e  s u b j e c t  s h o u l d  a t t e m p t  t h e  t a s k  j u s t  
to s e e  if a n y  o f  t h e  p e g s  c a n  be p u t  in. A n y  f a c t o r  w h i c h  m a y  e f f e c t  the 
s u b j e c t ' s  p e r f o r m a n c e  s h o u l d  be n o t e d ,  e . g .  s o r e  f i n g e r ,  b a n d a g e ,  e tc .
Ir a p e g  is d r o p p e d  to t h e  f l o o r ,  t h e  e x a m i n e r  s h o u l d  n o t  m a k e  a n  a t t e m p t  to 
p i c k  it u p  d u r i n g  t h e  t r i a l :  r a t h e r ,  o n e  o f  t he  p e g s  c o r r e c t l y  p l a c e d  s h o u l d
be t a k e n  o u t  a n d  u s e d  a g a i n .  ( U s u a l l y ,  t h e  f i r s t  or s e c o n d  p e g . )
S U P P L E M E N T A R Y  I N S T R U C T I O N S  ( K I D D I E )
T h e  d e s c r i p t i o n ,  m a t e r i a l s  n e e d e d ,  i n s t r u c t i o n s  a n d  s c o r i n g  f o r  t h e  K i d d i e  
v e r s i o n  a r e  i d e n t i c a l  in all a s o e c t s  to t h e  A d u l t  v e r s i o n ,  w i t h  t h e  f o l l o w i n g  
e x c e p t i o n .  O n l y  t h e  f i r s t  t w o  r o w s  of t h e  P e g b o a r d  a r e  to be f i l l e d ,  t h u s  
t o t a l i n g  10 p e g s .  P a r t i c u l a r  c a r e  is n e c e s s a r y  in p o i n t i n g  o u t  t h e  c o r r e c t  
d i r e c t i o n ,  as w e l l  as t h e  c o r r e c t  s e q u e n t i a l  orae-r. If a c h i l d  u s e s  the w r o n g  
o r d e r  ( p u t s  10 p e g s  in r a n d o m l y  b e c a u s e  he is u n a b l e  to p u t  t h e m  in the 
c o r r e c t  o r d e r ) ,  t h e  t e s t  s h o u l d  b e  g i v e n  a "D" f l a g  f o r  a n o n s t a n d a r d  
a d m i n i s t r a t i o n .
S C O R J N G
R e c o r o ,  in s e c o n d s ,  t h e  l e n g t h  of t i m e  r e q u i r e d  to p e r f o r m  e a c h  t r i a i  
b e g i n n i n g  w h e n  t h e  s u b j e c t  s t a r t s  t h e  t a s k  u n t i l  t h e  l a s t  peg is p u t  in, or  
t h e  t e s t  is d i s c o n t i n u e d .  A t r i a l  m a y  b e  d i s c o n t i n u e d  a f t e r  f i v e  m i n u t e s .  I ’ 
s u c h  c a s e s  , t he d i f f i c u l t y  is d e s c r i b e d  a n a  t h e  s c o r e s  a r e  g i v e n  " A "  f l a g s  
i n d i c a t i n g  an i n c o m p l e t e  t e s t .
T h e  s e c o n d  s c o r e  is t h e  n u m b e r  of " d r o p s "  m a d e  d u r i n g  e a c h  t r i a l .  A " d r o p ” i ' 
a n y  u n i n t e n t i o n a l  d r o p  of a p e g  f r o m  t h e  t i m e  the s u b j e c t  a t t e m p t s  to p i c k  u p  
t h e  p e g  f r o m  t h e  t r a y  u n t i l  it is p l a c e d  c o r r e c t l y  in t h e  h o l e .  If m o r e  t h a n
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o n e  p e g  is p i c k e d  up f r o m  t h e  t r a y  a n d  t h e  s u b j e c t  i n t e n t i o n a l l y  d i s c a r d s  all 
b u t  o n e  of t h e  p e g s ,  it is n o t  c o n s i d e r e d  a d r o p .  If a p e g  is i n t e n t i o n a l l y  
l a i d  d o w n  o n  t h e  s i d e  of t h e  t r a y  or t a b l e ,  in o r d e r  to p u r p o s e f u l l y  
m a n i p u l a t e  t h e  p e g ,  it is n o t  c o n s i d e r e d  a o r o p .  If o n e  p e g  is t u r n e d  w i t h  
t h e  h a n d  n o t  b e i n g  t e s t e d ,  t h i s  is n o t e d .  If, h o w e v e r ,  t h i s  o c c u r s  m o r e  t h a n  
o n c e ,  t he s c o r e  is g i v e n  a " D " f l a g  f or a n o n s t a n d a r d  a s s e s s m e n t .
T he  t h i r d  s c o r e  is t he n u m b e r  of p e g s  c o r r e c t l y  p l a c e d  in t h e  h o l e s  for e a c h  
t r i a l . Th e  t a s k  is p e r f o r m e d  o n c e  w i t h  t h e  d o m i n a n t  a n d  t h e n  o n c e  w i t h  t h e  
n o n d o m i n a n t  h a n d .  F o r  e a c h  h a n d ,  t h e  t h r e e  s c o r e s  a r e  s u m m e d  ( t h e  t o t a l  t i m e ,  
t o t a l  n u m b e r  of d r o p s  and t he t o t a l  n u m b e r  of p e g s  c o r r e c t l y  p l a c e d  in t h e  
b o a r d )  to g e t  c o m p l e t e  s c o r e .
1 IN T E R P R E T A T I O N
W h e n  a t e s t  s u c h  as t h e  G r o o v e d  P e g b o a r d  t e s t  is to b e  u s e d  f o r  p e r s o n n e l  
s e l e c t i o n ,  t h e  i d e a l  p r o c e d u r e  is to e s t a b l i s h  its v a l i d i t y  l o c a l l y ,  by 
t e s t i n g  all n e w l y  h i r e d  e m p l o y e e s  a n d  c o r r e l a t i n g  s c o r e s  w i t h  t h e i r  s u b s e q u e n t  
p e r f o r m a n c e  ( s u p e r v i s o r  r a t i n g s  or t i m e  t h e y  r e m a i n  e m p l o y e d ) .  T h i s  a p p r o a c h  
to v a l i d a t i o n  r e q u i r e s  t h a t  t e s t  s c o r e s  s h o u l d  n o t  b e  u s e d  to s e l e c t  e m p l o y e e s  
u n t i l  e v i d e n c e  h a s  a c c u m u l a t e d  of i ts v a l i d i t y ,  a n d  t h a t  t e s t  s c o r e s  be 
i n a c c e s s i b l e  to s u p e r v i s o r s  or o t h e r s  w h o  a f f e c t  t h e  w o r k e r ' s  r a t i n g s  or j o b  
l o n g e v i t y .  An a l t e r n a t i v e  v a l i d a t i o n  p r o c e d u r e  is to a d m i n i s t e r  t h e  t e s t  to 
all p r e s e n t  e m p l o y e e s  a n d  c o r r e l a t e  s c o r e s  w i t h  r a t i n g s  or w i t h  s u b s e q u e n t  
p e r f o r m a n c e .  ( A n a s t a s i ,  1 9 8 2 ,  pp 6 5 - 1 0 1 ) .  T h e  G r o o v e d  P e g b o a r d  t e s t  s h o u l d  
c o r r e l a t e  m o s t  h i g h l y  w i t h  t h o s e  j o b s  w h i c h  r e q u i r e  s p e e d ,  f i n g e r  d e x t e r i t y  
a n d  m a n u a l  d e x t e r i t y .  It s h o u l d  be of r e l e v a n c e  to p e r f o r m a n c e  o n  a s s e m o l y  
a n d  m a c h i n e  o p e r a t i n g  j o bs .  We at L a f a y e t t e  I n s t r u m e n t  C o m p a n y  a r e  a l w a y s  
i n t e r e s t e d  in v a l i d a t i o n  d a t a  w h i c h  y o u  m a y  c o l l e c t  in v a r i o u s  i n d u s t r i a l  
s e t t i n g s  or a c a d e m i c  s t u d i e s .
Of c o u r s e ,  s c o r e s  o n  s u c h  a t e s t  a r e  of d i a g n o s t i c  u t i l i t y  in
n e u r o p s y c h o l o g i c a l  o r a c t i c e  o n l y  w i t h i n  t h e  c o n t e x t  of an e x t e n s i v e  s a m p l i n g  
of m e d i c a l ,  c o g n i t i v e ,  m o t o r ,  s e n s o r y  a n d  p e r s o n a l i t y  f a c t o r s .  K e e p i n g  t n i s  
p r o v i s i o n  in m i n d ,  it s h o u l d  be n o t e d  t h a t  M a t t h e w s ,  C l e e l a n d  & H o p p e r  ( 1 9 7 0 ;  
f o u n d  t h a t  p a t i e n t s  w i t h  m u l t i p l e  s c l e r o s i s  (MS) w e r e  s i g n i f i c a n t l y  s l o w e r  
t h a n  '’c o n t r o l "  p a t i e n t s  w i t h  o t h e r  c e n t r a l  n e r v o u s  s y s t e m  i m p a i r m e n t s .  MS 
p a t i e n t s  (N = 30) h a d  a m e a n  of 3 2 3 . 4 0  s e c o n a s  ( S . D .  = 1 7 6 . 9 8 )  w h i l e  c o n t r o l s
(N = 30) h a d  a m e a n  of 1 7 1 . 7 7  s e c o n d s  ( S . D >  = 4 8 . 2 0 ) .  The d i f f e r e n c e  w a s  
s i g n i f i c a n t  (t = 5 . 1 3 ,  p. .0 1,  r = . 6 9 0 ) .  O u t  of 24 t e s t s  in t h e  s t u d y ,  t h o s e  
" o f  c o n s i d e r a b l e  u t i l i t y  in i n t e r g r o u p  d i s c r i m i n a t i o n  (p. 6) w e r e  t h e  G r o o v e d  
P e g b o a r d  t e s t ,  t h e  S t a t i c  S t e a d i n e s s  T e s t  ( e q u i v a l e n t  to L a f a y e t t e  # 3 2 0 1 1 )  , 
t h e  M a z e  C o o r d i n a t i o n  T e s t  ( s i m i l a r  to L a f a y e t t e  # 2 0 0 1 5 )  a n d  m e a s u r e  of F i n g e r  
T a p p i n g  s p e e d " .
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N O R M S  BY A G E  A N O  S E X  K I D D I E  - A D O L E S C E N T  
( T o t a l  t e s t  t i m e  in s e c o n d s )
M A L E _ _ _ _ _ _ _ _ _ _ _ _ _ _   F E M A L E
D O M I N A N T N O N  D O M I N A N T D O M I N A N T N O N  D O M I N A N T
A G E M SD M SD M SD M SD
5 70 3 3 . 9 75 38. 1 66 3 2 . 3 73 3 6 . 8
6 58 2 6 . 1 64 33. 9 63 3 1 . 2 65 3 0. 1
7 48 2 4 . 6 51 22. 0 53 2 4 . 8 58 1 9 . 9
8 38 9 . 0 2 41 14 . 6 38 1 0 . 4 47 2 6 . 8
9 84 1 9 . 5 92 2 3 . 8 90 5 4 . 0 96 5 0 . 6
10 83 3 6 . 5 90 28 . 9 84 1 8 . 1 92 2 4. 4
11 76 1 8 . 1 86 3 1 . 0 79 1 7 . 0 92 24 . 8
12 78 2 4 . 4 85 3 2 . 2 80 1 9 . 5 87 2 1 . 6
13 78 4 0 . 5 81 2 3 . 8 81 5 2 . 6 84 42 . 4
14 79 2 5 . 2 86 44 . 5 77 5 4 . 3 78 1 7 . 6
A G E  C U R V E S  ON T H E G R O O V E D  P E G B O A R D
T h e  foil o w i n g c u r v e s a r e  p r e s e n t e d  f or d o m  i n a n t  a n d n o n - d o m i n a n t  h a n d s . The
m a l e s a r e  r e p r e s e n t e d by s o l i d l i n e s  a n d  t h e  f e m a l e s  by d o t t e d l i n e s .  T he
m e a n a n d s t a n d a r d  d e v i a t i o n  a r e ol o t t e d f o r  e a c h  of t h e  g r o u p s T h e  c u r v e s
h a v e b e e n  p i o t t e d  o n t h e  b a s i s cf raw s c o r e s  f o r  c o n v e n i e n t  i n t e r p r e t a t i o n  at
e a c h age 1 eveii. S i n c e  t h e  d i f f i c u l t y  l e v e l  of t h e t e s t  c h a n g e s  b e t w e e n the
k i d d i e  a n d  a d o l e s c e n t / a d u l t  b a t t e r i e s ,  a c l e a r  b r e a k  in t h e  c u r v e  is s h o w n  at 
t h i s  p o i n t .  D a t a  p o i n t s  f o r  t h e s e  c u r v e s  a r e  a l s o  l i s t e d  on p a g e  7.
P a g e  3 l i s t s  s u m m a r y  d a t a  a n d  r e f e r e n c e s  f o r  o t h e r  p u b l i c a t i o n s  u t i l i z i n g  t he 
G r o o v e d  P e g b o a r d  T e s t .
3 2 0 2 5 ,  1 2 / 8 9 ,  P a g e  5 o f  6
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Grooved Pegboard 
Age curve reference points (Trites)
Males
Dominant
Age Mean Low/High 
(±1 SD)
15 ee 36/103
16 81 35/105
17 82 35/107
18 82 36/110
19 83 37/113
20 83 38/117
21 84 39/121
22 84 40/125
23 85 41/128
24 85 41/131
25 86 42/133
26 87 42/134
27 87 43/135
28 87 44/136
29 88 44/136
30 88 45/137
31 89 45/137
32 90 46/137
33 90 46/137
34 91 46/137
35 91 46/137
38 91 46/137
37 92 46/138
38 92 46/138
39 93 46/138
40 94 46/139
41 95 46/138
42 95 46/138
43 95 46/140
44 96 47/140
45 97 47/141
46 97 47/142
47 97 47/143
48 98 47/144
49 98 49/156
50 99 £0/158
The above scores were
SCORES
Non-Dominant
Mean Low/High Mean
(-I SD)
82 49/119 82
82 48/120 83
82 47/122 84
82 47/123 84
83 48/124 84
85 45/127 85
86 45/129 85
87 45/131 85
87 44/134 85
89 44/135 85
90 45/137 84
92 45/139 84
93 46/141 84
94 46/143 84
95 47/145 84
96 48/146 83
98 48/148 83
99 49/150 83
100 49/152 83
101 £0/153 83
102 50/155 83
103 50/157 83
105 51/159 83
105 52/160 83
106 52/161 85
108 52/162 86
108 51/163 89
108 51/163 90
109 51/165 92
109 51/165 94
109 52/166 98
109 52/166 101
110 52/167 104
110 52/169 108
110 52/170 111
110 52/170 113
by adding: time (in
Females
Non-Dominant
Low/High Mean Low/High
(-1 SD) (t1 SD)
28/117 82 59/97
27/122 82 57/98
26/127 82 55/102
26/131 82 53/105
25/134 83 52/109
25/137 83 50/113
25/141 84 49/118
26/143 85 48/121
27/144 86 47/124
28/143 87 47/127
30/142 88 47/129
32/140 89 45/131
34/139 90 46/133
36/137 102 45/135
37/135 92 45/137
39/132 93 45/138
40/130 S3 45/139
41/127 94 45/142
43/126 95 45/143
44/123 95 45/144
45/121 96 45/147
46/120 97 46/148
46/120 98 46/149
47/119 99 47/151
48/121 101 47/152
48/123 102 47/154
48/125 103 47/156
48/129 105 48/158
47/134 106 48/160
46/140 107 49/162
45/145 109 49/164
44/151 111 £0/166
43/158 113 £0/169
43/164 114 50/172
42/166 117 50/174
41/170 119 51/180
) required to fill pegboard,
223.
SCORES
Dominant Non-Dominant
Ages nean so Mean sd N
9 74.39 15.47 80.77 15.91 56
10 71.88 9.39 76.65 11.75 66
11 68.07 8.64 71.50 10.00 56
12 65.07 8.55 68.94 9.44 53
13 60.96 6.54 65.61 9.38 41
14 65.68 11.88 70.66 3.31 300
15-19 66.05 10.40 20.50 11.10 172
20-29 63.40 7.90 69.10 18.70 —
30-39 62.95 8.40 67.15 12.20 319
40-49 63.50 7.20 69.05 9.80 319
50-59 63.10 9.42 74.70 10.51 134
60+ 82.70 18.70 87.95 26.20 100
10-59 65.13 9.19 69.99 10.31 1460
Above scores derived without adding number of pegs dropped and number of 
pegs correctly placed in board to the subject's time.
References for the above group data:
Heaton R.K., Grant I., & Hatthews C.G. (1986). Differences in neuropsuychological test 
performance associated with age, education and sex. In Neuropsycho logical 
Assessment of Neuropsvchiatric Disorders. New York: Oxford.
Klouoff H. & Low M. (1974). Disordered brain function in young children and early 
adolescents: Neuropsychological and EEG correlates. In Reitan R. & Davison
L. (Eds.) Clinical Neuropsychology. New York: Wiley.
Knights R.H. & Houle P.D. (1968). Normative data on the motor steadiness battery for 
children. Perceptual and Motor Skills, 26, 643-650.
Matthews C.G. & Healand K. (1979). The effect of symptom duration on cognitive and 
motor performance in Parkinsonism. Neurology, 29, 951-956.
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ESH PATIENT FOLLOW -UP QUESTIONNAIRE
Directions: Earlier this year you were interviewed and took some neuropsychological tests. 
This questionnaire is to see how you are doing now. Please complete the following 
questions. Then place this questionnaire in the envelope provided and mail to: Robert Smith, 
Psychology Department, The College of William & Mary, Williamsburg, VA 23187.
Thanks for your help.
1. After you left ESH. did you go to your aftercare appointmeit? Y e s   N o __
2. Since you left ESH, have you received medications? Y e s____  N o ___
3. Since you left ESH. have you attended any therapy sessions,
AA or NA meetings? Y e s__ __ N o ___
4. On a scale of I to 100, where 1 is really bad and 100 is 
really good, how do you feel today?
I would like to know how you are doing. If you would like to tell me, please feel free to 
write in the space below. Again, thanks for all your help.
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ESH Patien t Foilow-up Q uestionnaire  
C om m unity A djustm ent. Recidivism  & {Neuropsychological F unction ing
Directions: Please complete the following questions and return to: Dr. Michael Ito. Departm ent o f  Psychology,
Reseaich and Forensic Services, Eastern State H ospital, 4601 Ironbound Road, P .O . Box 8791. W illiamsburg, VA 
23187. ATTN: RWS.
RE:
1. Has the above referenced patient shown up
for a scheduled post*dtscharge appointment? Yes _____ No
If the .uiswer to ft 1 is yes. please answer the following questions.
2. Has he received a prescription for
follow-up psychoactive medications? Y e s ______ No
3. Is he participating in any
ongoing aftercare programs'? Yes _____ No
4. What is your estimate o f  this patient's 
General Level ot Adaptive Functioning 
at this time, using the global rating 
scale o f  1*1007
Name ot person completing this fo m :
Title:  _____________
Agency:
Telephone Number: ________________
* A copy o f  the signed release o t information consent form is attached.
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